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Abstract 
 
BACKGROUND  
In a Delphi survey of research priorities, people affected by cerebral palsy indicated 
that they considered understanding causal pathways and prevention of cerebral 
palsy to be high research priorities. Increasing knowledge of aetiology and 
interventions for extremely preterm births has led to a decline in their risks of 
cerebral palsy, but 2 in 3 children with cerebral palsy are singletons born after at 
least 35 weeks gestation, for whom aetiological information is limited and birth 
prevalence unchanging. This thesis explores the aetiology of cerebral palsy in term 
and near-term singleton births.  
 
METHODS 
Two methodologies and a number of separate analyses were undertaken to 
complete this thesis. 1) A systematic review collated risk factors described in the 
literature for cerebral palsy in term births. 2) A total population case control study 
of cerebral palsy and perinatal death (CCCP) from Western Australian births 1980-
1995 was analysed to assess risk factors including those identified in the systematic 
review. Data were derived directly from medical records, and then augmented with 
data concerning birth defects from the Western Australian Register of 
Developmental Anomalies. The analysis of this study in which outcome was 
stratified by neonatal neurological status was undertaken with a view to creating 
aetiologically more homogeneous groups.   
 
RESULTS 
Systematic review results were usually compatible with CCCP results though 
variable choice of factors to examine and lack of standardisation of their definitions 
hindered robust comparison. Risk factor profile for term born cerebral palsy 
differed from that for preterm/all cerebral palsy. Our observations that risk factors 
were more important for some groups defined by neonatal neurological status than 
others supported the notion that they were aetiologically more homogeneous, 
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though there was still significant overlap in risk factor profiles.  Of the four major 
risk factors chosen for detailed analysis, a greater proportion of cerebral palsy in 
term and near-term born singletons could be attributed to birth defects, particularly 
if associated with fetal growth restriction, than to acute hypoxic events during 
labour and delivery or to inflammation or growth restriction in the absence of birth 
defects. A significant proportion of cases were not exposed to any of these risk 
factors, indicating further aetiological heterogeneity. Even in the group considered 
most likely to have acquired their cerebral palsy during an acute intrapartum 
hypoxic event, there was an excess of risk factors in the antenatal period. 
 
CONCLUSION 
Term and near term singletons comprise two thirds of all cerebral palsy, with most 
not neurologically depressed in the newborn period. Their aetiological pathways are 
diverse; however the major finding from this thesis is that birth defects and growth 
restriction are the dominant risk factors. The research agenda needs to shift to 
include a focus on them. Post doctoral research has been planned to: identify if this 
finding is repeatable by conducting new linkages between cerebral palsy and birth 
defect registers in later birth years and in additional populations; determine more 
about the antecedents of birth defects, growth restriction and their inter-
relationship to ultimately test strategies for prevention of identified sub-groups.  
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CHAPTER 1  
INTRODUCTION 
OVERVIEW 
This thesis is presented as a series of papers, with additional text and analyses 
where necessary, exploring the aetiology of cerebral palsy in singletons born at 
term and in some analyses, near-term. This chapter will provide a background to 
the research, a rationale for the investigation, introduce the research questions to 
be answered and will outline the chapters and papers that follow. 
 
BACKGROUND 
This doctoral program arose from my work establishing the New South Wales 
Cerebral Palsy Register (NSW-CPR). The NSW-CPR is a consent based register and 
during this time I personally interviewed over 500 families to gather their required 
information. One question on the registration reads: “At what gestation was your 
child born?” followed by: “Timing of cerebral palsy” and, “What was the confirmed 
cause?” The overwhelming majority of families that I interviewed stated that their 
child was born at term and their answers to the two following questions were 
almost always “unknown”. Medical files and referral letters confirmed their 
statements. The story I was hearing with uncanny regularity from mothers was:  
 
“…No one can tell us what happened… I had a normal pregnancy, he wasn’t early, 
the birth was ok - , just the usual... We went home with our beautiful boy and when 
he was nine months old I started bringing him to doctors… I knew there was 
something wrong, but it wasn’t until he was almost three that we were told he had 
cerebral palsy...”  
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The other observation that I noted at the time was, although the family stories were 
similar, the outcomes for their children were diverse, with all subtypes and 
severities of cerebral palsy represented.  
 
These families asked if I knew what could have happened and unfortunately I was 
only able to say that there was a real gap in research around term born infants in 
general. Apart from some notable exceptions1-12 the literature that did exist 
focussed on birth asphyxia following a major obstetric catastrophe, but this 
pathway was only rarely described by the families that I had spoken to.  
 
It was at that point I realised I might be able to generate new knowledge in the area 
of causal pathways to cerebral palsy in term born infants. The NSW-CPR was only in 
its infancy, with low overall ascertainment meaning that it was not yet appropriate 
to use for research. The Western Australian CP Register (recently renamed Western 
Australian Register of Developmental Anomalies – Cerebral Palsy (WARDA-CP)) 
records the highest proportion of term born singletons with cerebral palsy of any 
population based register in the developed world. There are two possible 
explanations for this. Western Australia may actually have a higher proportion of 
cerebral palsy or, they may have more complete ascertainment of the most difficult 
group to identify; term born singletons with mild impairment recognised later. Most 
registers with lower proportions suggest that they may under-ascertain cerebral 
palsy in this group. I approached the principal investigators of WARDA-CP to see if 
together we could design a research study on term infants using their register.   
 
Fortuitously, the total population case control study of cerebral palsy and perinatal 
death in Western Australia 1980-1995 (CCCP) was in the completion phase of data 
collection. The CCCP was the largest population based case control study in the 
world at the time and cases had been ascertained from WARDA-CP. A research 
partnership was thus formed, and this thesis comprises the findings of the 
subsequent investigations in term and near-term births (≥ 35 weeks gestation) from 
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this total population case control study. Throughout the thesis these investigations 
will now be referred to as the Term-CCCP study. 
 
STATEMENT OF THE PROBLEM 
WHAT IS CEREBRAL PALSY? 
Cerebral palsy is not a diagnosis, rather a clinical description, because the term 
implies nothing about aetiology, pathology (other than it is cerebral) or prognosis.13   
The brain injuries/abnormalities responsible for cerebral palsy can occur anytime 
from early in the first trimester through to early childhood; as a result it is an 
umbrella term covering many pathologies and aetiologies and its clinical 
descriptions are diverse.  
 
Two consensus definitions of cerebral palsy have been used in recent times. 
“Cerebral palsy is an umbrella term covering a group of non-progressive, but often 
changing, motor impairment syndromes secondary to lesions or anomalies of the 
brain arising in the early stages of its development”.14 More recently, “Cerebral 
palsy describes a group of disorders of the development of movement and posture, 
causing activity limitations that are attributed to non-progressive disturbances that 
occurred in the developing fetal or infant brain. The motor disorders of cerebral 
palsy are often accompanied by disturbances of sensation, cognition, 
communication, perception, and/or behaviour, and/or by a seizure disorder”.15 The 
main change to the definition has been the addition of associated impairments. The 
disability is still necessarily defined as motor; however this definition acknowledges 
the complexity of cerebral palsy.  
 
The definition used throughout this thesis is that which is used for the WARDA-CP, 
as cerebral palsy cases were identified from this register.16 WARDA-CP 
acknowledges the most recent consensus definition, but for register purposes a 
cerebral palsy registration requires five key elements: i) it is a group of disorders, ii) 
it is permanent but not unchanging, iii) it necessarily involves a disorder of 
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movement and/or posture and of motor function, iv) it is due to a non-progressive 
interference/lesion/abnormality, and v) this occurs in the developing immature 
brain. 
 
CEREBRAL PALSY CLASSIFICATION 
Cerebral palsy is usually classified by motor type, topography and severity. There 
are four main types of motor impairment in cerebral palsy, and for some more than 
one type may co-exist, but throughout this thesis subjects are classified by the 
predominant motor type:  
 Spasticity, characterised by overactive muscles that display a velocity 
dependent resistance to stretch.17 Spasticity is further described by 
topography; quadriplegia, diplegia or hemiplegia. Those with quadriplegic 
and hemiplegic cerebral palsy are more likely to be born at term.16, 18, 19 
 Dyskinesia includes both dystonic and athetoid motor impairments which 
often accompany spasticity. Dystonia is characterised by hypokinetic, 
involuntary abnormal twisting postures or repetitive movements with 
hypertonia.17 Tone is typically fluctuating. Conversely athetosis is 
characterised by hypotonia with hyperkinesias and involuntary writhing-
stormy movement and can co-occur with chorea.  The prevalence of 
dyskinetic cerebral palsy has recently been reported to be increasing in 
those born at term.18, 20 
 Ataxia results in tremors with a shaky quality, characterised by a loss of 
muscular coordination. Ataxia is a common secondary motor impairment, 
less frequently the primary motor impairment in cerebral palsy. 
 Isolated hypotonia refers to decreased muscle tone in the absence of other 
motor impairments that cannot be attributed to cognitive deficits.  Although 
many with cerebral palsy exhibit hypotonia (particularly of the trunk), very 
few meet this description and not everyone accepts that it should be 
included under the cerebral palsy umbrella; however WARDA-CP includes 
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those that meet its inclusion criteria. The small proportions of ataxia and 
hypotonia are spread evenly between term and preterm infants.16 
 
CEREBRAL PALSY SEVERITY AND ASSOCIATED IMPAIRMENTS 
For the purposes of this thesis, severity of motor impairment is defined as mild, 
moderate and severe. These categories can generally be equated to the Gross 
Motor Function Classification System (GMFCS)21 and (Manual Ability Classification 
System (MACS)22 as follows: Mild severity equates to walking independently 
(GMFCS I and II) and being independent when handling objects (MACS I and II). 
Moderate equates to walking with assistance (GMFCS III) and requiring assistance 
when handling objects (MACS III). Severe equates to requiring wheeled mobility 
(GMFCS IV and V) and being unable to handle objects (MACS IV and V). Recent 
surveillance of cerebral palsy has noted an increase in severity of cerebral palsy in 
those born at term, in contrast to those born preterm where severity is 
decreasing.16, 18 
 
For most, cerebral palsy is not purely a motor impairment. The likelihood and 
severity of associated impairments increases with the severity of motor 
impairment.23 For individuals with a severe motor impairment up to 70% will have 
epilepsy; 50% will have a severe intellectual impairment; 55% will be non-verbal; 
25% will be blind and 3% will be deaf.23, 24 Many will have more than one of these 
impairments, and the presence of these impairments complicates medical and 
therapy interventions, decreases health status and quality of life for the individual 
and their family and increases costs for the family and society.  
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BIRTH PREVALENCE OF CEREBRAL PALSY 
The true incidence of cerebral palsy cannot be estimated as there are infants who 
die in the neonatal and infant period with brain lesions, and there is an unknown 
proportion that would have met the criteria for cerebral palsy had they survived.13  
 
With that caveat in mind, the two largest cerebral palsy databases, the Australian 
Cerebral Palsy Register (ACPR) and the Surveillance of Cerebral Palsy Europe (SCPE) 
both report the overall proportion of live births with cerebral palsy (not due to post-
neonatal events) to be 2.0/1000.25, 26 This figure has remained stable over the 
preceding decades, however the proportions vary dramatically when stratified by 
gestational age. Figure 1 presents the proportions of live births by gestational age 
stratum in Western Australia (WA) from 1980 to the most recently released data 
2006.  
 
 
 
 
 
 
 
Figure 1:  Birth prevalence of cerebral palsy by gestational age in Western Australia 
1980-2006   
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As can be seen from Figure 1 the birth prevalence of cerebral palsy in term born 
infants has  not changed over a 26 year period and remains at 1.7/1000 live births 
(95% CI 1.4-2.1). Birth prevalence in those born between 32 and 36 weeks also 
shows little variation and no consistent trend. In contrast, during a time of 
constantly increasing perinatal survival in very and extremely preterm infants, much 
higher and increasing proportions of infants with cerebral palsy were observed in 
the 1980s followed by a continual steady reduction for very preterm births. 
Proportions of cerebral palsy in survivors of extremely preterm births continued to 
increase and did not start to decline until the new millennium. Figure 1 also 
demonstrates that relative risk increases with decreasing gestational age, and those 
born at term have the lowest relative risk. However, because singleton term births 
comprise 93% of all births in the population, two in three (67%) people with 
cerebral palsy were singletons born at term or near-term (Figure 2).  
 
 
 
 
 
 
Figure 2: Total population of cerebral palsy in Western Australia 
1980-1995 by gestation and multiplicity of birth  
 
Within this large group, 6% are born at 35 or 36 weeks, and 61% are born at 37 or 
more weeks gestation. These proportions are consistent with register reports and 
meta-analyses throughout the world.18, 27, 28  
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AETIOLOGY AND CAUSAL PATHWAYS 
Approximately 80% of families and people with cerebral palsy do not know what 
caused the brain damage that is responsible for their disability.25 It is estimated that 
this damage occurs during the antenatal, intrapartum and neonatal time periods for 
between 80-90%, and in the postnatal period (after 28 days of life) for 5-15%.25, 29 
For many years research focused on a single cause for infants born at term; 
asphyxia around the time of birth. In an attempt to prevent asphyxia electronic fetal 
monitoring was introduced. Its use reduced neonatal seizures, but failed to 
decrease perinatal mortality, low Apgar scores or cerebral palsy. Instead there was 
a notable increase in caesarean sections.30 This was followed by a shift in focus 
towards very and extremely preterm birth due to their increasing perinatal survival, 
and alarming increasing proportions of infants with cerebral palsy. However, there 
has now also been an attempt to clarify other risk factors for cerebral palsy but no 
synthesis focusing on term infants. Risk factors identified broadly include: 
 Prior to conception: previous gynaecological history of stillbirth or neonatal 
death/multiple miscarriages/premature birth, family history of cerebral 
palsy, maternal intellectual impairment, epilepsy and low socio-economic 
status. 
 Antenatal: Placental abnormalities, birth defects, multiple births, male 
gender, maternal thyroid disorders, pregnancy complications including 
preeclampsia, bleeding after the first trimester, infection and inflammation 
and intrauterine growth restriction (IUGR).  
 Intrapartum and neonatal period: Sentinel birth events, meconium 
aspiration, stroke, seizures, jaundice, hypoglycaemia and infection. 
 Postneonatal period: Infections, accidental and non-accidental injuries, 
stroke both spontaneous and following surgical procedures. 
 
It is increasingly apparent that cerebral palsy can have many aetiologies, and that 
few consist of single sufficient causes but of causal pathways, or sequences of 
interdependent factors or events that culminate in the relevant brain anomaly. The 
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advantage of clarifying causal pathways is that a preventive strategy might be 
identifiable that can be implemented well before the final event that directly causes 
the brain damage.29  
 
With this paradigm, the research focus for aetiology now needs to shift again to 
identifying discrete (groups of) causal paths (instead of considering cerebral palsy as 
a single homogeneous group) and how their component risk factors interact.  
 
Currently, there are four primary preventive interventions shown to be effective in 
reducing the incidence of cerebral palsy arising from early pregnancy pathways. 
They are rubella vaccination, iodine supplementation in areas of severe deficiency, 
preventing methyl-mercury contamination and anti-D vaccination in cases of 
potential Rhesus iso-immunisation.29 These practices are now well-established in 
Australia, and other developed countries and therefore will not further reduce 
incidence. More recently, meta-analyses have identified two secondary preventive 
interventions that reduce the incidence of cerebral palsy. Antenatal magnesium 
sulphate for neuroprotection of infants born less than 30 weeks31 and therapeutic 
hypothermia for term born infants with moderate to severe hypoxic-ischaemic 
encephalopathy (HIE) or birth asphyxia.32, 33 It is expected that these interventions, 
now both supported by national clinical guidelines, will reduce proportions of 
cerebral palsy in the sub-groups that they target. It is currently estimated that 
therapeutic hypothermia (aimed at term born infants) may reduce birth prevalence 
of cerebral palsy by 3.5%. Much is left to do, both to prevent rare intrapartum 
events where possible34 maximise the effectiveness of therapeutic hypothermia35 
and to identify other discrete groups of causal pathways to cerebral palsy for term 
born infants. 
 
WHAT RESEARCH DO FAMILIES AND PEOPLE WITH CEREBRAL PALSY WANT? 
At the beginning of this doctoral program I set out to identify research priorities for 
cerebral palsy from the perspectives of consumers, researchers and clinicians. 
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Theoretical literature around consumer involvement necessitated that there should 
be no health professional involvement in the consumer survey, and for consumers 
to be legitimate equal partners. As a result three separate surveys were developed, 
one for consumers, one for intervention researchers and clinicians and one for 
aetiology researchers. Consumers voted over three rounds on 50 research 
questions that they had developed themselves. Twenty seven questions were 
ranked a low priority but they agreed that 23 research questions were a high or very 
high priority. The highest ranking research priority was “How can cerebral palsy be 
prevented?” The seventh ranking research priority was “What are the causes and 
causal pathways to cerebral palsy?”  
 
Genuine consumer involvement in research is increasingly viewed as ethically 
imperative. Thus, an important feature of this thesis is that it sits squarely within 
consumer generated research priorities for cerebral palsy and was instigated 
because of discussions with consumers while completing the CP Register 
registration with them. The full paper is now included and forms part of the 
background to the thesis.  
 
PAPER 1: CONSENSUS RESEARCH PRIORITIES FOR CEREBRAL PALSY: A DELPHI SURVEY OF 
CONSUMERS, RESEARCHERS AND CLINICIANS.   
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AIM Research funds for cerebral palsy are scarce and competition for them is
strong. This study aimed to identify questions for future research that were
agreed to be a high priority.
METHOD An expert panel of consumers, researchers, and clinicians was
assembled (n=127) and surveyed using a Delphi survey comprising three
rounds. In round I, participants identified three important research topics. Three
parallel surveys were constructed: (1) consumers; (2) intervention researchers
and clinicians; and (3) aetiology and prevention researchers. In rounds II and III,
participants rated priorities using a seven-point Likert scale. Questions reaching
consensus were itemized and those not reaching consensus were discarded.
RESULTS Consumers identified questions in the themes of prevention ⁄cure,
quality of life ⁄community participation, and service provision ⁄ intervention.
Intervention researchers ⁄clinicians identified questions in the themes of effective
outcomes and effective research ⁄services. Aetiology and prevention researchers
identified questions in the themes of infection ⁄ inflammation, focus on timing,
haematology, research tools, neuroregeneration, and genetics. Fifty per cent of
the consumers’ priorities were also identified by professionals.
INTERPRETATION Research priorities change as evidence is established. Phase II
of this project is to develop a web portal with international collaboration. As
evidence builds for one research question, it will be added to the web portal
and unanswered questions will become the priority.
Cerebral palsy (CP) is the most common physical
disability in childhood. Despite clinical and research
advances, its incidence remains stable.1 The condition is
lifelong with no known cure. There is a need for research
in aetiology, prevention, and effective intervention for
maximizing potential and optimizing quality of life.
No evidence exists of explicit published prioritization
for CP research that is itself developed through a scientific
process. Many individual research questions are identified
at the conclusion of studies. However, no published study
could be identified that provides guidance on the relative
importance and ranking of the questions or where best to
direct limited research funds to drive the field forward.2
The World Health Organization has identified that a
collaborative, widely consulted, systematic approach to
research priority setting is essential.3 Thus, establishing a
unified research agenda for CP and consensus on essential
and urgent research topics may provide the possibility of
accelerating breakthroughs.
Key stakeholder groups exist in CP with an interest
in a priority-driven research agenda. Consumers (people
with CP and their families) have the most vested inter-
ests in research, and must be included on an expert
panel for developing research agendas.4 Additional
groups include researchers ⁄clinicians who provide inter-
vention for people living with CP, those researching the
aetiology ⁄prevention of CP, and policy makers and
administrators ⁄ senior management of key organizations
(Table SI).
It is essential to involve as many legitimate stakehold-
ers as possible in the identification and prioritization of
research topics.3,5 Not only does this ensure the inter-
ests of all relevant people are considered, but it might
also increase ownership of the ensuing research and the
Correction added after online publication on
2 October 2009: 1) the citation of Table I on
page1 has been changed to Table SI; 2) Table I
has been moved to page 5.
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likelihood of the results influencing clinical practice and
policy.3 The more groups and individuals who are
involved, however, the greater the potential difficulty in
reaching consensus.6
The aim of this study was to identify research ques-
tions for CP by conducting a three-part Delphi survey.
The objectives of the study were as follows: (1) to
assess the extent to which a cohort of consumers,
intervention researchers ⁄ clinicians, and aetiology ⁄preven-
tion researchers could identify high-priority questions
for CP research; (2) to determine if consensus for the
priorities in CP research could be established by each
group; and (3) to identify the extent to which consum-
ers and professionals have similar consensus priorities
for research.
METHOD
Design
This study used the well-established Delphi survey, which
involves asking experts a recurring progression of
questions through a series of questionnaires.7–9 It is a way
of structuring a group communication between experts,
where individual participants give feedback that contrib-
utes to emerging consensus.10 Delphi surveys eliminate
potential sources of conflict experienced in committees
and panels9 because they are anonymous and they provide
the opportunity to revise individual views in response to
group trends.9
The Delphi method has been used to develop research
priorities in many areas of health including midwifery,
emergency and critical care nursing, and for general practi-
tioners. We selected it because it is known to be effective
when (1) consensus is sought in an area where none previ-
ously existed, (2) the research problem does not lend itself
to precise analytical approaches but can be illuminated by
subjective collective judgments, (3) the study participants
have diverse backgrounds in their experience and expertize
and therefore consensus cannot easily be reached, (4) more
research participants are needed than can effectively
interact face-to-face, and (5) frequent meetings of all par-
ticipants are not feasible.2 All these indictors were true
for CP, where input was sought from a wide variety of
disciplines across the world and from consumers. The con-
sensus-building nature of the Delphi technique combines
the rigor of traditional surveys and the collaborative effect
of focus groups.8
In this study a three-round survey strategy was used,
because additional rounds produce minimal change in
opinion.11 The overarching process is summarized in
Figure 1. The first step was systematically (literature
review) and subjectively (round I survey with open-
ended questions) to identify topic areas that were con-
sidered to be essential. All topic areas identified in both
the literature review and the round I survey were
included in round II. The second step involved testing
consensus using a quasi-experimental design, to verify
the topics agreed to be important. The third step was
to devise three lists of agreed priorities for CP research
and to identify themes from the perspectives of (1) con-
sumers, (2) intervention researchers ⁄clinicians, and (3)
aetiology ⁄prevention researchers.11 The final step was to
analyse links between the consumers’ and professionals’
themes and lists of agreed priorities.
Ethics
Approval for this study was granted by The Spastic
Centre of New South Wales Human Research Ethics
Committee (HREC EC00402), which is a recognized
committee of the National Health and Medical Research
Council, Australia.
Participants
A sampling frame consisting of 310 potential participants
was identified through purposive sampling.
(1) Consumers who had attended research information
sessions provided by the first author over the preceding
year, or who had made an enquiry to the research team,
were approached. This identified consumers who had a
high research interest, to maximize participation and mini-
mize drop out over the three surveys. Gross Motor Func-
tion Classification System (GMFCS) levels of adults with
CP who participated were not all available. Children of
parents who participated had GMFCS levels ranging from
I to V.
(2) Potential participants for the intervention survey
were identified as those who had multiple publications in
CP research or who were clinicians in positions of leader-
ship throughout Australia.
(3) Potential participants for the aetiology ⁄prevention
survey were identified as those who had multiple publica-
tions in CP aetiology ⁄prevention research.
Analysis
In the analysis of round I, identified research areas were
reviewed and developed into mutually exclusive research
questions.
Analysis of surveys in rounds II and III used descriptive
statistics. Median scores and interquartile ranges (IQRs)
were calculated for the groups’ responses to each question
because the seven-point Likert scale data was ordinal.9
Responses where the median was 6.00 (high priority) with
an IQR of 1.00 were considered important research ques-
tions that had reached consensus. This cut-off point was
chosen because more than 75% of the group rated the pri-
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ority as higher than 5.00 (fairly high priority). Final rank-
ings at the completion of round III were assigned using
mean scores.
Within this study, consensus was considered to have two
key elements, stability and convergence. Stability was the
consistency of responses across rounds II and III; conver-
Investigators conduct a comprehensive literature review to
(a) identify literature generated research questions; and (b)
identify experts to invite to participate
Round I surveys emailed/sent (and 1 reminder sent) to
identified experts requesting: (a) participation; (b)
demographic data; and (c) identification of 3 areas that need
to be researched for cerebral palsy.
Research problems identified and returned by participants.
Investigators review research problems submitted and
synthesize these into researchable questions. Questions
added to the literature generated questions (bar consumer
survey).
Round II survey emailed/sent. Includes all questions
proposed by participants and published literature. Participants
asked to rate the questions by priority using the 7-point scale.
1 = very low priority and 7 = very high priority
Median responses and inter-quartile ranges to round II
questions calculated. All questions with median of 6 or more
with an interquartile range of 1 or less were considered to
have reached high priority and placed on priority list.
Questions with consensus low and low median priority
discarded.
Round III survey emailed/sent. Included refined question list
with only questions that were a priority but had not yet
reached consensus. Participants asked to rate these non-
consensus questions using the same 7-point priority scale.
All questions that reached high priority consensus (median of
6 or more with an inter-quartile range of 1 or less) were placed
on final priority list. Questions with consenus low priority
discarded. Research priorities listed in rank order by mean
scores.
Consumers
n=50
invited
n=180
invited
n=80
invited
n=20 replied
38%
n=76 replied
42%
n=31 replied
39%
140
problems
became 50
questions
482
problems
became 74
questions
200
problems
became 166
questions
n=20 replied
100%
n=45 replied
60%
n=19 replied
61%
22 questions
high
consensus
16 questions
high
consensus
3 questions
high
consensus
n=19 replied
95%
n=32 replied
71%
n=18 replied
95%
Additional 1
question
high
consensus
Additional 7
questions
high
consensus
Additional 7
questions
high
consensus
23 questions
high
consensus
23 questions
high
consensus
10 questions
high
consensus*
Intervention Aetiology/
Prevention
* An extra 23 questions kept for aetiology that had
median of 6 and interquartile 1-2
Figure 1: Delphi survey process and analysis
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gence was the degree of agreement achieved reflected in
descriptive statistics.8
At completion of quantitative analysis, the agreed high
priorities were categorized into major and minor themes
for each of the three surveys. Finally, each question in the
consumer survey was compared and contrasted with each
question in both the intervention and aetiology ⁄prevention
surveys, to identify their level of ‘match’. Four categories
were developed: (1) close match – the chosen wording was
exact or almost exact; (2) similar intent – the content was
the same but worded differently; (3) similar focus, different
approach – general outcome identified as the same but a
different approach identified; (4) nothing similar found;
and (5) not applicable – not expected that this group would
identify this research question as a priority to them.
RESULTS
Round I
(1) Consumers. Of 50 surveys sent, 20 participants replied,
yielding an eligibility fraction for the study of 38%. All
participants were from New South Wales, Australia
(Table SI, supporting information published online).
(2) Intervention researchers ⁄ clinicians. Of 180 surveys
sent, 76 participants replied, yielding an eligibility fraction
for the study of 42%. The participants were from a diverse
range of medical and allied health backgrounds (Table SI).
Participants were from Australasia (n=68, 89.5%), North
America (n=4, 5.3%), and Europe (n=4, 5.3%).
(3) Aetiology ⁄prevention researchers. Of 80 surveys sent,
31 participants replied, yielding an eligibility fraction for
the study of 39%. The participants were from a diverse
range of professional backgrounds that commonly research
the aetiology of CP (Table SI, supporting information
published online). Participants were from Australasia
(n=17, 55%), North America (n=5, 16%), and Europe
(n=9, 29%).
The round I questionnaire asked participants to list three
problem areas associated with CP that might be addressed
by research. In parallel, the investigators conducted a litera-
ture review of research priorities in CP. For the interven-
tion and aetiology ⁄prevention surveys, the participants’
data on research topics was combined with research ques-
tions identified from literature. Eight hundred and twenty-
two research questions, topics, and ideas were generated.
Two investigators with expertize in CP research and con-
tent analysis reviewed each research question, topic, or idea
using the grounded theory approach. Through a process of
content analysis to the level of open coding, the items were
categorized into themes.12 Reliability was excellent, with
97% agreement for assignment to topic themes.8
This process allowed the initial 822 responses to be
reduced to 290 mutually exclusive research areas. The
topics were reworded into the format of research questions
for use in the round II surveys.2 The consumer survey
contained 50 items, all generated by consumers, with no
additional literature-based questions included. The inter-
vention survey contained 74 questions and the aetio-
logy ⁄prevention survey contained 166 questions (Fig. 1).
Round II
The round II questionnaire was sent to all participants in
round I. It was returned by 20 consumers, 45 intervention
researchers ⁄clinicians, and 19 aetiology ⁄prevention
researchers, yielding response rates of 100%, 60%, and
61% respectively. Participants rated the perceived priority
of each of the research questions using a seven-point Likert
scale (1, very low priority; 7, very high priority).
(1) Consumers. (a) Twenty-two research questions
reached a consensus high priority and these were added
immediately to the final priority list. (b) No questions
reached a consensus low priority and therefore none were
discarded. (c) Twenty-eight questions were overall rated
high (i.e. median greater than 5) but had not reached con-
sensus (i.e. IQR greater than 1).
(2) Intervention researchers ⁄ clinicians. (a) Sixteen
research questions reached a consensus high priority. (b)
Twenty-two questions reached a consensus low priority
and were discarded. (c) Thirty-six questions were rated
high overall.
(3) Aetiology ⁄prevention researchers. (a) Three research
questions reached a consensus high priority. (b) Seventy-
three questions reached a consensus low priority and were
discarded. (c) Ninety questions were rated high priority
overall (Fig. 1).
Round III
The round III questionnaire was sent to all round II partic-
ipants and returned by 19 consumers, 32 intervention
researchers ⁄clinicians, and 18 aetiology ⁄prevention
researchers, yielding response rates of 95%, 71%, and
95% respectively.
Round III only included items that were considered a
priority but had not yet reached consensus. The question-
naire also provided feedback on the round II group median
response for these research questions.2 This enabled
respondents to reflect on colleagues’ scores, as well as their
own, to help develop consensus.
(1) Consumers. One additional question reached con-
sensus high priority. The final list included 23 high-prior-
ity research questions. Questions were ranked in order of
mean scores, and categorized into three major themes: (a)
prevention and cure; (b) quality of life and community par-
ticipation; and (c) service provision and intervention, with
minor themes in each (Table I).
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Table I: High-priority questions for consumers and overlap with professionals
Research questions Median (IQR) Rank (mean)
Match
intervention
Match aetiology ⁄
prevention
Theme 1: prevention and cure
Aetiology
How can CP be prevented? 7.00 (1.00) 1 (5.98) n ⁄ a a
What are the causes of and casual
pathways to CP?
6.00 (1.00) 7 (5.80) n ⁄ a a
Neuroregeneration
What potential does the brain have
to repair injury?
6.00 (1.00) 3 (5.85) d a
Can stem cells have a therapeutic
effect for CP?
6.00 (1.00) 3 (5.85) d d
Theme 2: quality of life and community participation
Carers
What policies are needed to improve
quality of life for families caring
for Australianswith severe
disabilities?
7.00 (1.00) 8 (5.78) c n ⁄ a
Lifestyle
What factors have the greatest
impact on improving the lifestyle
and quality of life of individuals
with CP?
6.00 (1.00) 6 (5.83) b n ⁄ a
Employment
What are the barriers to
employment that exist for people
with CP?
6.00 (1.00) 14 (5.60) c n ⁄ a
How can people with CP be better
trained with the necessary skills
to enter the workforce?
6.00 (1.00) 16 (5.44) b n ⁄ a
Socioeconomics
What is the relationship between CP
and poverty?
6.00 (1.00) 21 (5.08) d n ⁄ a
Access
Can people with CP equitably
access the community?
6.00 (1.00) 22 (4.85) d n ⁄ a
Theme 3: service provision and intervention
Service models
What can be done to address the
mismatch between what service
parents and people with CP need
and what they actually receive?
7.00 (1.00) 12 (5.68) d n ⁄ a
What is the optimal intensity of
therapy programs?
6.00 (1.00) 9 (5.75) a n ⁄ a
What is the most efficient service
model so that maximal services
reach people with CP and their
families?
6.00 (1.00) 14 (5.60) d n ⁄ a
Effectiveness and outcomes
What are the optimal treatments for
CP?
6.00 (1.00) 2 (5.95) a b
What are the long-term outcomes
of treatments?
6.00 (1.00) 3 (5.85) a d
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(2) Intervention researchers ⁄clinicians. Seven additional
research questions reached consensus high priority. The
final list included 23 research questions. Questions were
ranked and categorized into two major themes: (a) effective
outcomes; and (b) effective research and services, with
minor themes in each (Table SII, supporting information
published online).
(3) Aetiology ⁄prevention researchers. Seven additional
research questions reached consensus high priority. The
final list included 10 research questions. Owing to the low
numbers of high-priority consensus questions, it was
decided to report on a further 23 questions that were
agreed to be a high priority but did not reach the consen-
sus definition of IQR=1 (Table SIII, supporting informa-
tion published online). Research questions on the priority
list were ranked and categorized into six major themes:
(a) infection and inflammation; (b) gestation; (c) haema-
tology; (d) neuroregeneration; (e) research tools; and
(f) genetics.
When comparing the consumer priority list with the
professionals’ priority lists there was nothing similar for 11
of 23 questions (48%), a similar focus but different
approach identified for 3 of 23 questions (13%), and a sim-
ilar intent or close match for 9 of 23 questions (39%).
DISCUSSION
All of the study’s objectives were answered by the findings.
The first objective was to assess the extent to which a
population of consumers, intervention researchers ⁄ clini-
cians, and aetiology ⁄prevention researchers could identify
high-priority areas of concern about CP research needs.
The results of this study demonstrate that each group
identified a wide range and large number of research
questions needing answers.
The second objective was to establish if consensus for
priorities in CP research could be established by each
group. Although 23 research questions were agreed as
high priorities for consumers and intervention research-
ers ⁄clinicians, a significantly lower number of questions
(n=10) reached consensus in the aetiology ⁄prevention
survey. This was not surprising given (1) there are mul-
tiple pathways to CP, (2) many specialties are needed to
Table I: Continued
Research questions Median (IQR) Rank (mean)
Match
intervention
Match aetiology ⁄
prevention
What is the effectiveness of
alternative therapies for the
treatment of CP?
6.00 (1.00) 11 (5.70) d n ⁄ a
What early intervention (dependent
on CP type) will prevent and
minimize structural impairments?
6.00 (1.00) 13 (5.67) c c
Does physiotherapy benefit people
with CP?
6.00 (1.00) 18 (5.25) d n ⁄ a
What are the most effective
methods of pain management so
the secondary complications can
be reduced?
6.00 (1.00) 19 (5.18) d n ⁄ a
What is the effectiveness of
hydrotherapy for people with CP?
6.00 (1.00) 23 (4.83) d n ⁄ a
Role of families in intervention
What are the most effective
methods of educating parents to
help improve their child’s
independence and function?
6.00 (1.00) 9 (5.75) d n ⁄ a
What is the impact of therapy type
and duration on parents of a child
with CP?
6.00 (1.00) 17 (5.38) d d
Is hands-on treatment by therapists
a more effective method than
guided therapy by parents?
6.00 (1.00) 20 (5.15) b n ⁄ a
aClose match; bsimilar intent; csimilar focus, different approach; dnothing similar; n ⁄ a, not applicable. IQR; Interquartile range.
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research each pathway, and (3) it is not expected that
any one pathway will be the dominant cause. We there-
fore believed it was valid and imperative to include all
aetiology ⁄prevention questions that were agreed to be a
high priority (n=33, IQR=2) but did not reach the con-
sensus definition of IQR=1.
The third objective was to identify the extent to which
consumers and combined professionals (intervention
researchers ⁄clinicians plus aetiology ⁄prevention research-
ers) have similar areas of concern and consensus priorities
for research. When comparing the responses of the two
groups, there was only one priority that overlapped: focus-
ing on the need for CP registers.When comparing the con-
sumers’ results with those of the combined professionals,
50% of the questions had overlap (Table I). There were
four areas identified by consumers that did not appear in
the results of either groups of professionals: the relationship
between CP and poverty, access in the community, effec-
tiveness of alternative therapies, and pain management.
There were several significant findings when analysing
the consumers’ results on their own and in comparison
with the professionals’ results. Consensus was reached for
22 of the 23 questions in round II, suggesting a high level
of stability between surveys for this group. The interven-
tion and aetiology ⁄prevention survey had a slightly lower
degree of stability. Convergence was also highest for con-
sumers as the range of scores for all questions was lowest
in this group. The aetiology ⁄prevention survey had several
questions with the full range of possible answers, suggest-
ing low convergence. Consumers ranked preventing CP as
their highest priority for research and were the only group
to identify exploring the therapeutic impact of stem cells.
This particular group of consumers provided a balanced
continuum of priorities, ranging from prevention to cure
and effective interventions across the lifespan.
No literature-based questions were used in the con-
sumer survey, to keep ideas purely as consumers’ points of
view. Yet, the only additional themes that appeared in the
intervention survey that did not appear in the consumer
survey were ‘measurement and methodologies’ and ‘rela-
tionships’ (Table SII). It was not expected that consumers
would consider the research tools required to answer their
questions. Relationships were ranked highly but did not
reach consensus, so were not reported in the final consum-
ers’ results.
Half of the consumer-generated questions were reflected
in the professionals’ priority questions. Important lessons
can be learnt from close examination of consumers’ priori-
ties that were not identified by professionals. Pain is an
important focus for consumers; so too is the effectiveness
of individual interventions including alternative therapies,
physiotherapy, and parent education. The efficiency and
effectiveness of service models, improving access, and
understanding the complex relationship between CP and
poverty were consensus high priorities. Consumers were
interested in policies at a societal level that may improve
their quality of life, whereas professionals were still focused
on health interventions aimed at improvements in families’
quality of life.
The potential limitations of this study are known weak-
nesses of the Delphi technique and include the subjective
process used for defining expert panellists for the sampling
frame, the representativeness of the panel assembled, and
the panellists’ ability to remain impartial in light of others’
views when rating items on multiple rounds. Policy makers
and administrators were included as participants, but not
analysed as separate groups, and ‘society at large’ was not
included at all. The Delphi technique is also limited by
whether the anonymous nature influences accountability
and response rates.2 The consumer survey was limited by a
small sample size. However, those who participated were
highly involved, and response rates were higher than the
other surveys. Small numbers also meant that multivariate
statistics could not be used to identify whether GMFCS
levels predict type of research questions seen as a high pri-
ority by consumers. Consensus, however, was highest for
consumers; this suggested that the consumers involved
considered the full range of disability in CP when prioritiz-
ing research.
The strengths of this study included acceptable response
rates for rounds II and III, ranging from 60 to 100%,13
and the sample being both multidisciplinary and inter-
national, so increasing the likelihood that the findings were
representative of those who research CP. The most impor-
tant strength of the study was that the consumers in this
study were equal members on the expert panel.
The process of documenting research priorities in CP
is critical to building the knowledge base for best-practice
intervention. These findings provide direction for future
CP research based on the consensus views of consumers
and internationally renowned researchers and clinicians.
The quest for answers to the research questions identified
by Delphi panellists is both urgent and imperative.2 It is
acknowledged that priorities for research change as evi-
dence builds to answer the questions. Phase II of this
project will be to develop a web portal. With inter-
national collaboration, outcomes of research will be
added to it, and unanswered questions will become the
next priorities.
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Additional supporting information may be found in the
online version of this article:
Table SI: Participants (one person in this profession
was predominantly working in policya or seniorb manage-
ment ⁄administration at the time of the study).
Table SII: High-priority questions for intervention
researchers and clinicians.
Table SIII: High-priority questions for aetiology ⁄
prevention researchers.
This material is available as part of the online article
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content or functionality of any supporting materials
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NB: The following tables referred to in the Delphi are available online  
Table  SI: Participants (one person in this profession was predominantly 
working in policy
a
 or senior
b
 management/administration at the time of the 
study) 
Consumers 
 Round I Round II Round III 
Adult with CP (GMFCS not 
available for all) 
n=5 n=5 n=5 
Parent of a child with CP 
(GMFCS I–V) 
n=15 n=15 n=14 
Total consumer sample n=20 (100%) n=20 (100%) n=19 (100%) 
Intervention researchers/clinicians 
Professions, n (%) Round I Round II Round III 
Allied health subtotal 64 (84) 36 (80) 29 (90) 
Occupational therapist
b
 28 (36.8) 18 (40.0) 13 (40.6) 
Physiotherapist
a,b
 15 (19.7) 6 (13.3) 5 (15.6) 
Speech pathologist 6 (7.9) 3 (6.7) 4 (12.5) 
Social worker
a,b
 4 (5.3) 4 (8.9) 3 (9.4) 
Psychologist 4 (5.3) 2 (4.4) 2 (6.3) 
Dietician 2 (2.6) 1 (2.2) 1 (3.1) 
Orthotist 2 (2.6) 1 (2.2) 1 (3.1) 
Biomechanist 2 (2.6)  0 (0.0)  0 (0.0) 
Registered nurse 1 (1.3) 1 (2.2)  0 (0.0) 
Medicine subtotal 12 (16) 9 (20) 3 (10) 
Paediatrician 3 (3.9) 3 (6.7) 2 (6.3) 
Rehabilitation specialist 3 (3.9) 2 (4.4) 1 (3.1) 
Orthopaedic surgeon 3 (3.9) 2 (4.4)  0 (0.0) 
Neurologist 1 (1.3) 1 (2.2)  0 (0.0) 
Hand surgeon 1 (1.3) 1 (2.2)  0 (0.0) 
Neonatologist 1 (1.3)  0 (0.0)  0 (0.0) 
Total intervention sample 76 (100) 45 (100) 32 (100) 
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GMFCS, Gross Motor Function Classification System.
Aetiology/prevention researchers 
Professions Round I Round II Round III 
Medicine subtotal 16 (52) 9 (49) 9 (50) 
Paediatrician
a
 4 (13) 2 (11) 2 (11) 
Paediatric neurologist 5 (16) 3 (16) 3 (17) 
Obstetrician 3 (10) 2 (11) 2 (11) 
Neonatologist 4 (13) 2 (11) 2 (11) 
Other subtotal 14 (48) 10 (51) 9 (50) 
Epidemiologist
a,b
 5 (16) 4 (21) 4 (22) 
Scientist (various 
specialties) 
7 (23) 4 (21) 3 (17) 
Registered nurse 1 (3) 1 (5) 1 (5) 
Allied health
b
 1 (3) 1 (5) 1 (5) 
Total aetiology/prevention 
sample 
31 (100) 19 (100) 18 (100) 
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Table SII: High-priority questions for intervention researchers and clinicians 
Research questions Median 
(IQR) 
Rank 
(mean) 
Theme 1: effective outcomes 
Function and participation 
What are the most effective interventions for improving 
participation and quality of life? 
6.00 (1.00) 1 (6.30) 
What interventions deliver the biggest functional gains? 6.00 (1.00) 2 (6.21) 
Relationships 
What strategies assist people with CP to develop friendships 
and relationships? 
6.00 (1.00) 3 (6.14) 
Long-term outcomes 
What interventions produce the best long-term outcomes? 6.50 (0.50) 4 (6.12) 
What are the most effective equipment and devices for 
improving independence and quality of life long-term? 
6.00 (1.00) 9 (5.70) 
What is the long-term safety and impact on function, 
participation, and quality of life of medical interventions that 
reduce spasticity? 
6.00 (1.00) 10 (5.60) 
Coping 
What family support strategies best reduce family stress and 
promote coping? 
6.00 (1.00) 5 (6.10) 
What interventions promote self-esteem? 6.00 (1.00) 8 (5.72) 
Employment 
What service factors improve the likelihood of people with CP 
gaining employment? 
6.00 (1.00) 11 (5.54) 
Prevention of deformity 
What are the safest and most effective surgical interventions to 
improve skeletal alignment and function? 
6.00 (1.00) 14 (5.52) 
What is the effectiveness of orthoses for improving function 
and preventing secondary deformity? 
6.00 (1.00) 17 (5.50) 
What is the most effective way to prevent hip dislocation? 6.00 (1.00) 18 (5.48) 
What are the best ways to prevent the secondary impairments 
and injuries? 
6.00 (1.00) 22 (5.43) 
Physical potential 
What is the best way to maximize mobility? 6.00 (1.00) 15 (5.52) 
What physical activity programs best improve function and 
fitness? 
5.00 (0.00) 23 (5.26) 
Theme 2: effective research and services 
Service models 
What is the optimal intensity of therapy programmes? 6.00 (1.00) 6 (5.81) 
What models of service, policies, and education programs best 
support transitions from paediatric to adult services? 
6.00 (1.00) 7 (5.78) 
What are the differences in outcomes, when services are 
provided by allied health versus parents versus community 
volunteers? 
6.00 (1.00) 12 (5.54) 
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What affects client satisfaction and service uptake? 6.00 (1.00) 16 (5.52) 
Measurement and methodologies 
What is the best research method to evaluate the relative 
contributions of the therapies, orthoses, and medical 
interventions? 
6.00 (1.00) 13 (5.53) 
What instruments measure the effectiveness of CP intervention 
and what is the sensitivity of these measures? 
6.00 (1.00) 19 (5.45) 
What are the most efficient ways to establish and maintain CP 
registers to facilitate research? 
6.00 (1.00) 20 (5.45) 
What are the most appropriate outcome measures for assessing 
function in the community? 
6.00 (1.00) 21 (5.44) 
IQR; interquartile range.
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Table SIII: High-priority questions for aetiology/prevention researchers 
Research questions Median 
(IQR) 
Rank 
(mean) 
Theme 1: infection and inflammation 
What is the association between altered fetal inflammatory 
response in CP mothers and infants and CP? 
6.00 (0.50) 8 (5.7) 
Are cytokines markers of infection or ischemia? 6.00 (1.00) 3  (5.9) 
What are the infectious agents involved in pregnancy that are 
strongly linked to CP? 
6.00 (1.00) 8 (5.7) 
Does earlier recognition of maternal infection lead to reduced 
incidence of hypoxic–ischemic encephalopathy? 
6.00 (1.00) 17 (5.6) 
Does cytokine elevation correlate with severity of injury? 6.00 (1.00) 24 (5.4) 
What are the molecular and cellular mechanisms that explain the 
epidemiologically observed association between chorioamnioitis 
and greater risk of CP?  
6.00 (1.50) 8 (5.7) 
How can TORCH infections be reduced? 6.00 (1.50) 32 (5.2) 
How can chorioamnionitis in pregnancy be identified, treated, and 
prevented? Who is most at risk? 
6.00 (2.00) 3 (5.9) 
Does intrauterine infection and fetal inflammatory response affect 
the fetal brain? 
6.00 (2.00) 5 (5.8) 
Do viral and bacterial exposure/infection interact with genetic 
factors or known major risk factors (intrauterine growth 
restriction, prematurity, multiple birth, antepartum haemorrhage) 
on a pathway to CP? 
6.00 (2.00) 8 (5.7) 
What are cytokines roles in brain development, pregnancy, and 
inflammatory homeostasis? 
6.00 (2.00) 8 (5.7) 
Theme 2: focus on timing: preterm, term, postnatal 
Do pathways to preterm birth differ in the ways they predispose to 
brain injury? 
6.00 (1.00) 17 (5.6) 
To what extent can CP be prevented in developing countries 
through the improved management of childhood illness? 
6.00 (1.00) 31 (5.3) 
What are the predictors and risk factors of CP in term infants (from 
socioeconomic to neonatal health)? 
6.00 (1.30) 24 (5.4) 
How can severe encephalopathy be reduced to moderate and 
moderate be reduced to mild? 
6.00 (1.30) 24 (5.4) 
Is both infection and acidosis required in term infants to cause CP? 6.00 (1.50) 24 (5.4) 
What are the most effective public health initiatives to reduce post 
natal CP? 
6.00 (2.00) 2 (6.0) 
What therapeutic drugs reduce the severity, if not stop the 
destruction of, oligodendrocytes in Panton–Valentine leukocidin? 
6.00 (2.00) 5 (5.8) 
What are the causes of neonatal encepahalopathy? 6.00 (2.00) 8 (5.7) 
Theme 3: haematology 
How do disorders of coagulation (fetal and maternal) affect the 
fetal brain? 
6.00 (0.75) 8 (5.7) 
What postnatal medication best reduces risk of severe 6.00 (1.70) 33 (5.1) 
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intraventricular haemorrhage? 
What are the underlying mechanisms of prenatal 
hypoxia/inflammation that result in brain damage? 
6.00 (2.00) 1 (6.1) 
How can perinatal stroke be prevented? 6.00 (2.00) 5 (5.8) 
Theme 4: research tools 
Do we have the tools (registers) to identify if we start to prevent 
CP? How can we best combine databases to increase accurate 
surveillance? 
6.00 (1.00) 17 (5.6) 
Can a gold standard classification system of CP based on 
underlying pathology be developed and agreed on? 
6.00 (1.30) 24 (5.4) 
How can the timing of lesions be most accurately identified?  6.00 (1.5) 24 (5.4) 
What strategy can be used to drive forward aetiological research by 
combining epidemiology with genetics, basic science, and other 
disciplines to identify causal pathways? 
6.00 (2.00) 8 (5.7) 
Theme 5: neuroregeneration 
Do neuroprotective interventions change severity and functional 
outcomes? 
6.00 (1.00) 24 (5.4) 
What are the mechanisms of neuroregeneration? 6.00 (1.3) 17 (5.6) 
How can we maximize neurodevelopmental outcome for babies 
born with perinatal hypoxic–ischemic injury secondary to 
intrapartum asphyxia?  
6.00 (1.5) 17 (5.6) 
Theme 6: genetics 
What are the maternal and fetal immune, clotting, and immune 
response genetic factors predisposing to CP? 
6.00 (1.5) 22 (5.5) 
Do genetic factors play a role in neonatal encephalopathy? 6.00 (1.5) 22 (5.5) 
What role do thrombophilic risk factors have in the pathogenesis of 
CP? 
6.00 (2.00) 8 (5.7) 
IQR; interquartile range. 
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PURPOSE OF THE STUDY 
This doctoral program is an investigation of the aetiology of cerebral palsy in term 
and near-term singletons. As discussed already in this chapter: 
 consumers have prioritised this type of cerebral palsy research  
 term and near-term singletons are the largest group of cerebral palsy  
a. their birth prevalence has not declined 
b. they have the most severe motor and associated impairments 
c. it is suggested that the proportion with severe outcomes is 
increasing  
d. their aetiology has been under-researched 
The overall aim is to contribute to identifying discrete groups of causal pathways to 
cerebral palsy for singletons born at or near-term by:  
 identifying aetiologically more homogeneous groups of cerebral palsy  
 identifying new associations within aetiologically more homogeneous groups  
 testing existing hypotheses in a total population of cerebral palsy 
 developing new hypotheses for further research in this area 
The following hypotheses and research questions will be addressed throughout the 
thesis. 
 
HYPOTHESES AND RESEARCH QUESTIONS 
HYPOTHESIS 1 AND RESEARCH QUESTIONS 
Risk factors for cerebral palsy in term infants exist. They will be of differing 
strengths and can be categorised as preconceptional, antenatal, intrapartum and 
immediate postpartum/neonatal. 
 What risk factors for cerebral palsy have been identified in the literature for 
infants born at term? 
 Has their preventive potential been adequately explored? 
Method: A systematic review of risk factors  
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 Are the risk factors identified in the literature the same as those in our total 
population case control study? 
Method: Conditional logistic regression analysis from Term-CCCP of risk factors 
followed by a qualitative comparison with systematic review findings. 
 
HYPOTHESES 2 AND RESEARCH QUESTIONS 
Neonatal neurological status will define aetiologically more homogeneous groups of 
cerebral palsy and perinatal death. 
Major risk factors (sentinel events, intrapartum inflammation, intrauterine growth 
restriction and birth defects) are on specific causal pathways to both cerebral palsy 
and perinatal death. 
 How do major risk factors distribute between groups with different neonatal 
neurological status?  
 Do combinations of major risk factors exist and do they define distinct 
(groups of) pathways? 
 Are these major risk factors associated with specific subtypes of cerebral 
palsy? 
 Does simultaneously investigating pathways to perinatal death improve our  
understanding of pathways to cerebral palsy? 
Method: Unconditional Logistic regression and population attributable fractions 
(calculated from Term-CCCP) of risk factors within neonatal neurological status 
groups.  
 
HYPOTHESIS 3 AND RESEARCH QUESTIONS 
Those that have cerebral palsy preceded by hypoxic-ischaemic encephalopathy 
(HIE+CP) will have a range of antecedents of which a sentinel event is only one. 
 What proportion of HIE+CP have sentinel events? What types of sentinel 
events are seen in these infants? 
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 What proportion of HIE+CP are growth restricted? What type of growth 
restriction is seen in these infants? 
 What proportion of HIE+CP have birth defects? What birth defects are seen 
in these infants? 
 What proportion of birth defects recognised by the age of six years was also 
recognised in the newborn period?  
Method: Descriptive statistics, and multivariate unconditional logistic regression for 
HIE+CP of risk factors calculated from Term-CCCP. 
 
HYPOTHESIS 4 AND RESEARCH QUESTIONS 
Those that have evidence suggesting that a hypoxic-ischaemic injury occurred 
during the intrapartum period, will also have other risk factors that may contribute 
to their pathway to cerebral palsy. 
 What proportion of cerebral palsy can be attributed to acute intrapartum 
hypoxia?  
 Do other aetiological risk factors exist on pathways that include acute 
intrapartum hypoxia? 
Method: Unconditional logistic regression and descriptive analysis of each case in 
the Term-CCCP with moderate to severe neonatal encephalopathy, cerebral palsy 
type either spastic quadriplegia or dyskinesia and either a sentinel event and/or 
newborn acidaemia. 
 
HYPOTHESIS 5 AND RESEARCH QUESTIONS 
In singleton term infants with cerebral palsy without newborn encephalopathy (or 
admission to NICU as a newborn) there will be some subtle neurobehavioral 
predictors. These predictors will be associated with a subtype of cerebral palsy. 
 What proportion of children with cerebral palsy was born at term and 
received only routine postnatal care? 
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 Do distributions of motor type, topographical patterns, and severity differ 
between those term-born children with cerebral palsy who had been 
admitted for special care compared to those not admitted for special care?  
 Do neonatal predictors for cerebral palsy exist for term infants receiving only 
routine postnatal care? 
Method: Descriptive statistics and multivariate unconditional logistic regression 
from the Term-CCCP. 
 
THESIS OUTLINE 
Figure 3 is a concept map of this thesis. Chapter 1 introduces the problem and 
outlines the thesis. Chapters 2 and 3 describe the methodology of the total 
population case control study (CCCP), data preparation for the Term-CCCP and 
linkage to the birth defects register for acquisition of more complete information 
concerning birth defects. Chapters 4 and 5 identify major risk factors for term 
cerebral palsy that will be used throughout the thesis (Hypothesis 1). The remaining 
chapters use aetiologically more homogeneous groups from the Term-CCCP that 
were obtained by stratifying both cerebral palsy and neonatal death on newborn 
neurological status: no encephalopathy (no NE), neonatal encephalopathy (NE) and 
neonatal encephalopathy considered to be hypoxic ischemic in origin (HIE) . Chapter 
6 focuses on four major risk factors and their pathways to intrapartum stillbirth, 
cerebral palsy or neonatal death following no NE, NE or HIE (Hypothesis 2). Chapter 
7 specifically focuses on these major risk factors and cerebral palsy following HIE 
(Hypothesis 3). Chapter 8 investigates the possibility that the most homogeneous 
outcome group HIE+CP due to intrapartum hypoxia (presumed to be the sufficient 
cause) may be associated with additional antenatal factors (Hypothesis 4). Chapter 
9 explores predictors (Hypothesis 5) and risk factors for cerebral palsy following 
routine postnatal care (those least at risk), and suggests a means of achieving an 
earlier description of cerebral palsy for these infants. Chapter 10 completes the 
thesis by drawing conclusions, summarising the major findings and highlighting 
implications for further research. 
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Figure 3: Concept map of the thesis 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
SIGNIFICANCE OF THIS STUDY 
This study is the largest case-control study of cerebral palsy in term and near-term 
births in the world. Infants born at term contribute the majority of cerebral palsy, 
their cerebral palsy tends to be more disabling and its prevalence is not declining, 
yet apart from interventions for birth asphyxia, they have been the subject of little 
aetiological research. This study has the potential to generate further research 
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hypotheses and draw more attention to this group, to test established research 
hypotheses and contribute to a greater understanding of causal pathways to 
cerebral palsy in term infants.  
 
SYNOPSIS OF CHAPTER 1 
This chapter provided the background upon which this doctoral program is based. 
This was accomplished by describing the observations leading to the research, the 
consumer involvement in its development, presenting the purpose, hypotheses and 
research questions that will be answered. The following chapter presents a detailed 
discussion of the methods of the overarching study, the CCCP. 
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CHAPTER 2  
METHODOLOGY OF THE CASE-CONTROL 
STUDY  
INTRODUCTION 
Chapter 2 describes the methods of the overarching study, the Case-Control Studies 
of Cerebral Palsy and Perinatal Death in Term and Preterm Infants in Western 
Australia, 1980-1995 (CCCP). The data collection for this study was nearing 
completion when I commenced my PhD candidature, so I was not involved in the 
original design or data collection of the CCCP. I provide this discussion of the CCCP 
design for the following reasons: 
1) Methods sections of the papers that form the results section of this thesis 
have to be short to comply with word counts for journals. This chapter gives 
me the opportunity to expand on these sections. 
2) Although I wasn’t involved in the design of this overarching study I have 
studied it at length to obtain the skills to design and initiate further studies. 
3) Critical examination of the CCCP enables a realistic assessment of 
trustworthiness of results obtained (in the ensuing chapters).  
 
STUDY BACKGROUND AND AIMS OF THE CCCP 
The CCCP was designed and developed by Professors Eve Blair, Fiona Stanley, Jenny 
Kurinczuk, Beverley Petterson and Paul Burton in 1995. At this time, CP Registers 
around the world were all showing sharp increases in prevalence of cerebral palsy 
in those born below 32 weeks gestation, coinciding with reductions in neonatal 
mortality. There was limited knowledge of the aetiology of cerebral palsy for these 
babies and there were a number of new treatments available for use in the 
Neonatal Intensive Care Unit (NICU) that had been proven effective in reducing 
respiratory distress syndrome, and were partly responsible for reductions in 
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mortality. For term births, the previous case-control study of spastic cerebral palsy36 
had confirmed a result from the National Collaborative Perinatal Project (NCPP) that 
birth asphyxia was less important than previously thought,8 but obstetric litigation 
was increasing in cases where cerebral palsy was the outcome. Finally there was an 
increasing proportion of  multiple births across the developed world, and the risk of 
cerebral palsy had been confirmed to increase for each additional fetus in a 
pregnancy.37 This increase in multiple births was occurring at the same time as a 
rapidly increasing use of in-vitro fertilisation and a tendency to later child bearing. 
This climate dictated the two general aims of the CCCP: 1) To identify causal 
pathways to cerebral palsy in both term and preterm infants and 2) To evaluate the 
effect of current perinatal practices such as the use of antenatal steroids in preterm 
labour for lung maturation, magnesium sulphate as a tocolytic and for 
preeclampsia, and neonatal surfactant also for lung maturation to prevent 
respiratory distress syndrome, on rates of cerebral palsy and neonatal mortality.    
 
RESEARCH DESIGN   
The CCCP is a total population Case Control study of Cerebral palsy and Perinatal 
death based in Western Australia.  
 
Total population studies are indispensable for providing unbiased estimates of 
prevalence and indicating the relative contributions to outcome of a range of risk 
factors. It has repeatedly been shown that total population studies provide 
relatively robust and repeatable observations, while clinic-based samples asking the 
same question get widely varying answers.38 Just as the randomized clinical trial is 
the gold standard for evaluating medical interventions, the population study is the 
gold standard for studying the natural history of human disease.  
 
The alternative design to a case control study is the prospective cohort study. 
However, prospective studies of uncommon outcomes necessarily require 
extremely large sample sizes with corresponding expenditures. This was best seen 
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when the National Collaborative Perinatal Project (NCPP) followed over 50,000 
women prospectively through their pregnancy and until their child was seven years 
old. Because cerebral palsy is a relatively rare outcome that study included only 189 
cases at the completion of follow up.39 The CCCP commenced with four times as 
many cases, giving much more statistical power and making the retrospective case 
control study an economically more feasible alternative. The trade-off for the large 
numbers of cases possible in retrospective population studies is the lack of 
meticulously detailed data possible in relatively small clinical cohorts or studies of 
animal models in which the data to be collected is specified in the research 
protocol. Instead, case-control studies that are population based but prospective in 
their data collection can be seen as a window into what occurs in “real life”, rather 
than under “research conditions”. In this era where translation and uptake of 
evidence into practice is high on the agenda, this aspect of case-control studies may 
add extra importance to this design. No one design answers all questions and only 
the convergence of information from a variety of study designs can provide the 
complete picture of a clinical entity.  
 
A total population case control study is an appropriate design for developing 
hypotheses (exploratory) and testing hypotheses (analytic) of the aetiology of 
cerebral palsy.  The CCCP had both aims as so little was (and still is) understood 
about the full causal pathways to cerebral palsy. Case-control studies can be 
completed more quickly if there is a lag time associated with identification of cases. 
This is the case for cerebral palsy, as it takes five years from birth to identify and 
confirm a complete cohort for each birth year. For example, in the birth year 1995 
the last cases would not be identified and confirmed until the year 2000.  
 
ETHICAL APPROVAL 
To ensure that the CCCP was a total population case control study, ethical approval 
was sought and obtained for a waiver of consent from all subjects involved, 
provided no subject was contacted by the study investigators. Consequently, ethical 
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approval was required from the Western Australian Department of Health 
Confidentiality of Health Information Committee (CHIC), Princess Margaret Hospital 
(PMH) and each area health service throughout Western Australia. This was an 
extremely difficult process and contributed to a slower than originally expected 
completion, as each individual hospital within the health service required 
reassurance that confidentiality of their patients’ information would be maintained.  
 
Confidentiality was ensured by allocating a unique identifier to each study subject:  
on the completion of data collection for that subject (when the medical files at each 
relevant location pertaining to that subject had been perused), names and address 
were removed from the paper file (before electronic data entry) and securely stored 
with only the unique identifier in an off-site location. This precaution was taken 
against the possibility of a future requirement for identification which would 
require further ethics approval. This did occur in 2012, when ethical approval was 
obtained for linkage to the birth defects register in Western Australia. The original 
data forms (with names or addresses removed) were then stored in a locked 
cabinet (with key access only available through the Chief Investigator (EB)), in a 
locked office, within a secure wing of a secure research building – Telethon Institute 
for Child Health Research, Perth, Western Australia. 
 
DEFINING THE SOURCE POPULATION 
All births in Western Australia from the years 1980-1995 comprise the sampling 
frame from which cases, controls and perinatal deaths were selected (Figure 4).   
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Figure 4 Sampling frame for CCCP 
 
CASE SELECTION FOR CCCP 
Cerebral palsy cases were ascertained through the WARDA-CP. This register 
identifies cases using multiple ascertainment strategies, based on an active 
surveillance principle. The WARDA-CP has many strengths; it has been collecting 
information and identifying cases in the same way since it’s commencement in 
1977, with births dating back to 1956. This continuity of case ascertainment ensures 
that fluctuations in results obtained are not due to methodological changes. Cases 
are notified to WARDA-CP by health professionals from the following: Preterm 
follow up studies, metropolitan and regional hospital physiotherapy departments, 
private neurologists and paediatricians, The Centre for Cerebral Palsy, rural 
paediatric service, Disability Services Commission, Regional Child Health and 
Development Centres, State Child Development Centre, and interstate 
paediatricians who identify those that were born in WA but moved before their 
cerebral palsy was recognised. Health department hospital morbidity data is also 
reviewed regularly. Consent has never been required for registration which is now a 
statutory requirement. Combined with the multiple sources and strategies that are 
used in ascertaining cases of cerebral palsy, this minimises the potential for 
ascertainment bias in the CCCP that sometimes exists in case-control studies. In 
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addition, meetings of register staff with clinicians contributing to the register are 
held regularly to increase reliability of classifying case description. 
 
Cases are followed by staff at the register until they are five years of age. By this age 
the great majority of motor disorders that are either progressive or that have been 
resolved (and therefore do not meet the criteria for cerebral palsy) will have been 
recognised and can be excluded from registration. Thus, all cases in the CCCP have 
had their description of cerebral palsy confirmed at or around their fifth birthday.  
 
Cases comprised all singleton and multiple births that were registered with WARDA-
CP with a confirmed description of cerebral palsy at or around age five excluding 
those with: a confirmed postneonatal cause, minimal impairment or whose medical 
record could not be located a the hospital of birth. It therefore considers a total 
population of children with cerebral palsy meeting these criteria and 
misclassification is highly unlikely due to the rigour of the register when accepting 
and confirming a case.   
 
CONTROL SELECTION 
Control selection was conducted by an independent co-ordinator who had access 
only to the matching variables (date of birth, gestation of birth, multiplicity of the 
pregnancy), hospital of delivery and outcome at first hospital discharge. Controls 
were selected from neonatal survivors on the Maternal and Child Health Research 
Database (MCHRD) who were not registered as having cerebral palsy. The MCHRD 
links with the birth and death registries of Western Australia and holds additional 
pregnancy and delivery information on >99.5% of registered births in Western 
Australia.  
 
Each case was individually matched to a control for date of birth (within one year), 
gestational age (within one week) and plurality. If multiple matches for a case were 
identified one was selected at random. The data collectors reported to the study co-
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ordinator if a selected subject’s medical records could not be located at the birth 
hospital. If the missing records pertained to a control, the co-ordinator added 
another suitable match to the list of records to be reviewed, thus maintaining 
blinding of data collectors. 
 
INTRAPARTUM STILLBIRTH AND NEONATAL DEATH COMPARISON GROUP SELECTION 
A representative selection of intrapartum stillbirths and neonatal deaths, not the 
result of lethal birth defects or terminations of pregnancy, were identified from the 
MCHRD as an additional comparison group. They were not matched to cases as the 
controls were. In order to obtain representative samples with a similar total number 
as the control group, all eligible intrapartum stillbirths delivered in 1985, 87, 89, 91, 
93 and 95 and all neonatal deaths in 1985, 87, 91 and 95 were selected. This 
sampling frame ensured representativeness by selecting all eligible deaths within 
calendar years, though the earliest years were excluded as the quality of medical 
recording improved with time. It was not of course possible to blind data extractors 
to perinatal death outcomes as these were evident in the medical record and they 
were also required to collect post mortem information.  
 
MINIMISING OTHER WELL KNOWN CASE CONTROL BIASES 
Since the medical records were created prospectively both recall and assessment 
biases were not applicable. No subject was questioned regarding exposures or for 
additional information and no one was assessed purely for the purposes of this 
study. However, studies such as the CCCP that rely purely on medical records are 
open to bias as the recording of information tends to be selective rather than 
comprehensive in routine medical care. Outcome bias was minimised as data 
abstractors were trained research nurses blind to case/control status when 
collecting data from medical records of hospitals of birth, any additional 
transferring or receiving hospitals, general practitioners and obstetricians identified 
in medical records as associated with pregnancy, delivery or neonatal care.  
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MINIMISING CONFOUNDING – MATCHING  
The CCCP attempted to minimise confounding by matching cases with live controls 
on gestational age (within one week), plurality and year of birth (within the same 
birth year). Both multiple pregnancy and low gestational age are well identified risk 
factor for cerebral palsy and other poor outcomes. The risk of poor outcomes 
increases as gestational age decreases and the existence of and response to many 
exposures differs dependent on gestational age. Similarly the risk of cerebral palsy 
increases as multiplicity of a pregnancy increases as they are exposed to factors that 
cannot occur in a singleton pregnancy. Therefore it would not be appropriate to 
compare exposures between singletons and multiple births or between groups with 
significantly different gestational age profiles.  
 
Year of birth was chosen as an important matching variable because neonatal 
intensive care practices anticipated to affect the risk of cerebral palsy were 
changing rapidly. However as indicated by the variations in proportions of birth with 
cerebral palsy over this period, matching on year of birth was important primarily 
for very and extremely preterm births.  
 
ASSESSING BIAS 
In the systematic review in chapter 4, I assessed the risk for bias in each study and 
excluded those which had an unacceptably high risk of bias. I have completed that 
same assessment for the CCCP, which demonstrates that this study has low risk for 
bias.  
Infant selection – Adequate; Assessment of cerebral palsy – Adequate; Assessment 
of risk factors – Adequate; Assessor blinding – Adequate; Follow up time – 
Adequate; Control for confounding – Adequate; Number of observations – 
Adequate; Report dose response – Adequate. 
 
 
 Page | 39  
 
SYNOPSIS OF CHAPTER 2 
This chapter has shown that the CCCP is a total population case control study which 
has minimised ascertainment and selection bias by: using a well established 
cerebral palsy register for selection of all cases minimising misclassification, not 
requiring consent thereby limiting non-response, and eliminating potential recall 
bias. Blinding of study staff at each possible point was instigated, but errors in 
exposure rates recorded may have occurred because of a reliance on medical 
records. Overall the CCCP is a very high quality case-control study with potential 
biases limited where-ever possible. The following chapter describes methods used 
specifically for the Term-CCCP. 
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CHAPTER 3 
DATA PREPARATION  
INTRODUCTION 
Chapter 3 describes the development of hypotheses and preparation of data 
pertaining to term and near-term births that were used in the analyses reported in 
this thesis.  
 
ETHICAL APPROVAL 
As discussed in Chapter 2, ethical clearance had been granted for the CCCP by 
multiple separate ethics committees in Western Australia. Additional ethical 
clearances obtained in order to conduct the analyses described in this thesis 
consisted of: 
1. Applying and receiving approval from CHIC and PMH for myself and 
supervisor Nadia Badawi to be included as investigators on the CCCP 
(Appendix B). 
2. Applying (Appendix C and D) and receiving (Appendix E) approval from the 
University of Sydney for ratification of the project.  
3. Applying and receiving ethical approval (Appendix F) for data from the 
Western Australian Department of Health. These data consisted of 
information about any birth defects recognised by six years of age in CCCP 
subjects as registered on WARDA. This was necessary as only a proportion of 
all birth defects are identified by the end of the newborn hospital admission, 
thus CCCP data concerning birth defects (collected from obstetric and 
neonatal records) was (correctly) assumed to be incomplete. 
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RESEARCH DESIGN – ANALYSIS OF TERM AND NEAR-TERM DATA  
DEVELOPING HYPOTHESES 
The research questions for this thesis were developed following a number of 
intersecting strategies: 
 
As Research Fellow to the newly initiated NSW cerebral palsy register (NSW-CPR) I 
had many discussions with parents when registering their children with cerebral 
palsy on the NSW-CPR. Registration entailed enquiry as to presumed aetiology of 
their child’s cerebral palsy. Very quickly a pattern emerged with the majority of 
children being born at term without a catastrophic birth event. No papers that I 
could identify focussed on term infants without encephalopathy in the newborn 
period. The majority were primarily concerned with encephalopathic infants with 
seizures, particularly following catastrophic birth events. It became clear that 
investigating cerebral palsy aetiology in infants with no obvious neonatal signs 
would be almost impossible prospectively because following 1000 mother and child 
pairs for five years would identify just one child with cerebral palsy.  In these infants 
the earliest predictors were delayed developmental milestones, followed by a “wait 
and see” approach on the part of medical caregivers with the description of 
cerebral palsy given any time between six months and five years of age. Using CCCP 
data was my best chance of answering questions pertaining to this group.  
 
During one week in Perth at the beginning of my candidature my supervisors (NB 
and EB) and I submitted an ethics application to allow a copy of the Term-CCCP data 
to be taken to NSW, explored the variables in the data set and identified gaps in the 
literature that might be answered with this data set. These discussions continued 
throughout the candidature and later included KBN and JK for their neurologic and 
obstetric expertise. The final hypotheses and research questions that were 
answered for this thesis are listed in Chapter1. 
 
 Page | 42  
 
I conducted a systematic review of the literature for risk factors for cerebral palsy in 
term born infants (Chapter 4) to focus these efforts.  
 
SAMPLE SIZE  
When exploratory studies are undertaken it is always better to have a larger sample 
size. This study represents a “sample” of all cerebral palsy in that,“all cerebral palsy 
cases” in the CCCP were limited to Western Australian births in the years 1980-1995 
inclusive. 1980 was chosen as the start of the cohort for a practical reason; this was 
when gestational age was first systematically recorded in the Maternal and Child 
Health Database. Gestational age is a key variable for cerebral palsy, and was a 
matching variable. The final year of ascertainment was chosen as birth year 1995 as 
full ascertainment for this birth year would not be completed until the end of the 
year 2000, which was when the data collection commenced. For this thesis, the 
Term-CCCP (singletons born after at least 35 weeks gestation) included 508 
controls, 494 cases and 173 perinatal deaths. 
 
The power of any specific analysis depends on the true prevalence of the exposure 
among the controls and the true odds ratio being estimated. With these numbers it 
was estimated that there was >=80% power at p<0.05 to detect associations likely 
to be of clinical importance (odds ratios <0.4 or >1.8), if the exposure was observed 
in 5-50% of controls. It was acknowledged that power would decrease as each 
outcome was further sub-divided for more aetiologically homogeneous outcome 
groups, but anticipated that this would be balanced by an increase in the true odds 
ratio in groups where the causal association lay.   
 
OBTAINING AND UNDERSTANDING THE DATA SET 
On receipt of the multiple encrypted csv. (character separated values) files, I 
uploaded them into a single SPSS (Statistics Package for the Social Sciences Version 
19) data file after decryption. Once the data was in SPSS format, to familiarise 
myself with each of the variables I added data labels, checked values against the 
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coding manual provided and categorised each variable as continuous, categorical or 
ordinal. Where I had questions about categorisation I wrote them into the manual 
for upcoming supervisory meetings.  
 
DEVELOPING CODING MANUALS 
Three sections of the files, involving the observations of those neonates who were 
admitted to intensive care, had not been coded at the time I received a copy of the 
database. NB and I developed coding manuals for these three sections: Daily 
neonatal morbidity of those admitted to a NICU; cranial imaging results and 
neurological consultations. We then coded half the relevant files into the database, 
and a research assistant coded the remaining files. 
 
CATEGORICAL AND CONTINUOUS VARIABLES 
Initially three dichotomous categorical outcome variables were specified:  
Cerebral palsy: yes=1/no=0;  
Intrapartum stillbirth: yes=1/no=0;  
Neonatal death: yes=1/no=0. 
 
All outcome variables that I developed throughout the study were also dichotomous 
variables.  
Cerebral palsy without admission to a NICU as a newborn yes=1/no=0;  
Cerebral palsy without encephalopathy: yes=1/no=0;  
Cerebral palsy following neonatal encephalopathy: yes=1/no=0;  
Cerebral palsy following hypoxic ischaemic encephalopathy: yes=1/no=0;  
Neonatal death without encephalopathy: yes=1/no=0;  
Neonatal death following neonatal encephalopathy: yes=1/no=0;  
Neonatal death following hypoxic ischaemic encephalopathy: yes=1/no=0. 
 
Exposure variables were either continuous variables or categorical variables, with 
the majority of the exposure variables being categorical. Examples of continuous 
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variables were: birthweight, gestational age, lowest and highest recorded fetal 
heart rate, duration of resuscitation and maternal age. Examples of categorical 
variables were: clinical description of small for gestational age, neonatal infections, 
marital status and insurance status.  
 
CREATING DUMMY VARIABLES  
Categorical exposure variables had yes/no/unknown categories or multiple 
response categories. For example the variable “caesarean section” had the 
following categories:  
 
Caesarean section 
no c/s =0 c/s without labour – elective =1 
c/s without labour – emergency =2 
 c/s after commencement of labour =3 
c/s unspecified =4 
“unknown” =9 
 
Variables in this form can only be used for description. Therefore dichotomous 
variables were created when required for a logistic regression analysis. Staying with 
the same example, to create a dichotomous variable for “any caesarean section” 
caesarean section codes 1, 2, 3 and 4 were re-coded as 1, code 0 remained 0 and 
code 9 was set to missing.  
 
Continuous variables were also transformed into categorical variables when the 
literature or practice suggested appropriate cut points for particular analyses. To 
minimise the chance of gerrymandering, cut points were decided upon before the 
analyses was performed. For example Apgar scores range from 0-10 but there are 
well established cut points for Apgar scores, such as <7 at ten minutes and ≤3 at five 
and ten minutes. For some analyses it was important to identify those who fell into 
these categories, so dichotomous variables were constructed for “Apgar <7 at ten 
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minutes” for which all those with an Apgar score at 10 minutes of <7 were coded as 
1 and those with a score of 7 or more at 10 minutes were coded as 0. When 
exploratory analyses were deemed necessary (eg. when there was no literature to 
provide guidance) appropriate cut points were sought and identified by the 
description of the data.  
 
CREATING COMPOSITE VARIABLES 
Other variables needed to be developed by combining two or more separate 
indicators. One important construct was “moderate to severe neonatal 
encephalopathy (NE)”. This variable was crucial to a number of our hypotheses, 
therefore literature was reviewed extensively to identify criteria for the NE variable 
that would be acceptable to clinicians and researchers and accurately reflected our 
concept of NE.  The criteria chosen were: Two or more days (for survivors), or any 
admission (for neonatal deaths) in intensive or special care with at least one of the 
following: seizures, abnormal consciousness (lethargic or comatose) or abnormal 
muscle tone. Therefore the dichotomous NE variable was created by including those 
meeting the criteria highlighted below.  
 
Intensive/special 
care AND 
Seizures OR Abnormal 
consciousness 
OR Abnormal tone 
Continuous  Continuous Categorical Categorical 
Number of days 
2 or more days 
(for survivors) or 
Any admission for 
neonatal deaths 
Time commenced  
Any time 
0= normal 
consciousness 
1= irritable 
2= lethargic 
3= comatose 
4= other abnormal 
0 = normal tone 
1= abnormal tone 
9= unknown 
 
To ensure validity of this composite variable, files were examined that just failed to 
meet these criteria eg. one day in NICU and abnormal tone for a survivor, or 3 days 
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in NICU and none of the other factors present. Without considering case control 
status EB and I independently reviewed each file to ensure that a) data was 
correctly entered and b) that the chosen criteria accurately identified those who 
should be classified as “moderate to severe NE”. When a clinical decision was 
required, NB was emailed the description of the newborn’s neurological symptoms 
(without data concerning case/control status) and asked the question “would you 
describe this as moderate to severe NE?”   
 
This re-examination of the original data files provided the opportunity to identify 
and correct coding and data entry errors. EB and I each had a copy of the data-sets 
throughout this time, so when changes were made to the data-set, there was 
always a double check and discussion before this occurred. 
 
The creation of the dichotomous “sentinel event” variable central to some analyses 
in this thesis involved a different process. The following obstetric events were 
identified in the literature as potentially asphyxial sentinel events: Intrapartum 
haemorrhage including placental abruption; shoulder dystocia; prolapsed cord; 
nuchal cord; uterine rupture; amniotic embolism and maternal cardiac arrest. Then 
each file was reviewed (without data concerning case control status) to ensure that 
each instance in which these factors were coded as present did represent a sentinel 
event. For example re-examination of the original paper files identified that 
intrapartum haemorrhage could be coded as  “yes” with notes  ranging from “some 
pink in the amniotic fluid with labour continuing and no further concerns” to 
“2600mls and complete abruption”. Similarly shoulder dystocia could be coded as 
“yes” with notes ranging from “mild dystocia, vertex vaginal delivery” to “body 
delivered 20mins after head due to severe shoulder dystocia”. All nuchal cord notes 
were reviewed and only those in which the cord was specified as being “tight” were 
coded as sentinel events. In the same way, files were reviewed for each prolapsed 
cord, uterine rupture, amniotic embolism and maternal cardiac arrest to ascertain 
whether or not a sentinel event had occurred. 
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I reviewed all these files without data concerning case control status, made a 
decision and then EB independently reviewed them. When there was a difference 
of opinion the files were reviewed together, and occasionally the relevant details 
were sent to JK (blinded to case control status) for an obstetric clinical decision. I 
also chose a random sample of the final decisions in each sentinel event type and JK 
judged whether or not it was a sentinel event. There were no discrepancies with JK, 
validating the sentinel event variable.   
 
The creation of dichotomous variables also included those that involved only 
continuous variables. For example, cord pH and base excess are both continuous 
variables which were combined into a composite categorical variable of “metabolic 
acidosis”. Cord or first blood sample pH<7 was combined with base excess >12 
based on definitions found in the literature. Any infants with both these indicators 
were then coded as metabolic acidosis=1, those that only had one indicator or 
neither were coded as metabolic acidosis=0.  
 
DATA CLEANING  
Frequencies of each variable were examined to check for impossible or unusual 
values and the distribution of each variable. Cross tabs of related variables were 
examined to check for illogical combinations of variables. Gaps, patterns and 
inconsistencies in the data were identified. Errors when recognized at this point 
could be checked against original files, and either changed to the correct value (if 
proved a coding error), changed to “unknown” where this was deemed appropriate 
or “missing” i.e. an impossible value.  
 
DATA DESCRIPTION AND SUMMARIZATION 
Following descriptive summaries, relationships between variables were explored by 
means of simple cross-tabulations and scatterplots. Variables were classified 
according to the order in which they occurred and tables were generated for each: 
Preconceptional (Appendix G); Antenatal (Appendix H); Intrapartum (Appendix I) 
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and Immediately postpartum and neonatal (Appendix J). The tables showing 
proportions of controls, cases and deaths with each variable value were then 
calculated based on the proportion of non missing data. Variables where there was 
a distinct pattern of increasing risk from controls to cerebral palsy and then 
perinatal death are shown in Appendix K. 
 
MISSING DATA 
A decision was made that if 40% or more of the data were missing we would not 
use the variable in further analyses. Of 57 primary preconceptional variables 
(Appendix G) eleven (19%) had >40% missing data: maternal education, smoking 
and alcohol consumption prior to pregnancy, gestational age that antenatal care 
commenced and variables concerning initiation, duration and regularity of maternal 
menstrual cycles. Of 53 primary antenatal variables (Appendix H) five (9%) variables 
had data missing for >40% of subjects: maternal weight gain in pregnancy, alcohol 
consumption during pregnancy, quantity of cigarettes smoked during pregnancy 
and hyperemesis. Of 65 primary intrapartum variables (Appendix I) none of these 
variables had over 40% missing data but one “placental histology” was noted not to 
have been performed in 96.8% of cerebral palsy cases. Of the 55 primary 
immediately postpartum and neonatal variables (Appendix J) none of these 
variables had over 40% missing data.  
 
ANALYSIS 
Each results chapter utilised different analyses which are presented in the relevant 
section. Primarily the odds ratio with a 95% confidence interval was used 
throughout as this is necessarily the test statistic used in case control studies.  
 
Use of the exposure rate in controls as an estimate of the exposure rate in the 
population depends on two assumptions that have been adequately addressed for 
this study: 1. The controls must be representative of individuals who do not have 
the condition. As this thesis is considering a sub-section of the population, singleton 
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survivors born term and near-term, their controls are representative of the 
comparable Western Australian cerebral palsy population 2. The outcome must be 
rare, and in this thesis all potential outcomes (cerebral palsy, neonatal death, 
intrapartum stillbirths) and their subgroups (eg cerebral palsy following neonatal 
encephalopathy) are rare events in the population. In this study, it is fair to say that 
the odds ratios are an adequate estimate of the risk ratio. However it is important 
to understand that odds ratios are always larger than relative risks for both positive 
and negative associations, and the difference is more pronounced the higher (or for 
negative associations the lower) the odds ratio of the variable of interest. 
 
To obtain odds ratios both conditional and unconditional logistic regression were 
used. In effect, through logistic regression we are predicting the odds of a child 
belonging to one of two groups (eg cerebral palsy yes/no) given certain other 
variables of interest (eg maternal fever in labour yes/no). Further, it quantifies the 
effect of this variable of interest and can do so while adjusting for the confounding 
effects of other variables of interest (eg. a sentinel event yes/no or maternal age). 
Conditional/unconditional logistic regression was used throughout this thesis as all 
outcome variables were dichotomous. It is a based on a similar equation to linear 
regression, but does not need to have an assumption of linearity, as would be the 
case with a continuous outcome variable.    
 
Generally when cases and controls are individually matched, greater power is 
achieved if the analyses compare the case only with their matched control 
(conditional logistic regression). However, for our study it was both reasonable and 
sometimes necessary to use unconditional logistic regression (ie comparing selected 
cases with all controls). The matched variables were gestational age, plurality and 
year of birth. In the analyses in this thesis we considered only subsamples of CCCP 
subjects defined by gestational age (using only births at 35+ weeks or 37+weeks) 
and plurality (only singletons), therefore in this thesis the whole sample (Term-
CCCP) was at least approximately matched on these two variables. The impact of 
ignoring matching (as was done on year of birth for unconditional logistic 
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regressions) is small unless the exposure changes dramatically during the study 
period. As discussed earlier, year of birth was an important matched variable 
primarily for the very and extremely pre-term births. This was not the case for the 
term and near term born infants. Finally, it was sometimes necessary to run 
unconditional logistic regressions, particularly for rare exposures because 
conditional regressions failed to converge. 
 
BIRTH DEFECT LINKAGE STUDY 
Both the literature and early analyses of this study made it clear that birth defects 
play a significant role in the aetiology of cerebral palsy in term and near-term 
singletons. The original CCCP data set only had birth defects that had been 
identified by the end of the neonatal period. We therefore applied for and received 
ethics approval to conduct a linkage study with the WARDA which accepts 
notifications of up to ten birth defects per person identified before the age of six 
years. 
 
Following receipt of the data NB and I (blinded to case control status) classified each 
set of birth defects as: 
Brain – with or without other birth defects 
Major (non brain) - further described by organ system for some analyses  
Minor only  
To maintain consistency we used definitions for discriminating between major and 
minor defects that are used by the WARDA. 
 
DEVELOPING MORE AETIOLOGICALLY HOMOGENEOUS GROUPS 
Throughout the development of this program of research we sought to divide the 
outcomes, i.e. cerebral palsy or perinatal death, into aetiologically more 
homogeneous outcomes indicated by the shaded boxes in Figure 5. Dependent on 
the question being asked, some analyses included only term singletons and some 
 Page | 51  
 
also included near-term singletons. At the beginning  of each chapter that considers 
Term-CCCP data, the specific groups being considered are defined using a similar 
flow diagram, so that readers are able to quickly identify which groups are the focus 
of each chapter. 
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Figure 5: Term-CCCP methodology *Some analyses included only term singletons others 
included near term  #One analysis included only those receiving routine postnatal care 
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REPORTING THROUGHOUT THIS THESIS 
All papers that were written for this thesis based on data from the Term-CCCP were 
developed using the Strengthening the Reporting of Observational studies in 
Epidemiology (STROBE) guidelines.40 The 22 item checklist was submitted with each 
paper indicating that its recommendations had been adhered to. 
 
SYNOPSIS OF CHAPTER 3 
This chapter outlines the methods of data preparation undertaken on receiving 
Term-CCCP data and the history of hypothesis generation. Chapter specific methods 
are included in each results chapter. The following chapter is the first of the results 
chapters: a systematic review of risk factors for term born infants. 
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CHAPTER 4 
SYSTEMATIC REVIEW OF RISK FACTORS 
INTRODUCTION 
To elucidate causal pathways, risk factors must be identified and tested for their 
additive or multiplicative effects toward the outcome, cerebral palsy. A number of 
studies have now been conducted with the aim of identifying risk factors. As a result 
there are many risk factors that have been individually identified, however they 
have not been systematically aggregated and critiqued to give researchers a focus 
to hypothesise new causal pathways for term infants. The following is a systematic 
review of 25 studies that aimed to identify risk factors for cerebral palsy. It has been 
published and for the purposes of this thesis takes the place of a less rigorous 
literature review. Chapters 4 and 5 answer the research questions associated with 
Hypothesis 1. 
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AIM The aim of this study was to conduct a systematic review in order to identify the risk factors
for cerebral palsy (CP) in children born at term. The secondary aim was to ascertain if the potential
for prevention of these risk factors has been adequately explored.
METHOD A MEDLINE search up to 31 July 2011 was completed, following the Meta-Analysis of
Observational Studies in Epidemiology guidelines. Publications were reviewed to identify those
with both a primary aim of identifying risk factors for all children or term-born children with CP
and a cohort or case–control study design. Studies were examined for potential chance or
systematic bias. The range of point estimates of relative risk is reported.
RESULTS From 21 articles meeting inclusion ⁄ exclusion criteria and at low risk of bias, data from
6297 children with CP and 3 804 791 children without CP were extracted. Ten risk factors for term-
born infants were statistically significant in each study: placental abnormalities, major and minor
birth defects, low birthweight, meconium aspiration, instrumental ⁄ emergency Caesarean delivery,
birth asphyxia, neonatal seizures, respiratory distress syndrome, hypoglycaemia, and neonatal
infections. Strategies for possible prevention currently exist for three of these.
INTERPRETATION Ten consistent risk factors have been identified, some with potential for
prevention. Efforts to prevent these risk factors to interrupt the pathway to CP should be extended.
Cerebral palsy (CP) is the most common physical disability of
childhood. CP describes a group of disorders of movement
and posture that are also often accompanied by associated
impairments and secondary musculoskeletal problems.1
Term-born children account for 50 to 65% of children with
CP, and they tend to be more severely impaired than children
with CP born preterm.2 Moreover, the severity of disability in
the term-born group seems to be increasing.3 The incidence
of CP among term-born infants ranges between 1 and 1.7 per
1000 live births, suggestive of a rare outcome.2–5 However,
with 130 million infants born worldwide each year,6 93% of
whom are born at term, such incidence rates suggest that
between 120 000 and 217 600 new cases of CP occur each
year among term-born children, making this an important yet
under-researched group with chronic lifelong disability.
Over the past 50 years real progress has been made in
the conceptual understanding of the aetiology of CP. We
have confirmed that sentinel events around birth are
responsible for a small proportion of CP. More typically,
risk factors and multiple events interact in a cascade with
additive effects.7,8 However, despite the progress in concep-
tual understanding, there has been no discernible decrease
in overall rates. Therefore, we asked what clinically mean-
ingful messages could be drawn from the literature of the
last 50 years to guide us towards prevention in the coming
decades.
The research questions for this study were (1) ‘What risk
factors for CP have been identified in the literature for infants
born at term?’ and (2) ‘Has their preventive potential been
adequately explored?’
SOURCES
We followed the recommendations for reporting in the Meta-
Analysis of Observational Studies in Epidemiology guide-
lines.9 The search strategy was developed by two of the
authors (SM and SG) and a librarian. We searched MED-
LINE and EMBASE for reports published up to 31 July 2011
(with no restriction on earliest search date) using a sensitive
methodological filter for aetiological studies. Search terms
were (risk factor*) OR (aetiol* OR etiol*) AND cerebral palsy,
as well as MeSH (Risk Factor OR Aetiology) AND cerebral
palsy with limits of humans.
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Inclusion criteria
Inclusion criteria for the study were as follows: (1) CP was the
primary outcome (using a known definition appropriate for
the time of the original study); (2) the primary aim of the study
was to identify risk factors for CP in (a) all births or (b) infants
born at term; (3) the study followed a cohort or case–control
design; and (4) the publication had been peer reviewed.
Exclusion criteria
Exclusion criteria for the study were as follows: (1) the primary
aim was (a) to identify risk factors in those born preterm, (b)
to classify aetiology by epoch without identifying specific risk
factors, (c) to identify risk factors for a broader definition of
adverse outcome that may include CP such as neurodevelop-
mental impairment, periventricular leukomalacia, learning dis-
ability*, epilepsy, etc., from which the risk factors specific to
CP cannot be identified, or (d) to identify genetic risk factors,
as systematic reviews dedicated entirely to genetic risk factors
have been recently published; (2) original observations were
not reported (e.g. literature reviews and editorials); (3) there
was no control group (e.g. case series, case reports); (4) the
study was carried out in developing countries and the risk fac-
tor profile pertained to causal pathways currently routinely
prevented or of limited applicability in developed countries
(e.g. jaundice resulting from rhesus isoimmunization). Figure 1
outlines the final selection process.
Methods
The first author (SM) reviewed all 4899 titles ⁄abstracts identi-
fied by our search strategy and two other authors (DT and
SG) between them reviewed each a second time. The authors
selected 122 for full-text review, of which 32 were identified as
likely to meet the inclusion criteria. A third independent
reviewer (EB) examined these 32 studies against the inclusion
and exclusion criteria and recommended that seven further
papers be excluded based on exclusion criteria 1a and 4. There
was full agreement with this decision. The reference lists of
the 25 articles selected were hand searched for further relevant
articles, but none was found.
The data extraction tool was designed a priori by the princi-
pal reviewer (SM) and included study design, country, birth
years, gestational age range considered, numbers with and
without CP, numbers and percentages with and without each
risk factor, definitions used for each risk factor, and unadjusted
and adjusted odds ratios if reported. Extraction of data from
each of the 25 articles was carried out independently by two
investigators (SM and DT ⁄NB). Discrepancies were discussed
and a final decision was made without requiring further con-
sultation (Table I).9-34
Two recent systematic reviews have attempted to identify
optimal tools to assess the risk of bias in reports of observa-
tional research.35,36 Neither review could identify an optimal
tool, but both recommended a transparent checklist over a
scale, based on weighted and summed scores from individual
sources. For this review we adapted a checklist37 which
includes criteria for information and selection bias and
addresses the domains of participants, measurement of vari-
ables, and control of confounding (Appendix SI, supporting
information published online). Domains were assessed as ade-
quately or inadequately addressed. If more domains were
assessed as inadequate rather than adequate, the study was
deemed inadequate for inclusion in the primary findings.
Across studies, risk factors were seldom reported in the
same manner. For example, previous live births were reported
in individual studies as primipara yes ⁄no; number of previous
births 0, 1, 2, 3, 4, >4; parity at least one live birth; parity 1, 2–
4, 5+; parity 3+; and mean number of previous deliveries for
cases and controls. The manner of reporting dictated which
studies could contribute results; for example, proportion of
mothers with no previous births could not be obtained for
those studies choosing to report mean number of deliveries. In
addition to risk factors being reported many ways, the inclu-
sion criterion for cases varied; some studies considered differ-
ing subsets of the total CP population, for example spasticity
only or exclusion of mild CP cases.
Quantitative meta-analyses were prohibited by such varia-
tions in definitions and categorizations of both exposures and
outcomes. Instead, we report on the consistency of unadjusted
risk associated with each factor and the range of point estimates
of measures of relative risk. Adjusted estimates of risk were not
considered because, where multivariate analyses were reported,
each study controlled for different combinations of covariates,
so the results were not comparable. However, most findings
were controlled for gestational age, plurality, and sex either by
matching in case–control studies or by stratification in cohort
studies. Finally, if all studies of term-born infants that investi-
gated a specific risk factor reported an increased risk of CP
without any confidence intervals including 1, further literature
was searched to identify if methods for preventing the risk fac-
tor or its consequence had been reported in systematic reviews.
RESULTS
A total of 25 articles met the inclusion criteria (Fig. 1); none
was published in a language other than English. Of these 25, 11
reported on term-born infants and 14 reported on all children
with CP. All included studies used a standard definition of CP
applicable to the year they were published, and all excluded
those with CP as a consequence of a postneonatal event. None-
theless, the inclusion criteria for CP were not homogeneous
across studies. Seven out of 25 studies excluded mild CP,
reporting on only those children with moderate to severe CP.
Nineteen out of 25 studies reported on all subtypes, whereas
five out of 25 were limited to spasticity subtypes, and the one
remaining paper reported on only those with CP/intellectual
disability, and partial epilepsy. Four out of 25 studies did not
include children with a congenital abnormality (birth defect), a*North American usage: mental retardation.
What this paper adds
• Ten risk factors were identified for CP in term-born infants by all studies
examining them.
• Few identified risk factors are currently preventable.
• Preventive efforts should be extended to include these risk factors
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factor which is well known to be associated with CP. Whereas
13 out of 25 reported on singleton births only, the others
included multiple births. The birth years of cases and control
individuals ranged from 1959 to 2005, with the majority (70%)
of individuals born between 1980 and 1999.
Articles were appraised for risk of bias (either chance or sys-
tematic) with a view to comparing results of studies with a low
risk of bias. Four studies were deemed to be at an unaccept-
ably high risk of bias (Table I) and were not included in the
primary results.16,19,20,32 Their exclusion reduced the number
of children with CP in the primary analyses by 457 (6.7%) and
the number of children without CP by 716 (0.02%). None of
these were term-specific studies.
The 21 articles considered at a lower risk of bias comprised
data from 6297 children with CP and their parents, and 3 804
791 children without CP and their parents.10–15,17,18,21–31,33,34
Populations considered were from Australia (six articles
reported on two distinct populations), continental Europe (six
articles reported on six distinct populations), the UK (two arti-
cles reported on two distinct populations), and the USA (eight
articles reported on three distinct populations). Where a study
was the subject of more than one publication, care was taken
not to count the same participants more than once for each risk
factor.
We extracted 808 estimates of risk pertaining to 88 separate
risk factors. Risk factors were removed from the primary anal-
ysis if (1) fewer than four of the 21 studies reported them, (2)
the risk factor was reported only by studies at high risk of bias,
or (3) the factor was a consequence of disease and unlikely to
be causal. Factors which were removed from primary analysis
are reported in Appendix SII (supporting information pub-
lished online). The primary findings thus comprised seven
preconceptional, 13 antenatal, 12 intrapartum, and six neona-
tal risk factors (Table II).
Excluded by abstract review:
Not CP specific
Methodology specific
Non-human studies
Assessment and scanning  description 
General review articles
Risk factor without CP as denominator 
CP impairment description
CP intervention
Epidemiology (without risk factors)
Neonatal encephalopathy
Post neonatal CP population
Term CP predictors
Preterm and low birth weight populations
Psychosocial discussion
875
21
24
255
478
282
927
1123
118
23
28
101
495
27
Potentially 
included articles
n=25
Excluded by full review:
Countries with differing risk profile
Study design criteria
29
61
Articles meeting inclusion 
criteria from hand searches
n=0
Excluded due to 
high risk of bias
n=4
Articles for systematic 
review n=21
Citations 
from 
electronic 
databases
n=4899
Articles included 
for independent 
review n=32 Articles excluded by 
independent review 
n=7
Articles 
selected for 
full review
n=122
Figure 1: Study selection. CP, cerebral palsy.
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Table II: Aetiological risk factors for cerebral palsy (CP) from studies at low risk of bias
Risk factor
All CP Term or >2500g CP
Nr of
papers
(n=11) Associationa
Range of
point
estimates
Nr of
papers
(n=11) Associationa
Range of
point
estimates
Preconceptional risk factors
Previous live births
None 6 ) ⁄ + 0.9–1.4 4 + 1.1–1.6
4+ 6 ) ⁄ + 0.6–2.9 4 § ⁄ + 1–1.3
Previous stillbirths ⁄neonatal death 4 + 1.8–5.4 2 ) ⁄ + 0.6–1.8
Previous miscarriage
Any 0 NA NA 3 ) ⁄ + 0.9–1.5
>3 1 + 2.0 0 NA NA
Maternal age at delivery
<20y 3 + 1.5–1.9 3 § ⁄ + 1.0–1.2
>40y 4 + 1.3–3.7 5 + 1.1–3.0
Race
White 4 ) ⁄ + 0.7–1.2 4 ) ⁄ + 0.9–1.4
African-American 2 + 1.5–1.8 1 + 1.3
Hispanic 1 § Unable to calculate 1 § 1.0
Asian 1 – Unable to calculate 1 – 0.7
Australian Aboriginal 1 + 2.5 0 NA NA
Immigrant parents 1 + 10.6 2 § ⁄) 0.6–1.1
Others ⁄unknown 2 § ⁄ + 0.9–1.5 1 § 1.0
Low SES (including education, work, SES
and private insurance)
2 § ⁄ + 1.0–1.4 3 § ⁄ + 1.0–1.6
Prior maternal diagnoses
Seizures, intellectual disability, thyroid disease 3 + 2.4–9.0 3 + 2.6–10.3
Diabetes, asthma, coagulation disorder,
surgical history, mental illness, poor obstetric history
3 + 1.2–2.4 3 § ⁄ + 1.0–1.9
Antenatal risk factors
Poly ⁄oligohydramnios 2 ++ 4.2–6.9 4 ) ⁄ + 0.6–3.2
Haemorrhage
‘Any’ or first trimester 6 ) ⁄ + 0.9–8 2 ) ⁄ + 0.5–1.2
Second or third trimester 6 ++ 1.6–3.7 2 + 1.3–1.6
Maternal disease in pregnancy
Hypertension 5 § ⁄ + 1.1–4.3 2 + 1.3–2.2
Psychiatric illness 1 + 9.3 2 § 0.9–1.1
Anaemia, rheumatic disease 2 – 0.2–0.7 2 § 0.9–1.1
Perinatal infection
CMV, rubella 1 + Unable to calculate 0 NA NA
UTI, GTI 3 § ⁄ + 1.0–4.2 0 NA NA
Chorioamnionitis 3 + 1.5–4.4 5 § ⁄ + 1.0–12.5
Pre-eclampsia 5 + 1.1–8.4 5 + 1.1–5.1
Placental abnormalities 6 + 1.5–7.6 3 ++ 2.4–4.9
Placenta praevia 1 – 0.7 4 + 2.4–6.2
Major and minor birth defects 4 ++ 2.6–20.7 3 ++ 2.2–27.4
Small for gestational age 5 ++ 1.9–7.5 4 + 2.1–4.5
Large for gestational age 1 + 2.6 1 § ⁄) 0.9–1.6
Low birthweight 5 ++ 2.8–13.1 5 ++ 3.4–8.2
Plurality Studies were restricted to singletons (n=11), or matched or stratified by plurality
(n=6)
Sex Studies were matched, or stratified by sex (n=8)
Gestational age Studies were either ‡37wks (n=8), or matched or stratified by gestational age (n=9)
Intrapartum risk factors
Length of labour
<3h precipitous 3 ++ 1.9–3.0 0 NA NA
2nd stage >1h 2 ++ 2.1–2.4 4 + 1.5–2
Prolonged labour 1 ++ 3.0 3 § ⁄ + 1–1.5
Membrane rupture
Preterm <37wks 2 § ⁄ + 1–1.9 0 NA NA
Prolonged >24h 1 § 0.9 4 § ⁄ + 1–2.4
Prolonged and preterm 1 ++ 3.32 1 + 1.5
Induction of labour 1 + 2.5 4 + 1.2–2.1
Augmentation 1 – 0.7 2 § ⁄) 0.8–1.0
Meconium
Stained liquor 2 ++ 1.8–3.8 6 + 1.3–5.3
Aspiration 2 ++ 10.3–15 2 ++ 25–27
Abnormal fetal presentation
Breech 4 ++ 3–6.5 4 ) ⁄ + 0.7–3.9
Other than vertex 2 ++ 3.8–4.2 5 + 0.6–5.3
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Preconceptional
All six studies considering a prior maternal diagnosis of sei-
zures, intellectual disability or thyroid disease (both hypo- and
hyperthyroidism) found these factors to be strongly associated
with an increased risk of CP. A range of other maternal disease
states were also reported to increase the overall risk of all CP,
but their effect was less marked when only term births were
considered (Table II).
A maternal obstetric history of stillbirth or neonatal death
was more strongly associated with CP in studies investigating
all CP than in those investigating term CP. One study of all
CP reported an association with an obstetric history of three
or more miscarriages. No study limited to term births
reported on this variable. No convincing evidence was found
for an association between birth order and CP.
Maternal age over 40 years posed a similar risk in all nine
studies that reported it. Low maternal age was not consistently
reported as a risk. Children of African-American parents living
in the USA and children of Australian Aboriginals living in
Australia were at increased risk. Low socio-economic status
was also reported to be associated with a small risk increase in
several continents.
Antenatal
Birth defects were the antenatal risk factor with the highest
relative risk for CP. The wide range of central estimates
between studies reflects variation in what was included as a
birth defect, particularly whether or not minor defects were
included. Small for gestational age status and low birthweight
also consistently increased risk with an accompanying dose–
response effect: the smaller the infant for gestational age and
the lower the birthweight, the higher the risk. Only one study
found no statistically significant association with measures of
reduced intrauterine growth.28 Placental abnormalities
(reported as small, calcified, unhealthy, infarcts, and ⁄or com-
plications) increased the risk of CP significantly in studies of
term-born infants.
Maternal diseases during pregnancy that presented the
highest risks for CP in the child were respiratory and heart
diseases, seizures, and incompetent cervix. However, because
they were examined individually in only one or two studies,
they are reported in Appendix SII with other risk factors that
show associations and promise for further studies but to date
have rarely been examined. Abnormalities of fluid volume
were identified as a statistically significant risk factor in studies
of all CP, with conflicting evidence for term-born infants.24,25
Bleeding in the second and third trimesters, hypertension in
pregnancy, and pre-eclampsia increased the risk of CP across
all gestations. Chorioamnionitis also increased the risk of CP
and was the most frequently reported perinatal infection.
Intrapartum
Birth asphyxia, despite the variations in reporting, was the
strongest and most consistent risk factor for the systematic
Table II: Continued
Risk factor
All CP Term or >2500g CP
Nr of
papers
(n=11) Associationa
Range of
point
estimates
Nr of
papers
(n=11) Associationa
Range of
point
estimates
Mode of delivery compared with spontaneous
Elective Caesarean section 2 § ⁄ + 1–2.5 1 § 1
Emergency Caesarean section 2 ++ 1.7–4.3 2 ++ 1.8–8.1
Caesarean unspecified 0 NA NA 4 ++ 1.6–4.0
Forceps 1 + 9.3 2 + 1.3–1.6
Vacuum 0 NA NA 2 ++ 1.6–3.9
Instrumental combined 1 + 1.3 2 ++ 1.9–2.0
Breech 0 NA NA 2 ++ 3.3–3.4
Sentinel events
Cord around neck 2 ++ 1.7–1.9 3 § ⁄ + 1–2.3
Specifically tight cord 1 + 1.3 0 NA NA
Cord prolapse 1 § 0.4 2 + Unable to
calculate
Placental abruption 3 + 1.1–13.1 5 + 2.0–9.4
Uterine rupture 1 § 0.9 0 NA NA
Haemorrhage ⁄ shock 1 + 1.7 3 + 2.4–9.4
Birth asphyxia 2 ++ 13–20 4 ++ 4.6–140
Neonatal risk factors
Neonatal seizures 2 ++ 5.6–40 3 ++ 3.7–63
Respiratory distress syndrome 2 ++ 2.3–18 3 ++ 2.1–18.1
Hypoglycaemia 3 ++ 4.3–20.5 2 ++ 2.7–11.6
Jaundice 2 ++ 2.8–3.7 3 ) ⁄ + 1.1–2.8
Infections including meningitis, sepsis 4 ++ 4.1–7.6 4 ++ 1.8–29
aOverall association: based on univariate analyses. ) ⁄ + OR § ⁄ + OR § ⁄), inconsistent results; +, all studies report an increased risk of CP in the
presence of this factor, some confidence intervals (CIs) included 1; §, all studies report no risk of CP in the presence of this factor; ), all studies
report a reduced risk of CP in the presence of this factor, some CIs included 1; SES, socio-economic status; ++, all studies report an increased risk
of CP in the presence of this factor, no CIs included 1; CMV, cytomegalovirus; UTI, urinary tract infection; GTI, genital tract infection; GA,
gestational age; NA, not available.
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review. Meconium-stained liquor and particularly meco-
nium aspiration were also strong risk factors for births at all
gestational ages. Instrumental deliveries (compared with spon-
taneous vaginal or elective Caesarean deliveries) were associ-
ated with increased risk of CP, as was a breech delivery.
Abnormal duration of labour and fetal presentation were
reported as statistically significant risk factors in studies con-
sidering all CP, but not in studies of term CP.
Neonatal
Overall, the magnitude of association was greatest for factors
in the neonatal period. Among the neonatal variables, the
presence of seizures was the strongest risk factor across all ges-
tational ages. Respiratory distress syndrome, hypoglycaemia,
and infections were similar in their magnitude of risk. There
was conflicting evidence whether jaundice increased the risk of
CP in term-born infants; however, in the two studies that
specified severe jaundice the risk was significant.
Prevention of risk factors
Across the four epochs, 10 of the 38 risk factors were consis-
tently associated with a statistically significant (p<0.05) risk of
CP in term-born infants. One of these, ‘birth asphyxia’, is cur-
rently being treated with hypothermia, reducing the risk of
permanent brain injury by 10%.38 There is sufficient evidence
to suggest preventive strategies to address some causes of low
birthweight, for example reducing alcohol consumption before
pregnancy, and meconium aspiration (e.g. curtailing post-term
pregnancy). Seven risk factors require further research to iden-
tify whether they lend themselves to prevention strategies, and
all need further research to maximize their preventive poten-
tial (Table III).
DISCUSSION
On reviewing the literature we found that lack of standardiza-
tion and specific reporting prevented optimal use of available
data (e.g. meta-analyses even of uncontroversial continuous
variables such as maternal age, parity, or birthweight could
not be conducted). Acknowledging these limitations, 38 risk
factors for CP were identified across four epochs and the con-
sistency of findings was determined. Study findings are
reported for two groups: those whose denominator was all CP
and those whose denominator was only term CP. In the case
of most risk factors, the strength of association with term CP
and all CP was different. However, risk factors such as older
maternal age at delivery, prior maternal disease, pre-eclampsia,
and birth defects were not associated with different risk, and
thus may be on causal paths to CP irrespective of gestational
age at birth. In fact, these factors may work together, as high
maternal age is also associated with a higher incidence of birth
defects, pre-eclampsia, vascular disease, and pre-existing
maternal diseases such as thyroid disorders.62,63 Interestingly,
Table III: Term aetiological risk factors and their potential for prevention
Risk factor
Possibility of
prevention Summary of current high-level evidence
Antenatal risk factors
Placental dysfunction
or abnormalities
? Insufficient data for the effectiveness of heparin for females considered at risk of placental
dysfunction. More research is required39
Major and minor
birth defects
? Conflicting evidence regarding the benefit of folic acid and supplementary vitamins40,41
Low birthweight 4 Reducing heavy alcohol consumption during pregnancy reduces low-birthweight rates.42
Insufficient data for magnesium supplementation during pregnancy43 and heparin39
Intrapartum risk factors
Meconium aspiration 4 Amnioinfusion in settings with limited perinatal surveillance only;44 curtailment of post-term
pregnancy reduces meconium aspiration;45 however, labour induction with prostaglandins
is associated with meconium release46 and surfactant47 and steroid therapy48 currently
have insufficient evidence
Caesarean section,
vacuum, breecha
? Females with continuous support during labour are less likely to have Caesarean or
instrumental births.49 External cephalic version (ECV) at term reduces risk of non-cephalic
and Caesarean births50 and tocolytics increase success of ECV.51 Insufficient evidence that
either moxibustion,52 or postural management53 corrects non-vertex presentation
Birth asphyxia 44 Cooling reduces mortality and major neurodevelopmental disability.38 Adjuvant therapies
currently being investigated include topiramate, erythropoietin, melatonin, and xenon
Neonatal risk factors
Neonatal seizures · No evidence that cooling prevents seizures.38 Little evidence exists to support the use of
anticonvulsants55
RDS ? In preterm infants multiple doses of exogenous surfactant prevents RDS in those at risk and
leads to improved clinical outcomes for those with RDS.56 No research specifically for
term-born infants
Hypoglycaemia · Early hypoglycaemia is associated with severe encephalopathy and poor long-term outcomes57
Infections including
meningitis and sepsis
? Insufficient evidence for prophylactic vs selective antibiotics for term newborn infants of
mothers with risk factors for neonatal infections;58 antibiotics for bacterial meningitis;59
antibiotics for late-onset sepsis;60 IVIG61
aInstrumental ⁄Caesarean delivery can also be a response to events with the potential to cause brain injury, in which case the association would
not be causal, but potentially preventing a worse outcome. ?, possible prevention strategies identified, further research required;4, prevention
strategies for some paths identified, further research required;44, prevention strategies identified and are effective for some paths, further
research required; ·, prevention strategies not yet identified, further research required; RDS, respiratory distress syndrome; IVIG, intravenous
immunoglobulin.
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the incidence of intrapartum complications and perinatal
death at term is also higher in older mothers.54
The primary findings consist of 10 risk factors in term-born
infants that were consistently reported as statistically signifi-
cant predictors of CP. These were placental abnormalities,
birth defects, low birthweight, meconium aspiration, instru-
mental ⁄emergency Caesarean delivery, birth asphyxia, neona-
tal seizures, respiratory distress syndrome, hypoglycaemia, and
neonatal infection. The literature was reviewed to identify if
any of these factors are currently preventable or if strategies
exist to reduce the likelihood of their occurrence. The only
risk factor for term-born infants for which a post-event treat-
ment is currently available is birth asphyxia. It is estimated that
one in every six to nine cases of CP due to birth asphyxia can
be prevented if the infant receives hypothermia within 6 hours
of the causal event.38 Within a causal pathway paradigm this is
an example of intervening on a proximal cause.64
Preventing more distal factors on the path may interrupt
the pathway earlier, before an injury occurs. The presence of a
non-cerebral birth defect is one distal factor that may lie on a
causal path. Presently, there is conflicting evidence concerning
the prevention of birth defects (other than neural tube defects)
with folate and supplemental vitamins.40,41 Another example
of a distal risk factor is placental abnormality during preg-
nancy. Interventions such as heparin show promise, but long-
term data are sparse and insufficient.39 The placenta is very
rarely sent for pathology; however, in a recent total population
case–control study of CP, in those born at or after 35 weeks’
gestation, macroscopic examination identified 8.8% of those
with spastic quadriplegia as having placental infarcts compared
with 2% of matched comparison children.65 The placenta is
an area of great interest for future CP research.
This review draws attention to adverse modes of delivery as
a potential risk for CP. Most instrumental deliveries are a
result of prolonged second stage labour, and emergency Cae-
sarean sections are undertaken mainly because of a failure to
progress. Thus, there is an argument for early introduction of
strategies to prevent prolonged labour such as active manage-
ment, mobilization, and doulas (continuous support).49 Elec-
tive Caesareans are another means of avoiding prolonged
labour, but it is clear that the large increase in elective Caesar-
ean sections in developing countries over the past 30 years has
not equated to a reduction in CP.66 Research efforts should be
focused on the means of accurately identifying females most at
risk who may benefit from an elective Caesarean section (e.g.
intrauterine growth restriction and multiple pregnancy) who
at this point may not be offered one, acknowledging that
Caesarean sections themselves are not risk-free.
When developing trials aimed at identifying strategies to
reduce the birth prevalence of CP in term-born infants, it is
imperative that strategies are investigated for both potential
distal (including placental abnormalities, low birthweight, rea-
sons for hypoglycaemia) and proximal (meconium aspiration,
birth asphyxia, neonatal seizures, respiratory distress syn-
drome, and neonatal infections) causes on the pathway to CP.
The major limitation of this study is that both risk factors
and population samples were variably defined. Currently avail-
able published papers on term CP were not of sufficient
uniformity to allow a meta-analysis to be performed. Compar-
isons between studies would be greatly facilitated if there were
standardized methods of reporting key factors such as gesta-
tional age, birthweight, maternal age, previous maternal dis-
ease, and socio-economic status. Birth asphyxia was the
strongest risk factor identified in this systematic review. How-
ever, the term ‘birth asphyxia’ is non-specific, and infants con-
sidered to be asphyxiated at birth may actually be found
to have other diagnoses such as sepsis or non-asphyxial
encephalopathy.
Combination risk factors (e.g. small for gestational age and
true knot in umbilical cord) were not reported in this review.11
To date, very few papers have reported combinations of risk
factors and their interactions. It is acknowledged that some
combined risk factors may strengthen and explain associations,
and within a causal pathway framework we encourage
researchers to investigate factors that may act synergistically.
Another limitation of the present review is that several stud-
ies did not report effect sizes for associations that failed to
achieve statistical significance. This selective reporting of sta-
tistically significant outcomes means that publication bias is
inevitable. Pragmatically, it is difficult for researchers to report
all their findings; however, failure to do so threatens the valid-
ity of any systematic review. Similarly, a number of studies
used combination or overarching outcome variables such as
‘maternal disease during pregnancy’ in response to the small
numbers of patients with any one specific risk factor in any
study. CP is a heterogeneous disability, so it can be anticipated
that it may be the result of a large number of causal pathways
which still need to be separately identified. But for this to
occur, and with the goal of prevention in mind, it is imperative
that we start to report specific risk factors rather than general
risk areas. We acknowledge that there is great difficulty
reporting the many specific and often non-significant findings;
however, if all research data sets prior to grouping and analysis
were available centrally, preferably as individual patient data,
then infrequently occurring risk factors that cannot be exam-
ined in any one study may be successfully investigated in com-
bined data sets. We therefore propose that, to successfully
identify causal pathways, a central clearing house of observa-
tional and experimental data aimed at prevention should be
considered.
Himmelmann et al.67 recently published a systematic review
of risk factors for CP in children born at term. These authors
restricted their review to publications at in or after 2000 with
the aim of identifying research breaking new ground. Our
review did not have a lower publication year limit, ensuring
that some of the earlier and most comprehensive studies on
risk factors for CP were not excluded. Himmelmann et al.
searched comprehensively for individual risk factors and
included studies looking at the outcomes of a risk factor, with
CP being one of many outcomes. In contrast, our review
reported only on studies whose primary aim was to identify
risk factors for CP. We were able to identify if risk factors
were reported consistently, and the strength of the estimated
risk. Our review complements theirs, with the limitations of
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each being at least in part addressed by the other, except that
meta-analyses were not possible in either review. Taken
together, the two reviews give a thorough overview of the state
of the literature regarding risk factors for CP in those born at
term and highlight the limitations inherent in utilizing the
data as they are currently available.
Following this review we make the following recommenda-
tions: (1) 10 risk factors for term-born infants have been con-
firmed in all studies investigating them and focused preventive
efforts should be directed towards them; (2) standardized defi-
nitions and categorizations of major risk factors should be
agreed upon internationally then utilized in further research;
(3) a clearing house should be established so that infrequently
occurring specific risk factors can be reported (e.g. as anony-
mised individual patient data allowing meta-analysis of such
risk factors).
CONCLUSION
Preventive strategies for CP in term-born infants are urgently
required because infants born at term contribute up to 65% of
CP cases, and their impairments tend to be more severe than
those of children born preterm. The last 50 years of CP
research have culminated in a much greater understanding of
its diverse aetiology. The next 50 years could culminate in
prevention and cure if we are prepared to pool our efforts.
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APPENDIX A: Assessing risk of bias 
 
1. Infant selection  
Cohort studies 
 Adequate: if infants recruited were representative of the entire population 
(entire source population, unselected sample of consecutive infants, or a 
random sample).  
 Inadequate: convenience sampling (arbitrary recruitment or nonconsecutive 
recruitment) or when selection was not random or unreported. 
Case-control studies 
 Adequate: cases and controls recruited from the same population. 
 Inadequate: cases and controls recruited from different source populations or 
unreported. 
2a. Assessment of outcome (cerebral palsy or not)  
 Adequate: ascertainment of cerebral palsy by medical records or direct 
observation by appropriately qualified personnel. 
 Inadequate: ascertainment of cerebral palsy by personal or telephone 
interview, self-administered questionnaire, or method unreported. 
2b. Assessment of exposures   
 Adequate: for each exposure identified as protective or positively associated, 
sources of data and details of assessment/measurement are identified. If a gold 
standard existed – it was used. 
 Inadequate: for each exposure identified as protective or positively associated, 
sources of data and details of assessment/measurement were not identified 
and/or gold standards were not used. 
3. Blinding of investigators  
Cohort studies 
 Adequate: outcome assessor blinded to exposure status.   
 Inadequate: outcome assessor not blinded to exposure status, report unclear, or 
unreported. 
Case control studies 
 Adequate: exposures assessed for study by persons blinded to cerebral palsy 
status. 
 Inadequate: not blinded or not clear from the text or unreported. 
4. Loss to follow-up or exclusions  
Cohort studies 
 Adequate: if loss to follow-up or invalid exclusions ≤10%.  
 Inadequate: if loss to follow-up or valid exclusions >10%. 
Case-control studies – accounting for all defined populations 
 Adequate: cases and controls recruited during the same period of time. 
 Inadequate: cases and controls recruited from different periods of time 
(typically historical controls) or unreported. 
5. Control for confounding factors 
 Adequate: unadjusted and adjusted analyses are presented as estimates with 
95% CIs. If any analyses were adjusted, the factors for which it is adjusted 
were precisely specified and rationales for inclusion clear.  
 Inadequate: if the study did not precisely specify which factors were included 
in adjusted analyses and/or unadjusted analyses were not presented in addition 
to adjusted analyses, with 95%CIs.  
6. Number of observations on which conclusions are made 
 Adequate: a minimum of 100 cases. 
 Inadequate: less that 100 cases. 
7. If studies report a positive or protective association on quantitative measures 
 Adequate: they test for a dose response gradient and report appropriately. 
 Inadequate: do not test for a dose response gradient and/or do not report 
appropriately. 
 NA for studies with no quantitative measures. 
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SYNOPSIS OF CHAPTER 4 
This chapter systematically reviewed previous studies that had the aim of 
identifying risk factors for cerebral palsy in term born infants. Risk of bias was 
assessed as low for 21 of the 25 studies, and we reported on the consistency of 
unadjusted risk and the range of point estimates of risk factors reported in these 
studies. Ten risk factors were identified as always statistically significant and a 
further 28 were associated, but sometimes the finding was not statistically 
significant. The following chapter now analyses the Term-CCCP (37+weeks gestation 
only), and compares this study’s risk factors to those identified for term infants in 
the systematic review.  
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CHAPTER 5 
RISK FACTORS IN TERM-CCCP 
INTRODUCTION 
The Term-CCCP is the largest known case-control study of term infants and cerebral 
palsy, and as previously mentioned in Chapter 2 has a low risk of bias. Univariate 
risk factors were identified from among the 200 variables collected for the 459 
singleton term born cases and 468 singleton term born controls and compared with 
those identified in the systematic review of risk factors for term cerebral palsy.41 
Specifically, in this chapter I report: 
 A comparison of odds ratios  obtained in the Term-CCCP and those obtained 
from studies identified in the systematic review that considered only term 
births, were considered at low risk of bias and only when four or more 
studies had examined a risk factor (Table 1).  
 A comparison of findings between the Term-CCCP and risk factors not 
presented in the primary analysis due to less than four studies investigating 
them (Table 2).  
 Risk factors identified in the Term-CCCP that were not investigated in any 
studies reported in the systematic review, which may represent novel 
findings (Table 3).  
Finally, a discussion of these findings is also included, and decisions made as to 
which risk factors to focus on for the following chapters. 
 
Figure 6 shows the groups used for these analyses. 
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Figure 6: Group selection for Chapter 5 analyses 
 
RESULTS 
 
Table 1 Aetiological risk factors: comparison of systematic review and Term-CCCP  
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Table 2: Secondary findings of the systematic review and the corresponding CCCP findings 
 
 
Preconceptional 
 
   
Risk factors for CP identified by less 
 than 4 studies   
 Term-CCCP  
Sibling disability (motor or intellectual)  
Previous infertility  
Previous premature birth  
Unsupported or single mother  
Consanguinity (a known risk factor in 
societies where consanguinity occurs 
frequently; rare in developed countries) 
Non metropolitan address  
Family history of mental illness or 
congenital abnormality  
Birth interval >3 years 
 Maternal height  
Previous hypertension 
+ + 
- / + 
- / + 
- / + 
- / + 
 
 
+ + 
- - 
 
+ + 
§ 
+ + 
1.0 (0.2-5.2) 
1.1 (0.5-2.1) p0.805 
1.4(0.9-2.0) p0.103 
1.5 (1.0-2.3) p0.043 
No information 
 
 
1.2 (0.9-1.5) p0.975 
 FH birth defects 1.7 (1.1-2.5) p0.012            
 
1.2 (0.3-4.8) p0.710                      
M(SD) CP 162.7(6.6); 163(6.7)  
1.0 (0.3-3.2) p0.963 
D-risk 
Agree 
Agree 
I-risk 
 
 
 
D-risk 
I-risk 
 
D-risk  
Agree 
D-risk 
Antenatal 
 
   
Risk factors for CP identified by less 
 than 4 studies   
 Term-CCCP  
Maternal smoking during pregnancy  
Parental exposures (toxins and x-rays) 
Commencement of antenatal care and 
number of visits  
Rh negative mother  
Raised α fetoprotein  
Gestational diabetes  
Trauma  
Decreased/abnormal fetal movements  
+ 
- / + 
§ 
 
+ 
+ 
§/ + 
+ 
- / + 
1.2 (0.9 – 1.7) p0.259 
No information 
Over 60% time unknown 
 
1.0 (0.7-1.7) p0.987       
CP 0%; controls 0%                                            
0.5 (0.2-1.3) p0.158 
1.3 (0.6-2.8) p0.458 
1.3 (0.8-2.0) p0.352                                     
Agree  
 
 
 
D-risk  
D-risk  
D-risk 
Agree 
Agree 
Intrapartum 
 
   
Risk factors for CP identified by less 
than 4 studies   
 Term-CCCP  
Minimum fetal heart rate <60bpm 
Late decelerations  
Description of delivery; failed/difficult  
Time of birth re staffing; night  
Long cord  
Short cord  
Birth trauma to head  
Fever during labour  
Episiotomy  
Uterine dysfunction  
Failure to respond to fetal 
distress/condition 
 
+ + 
+ 
+ + 
§ 
+ 
- / + 
+ 
+ 
- - 
+ 
+ + 
7.1 (3-17) p<0.001 
No information 
“horrible” 8 (1.9-37.6) p0.004 
1.0 (0.8-1.8) p0.689 
No information 
0.7 (0.2-2.6) p0.608 
CP 26.9%; controls 21.8% 
2.3 (0.9-6.0) p0.082 
No information 
No information 
Not investigated 
Agree 
 
Agree 
Agree 
 
Agree 
Agree 
Agree 
Neonatal 
 
Risk factors for CP identified by less than 4 
studies   
Term-CCCP  
Heart rate abnormalities identified in 
the neonatal period 
+ + 
 
No information 
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Apnoeas 
Pneumonia 
+ + 
+ + 
59 (8-455) p<0.001 
No information 
Agree 
    
 
 
 
+ +  All studies report an increased risk of CP in the presence of this factor, no CIs include 1 
+ +  All studies report an increased risk of CP in the presence of this factor, no CIs include 1 
+  All studies report an increased risk of CP in the presence of this factor, some CIs include 1 
§  All studies report no risk of CP in the presence of this factor 
-  All studies report a reduced risk of CP in the presence of this factor, some CIs include 1 
- -  All studies report a reduced risk of CP in the presence of this factor, no CIs include 1 
- / + OR § / + OR § / -   Inconsistent results 
 
Agree    The Term-CCCP findings agree with the findings from the systematic review 
I-risk      The Term-CCCP findings suggest a higher risk for CP following this factor than was identified in the     
systematic review 
D-risk     The Term-CCCP findings suggest a lower risk for CP following this factor than was identified in the 
systematic review 
 
 
Table 3: Factors not identified in the literature review ; Term-CCCP findings 
 
 
Preconceptional No (%) 
CP cases  
No (%) 
controls 
RR (95% CI) 
Maternal medical history of migraine  
Maternal medical history renal disease  
Maternal medical history GTI gram neg/pos or strep B 
Family history of CP 
Family history of intellectual disability  
14 (3.6) 
11 (2.7) 
13 (3.5) 
6 (1.5) 
26 (6) 
 
8 (1.9) 
8 (1.2) 
6 (1.5) 
0 (0) 
15 (3) 
 
1.9 (0.7-4.7)  
2.0 (0.6-5.8)  
2.2 (0.8-5.7) 
12.4 (0.7-222) 
2.4 (1-5.9) 
 
Antenatal     
Maternal recreational (only) drugs in pregnancy 8 (2.5) 4(1.2) 2.0 (0.6-2.7) 
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COMPARISON OF SYSTEMATIC REVIEW AND TERM-CCCP DISCUSSION  
PRECONCEPTIONAL FACTORS 
In the systematic review, no investigated preconceptional risk factors were 
consistently reported as posing a statistically significant risk.  
 
Maternal age and parity are logically related to each other and also to social factors 
that affect family size and age of child bearing which vary between cultures and 
over time within a population. These social factors may be as important as the 
biological factors in determining cerebral palsy risk and may explain why no 
consistent relationships between cerebral palsy risk and maternal age or parity 
were identified in the systematic review. In the Term-CCCP we identified statistically 
significant increased risk for both the first birth (of a magnitude consistent with the 
range of odds ratios reported in the systematic review) and double the odds for 
four or more previous births. Additionally there were increased odds ratios in the 
Term-CCCP associated with maternal age under 20 and maternal age over 40 that 
exceeded those found in the systematic review. Not holding private health 
insurance was associated with a small statistically non significant risk, similar to that 
identified in the systematic review. Data for other variables related to socio-
economic status (maternal education and employment status) were missing for too 
many Term-CCCP subjects to enable further analysis.  
 
Contrary to findings of the systematic review, the Term-CCCP with its extremely 
small numbers, found no evidence of an increased risk associated with prior 
maternal history of seizures, intellectual disability or thyroid disease. This data set 
relied on information found in the medical files, so if health professionals had not 
enquired about, tested for or treated these conditions specifically they could not be 
recorded as abnormal, hence these conditions are likely to be under ascertained, 
particularly in milder cases. A novel finding from the Term-CCCP was the significant 
increase in risk associated with a family history of intellectual disability and birth 
defects that was not identified in the systematic review. This was also the case for a 
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family history of cerebral palsy. Small numbers prevented this finding reaching 
statistical significance, but six cases (1.5%) and no controls had a family history of 
cerebral palsy. Maternal diabetes, asthma and coagulation disorders occurred rarely 
in the Term-CCCP and tended to be non-significantly associated with cerebral palsy, 
consistent with the findings of the systematic review. Previous recurrent 
miscarriage has been reported to be a risk factor for cerebral palsy in preterm 
births, and in studies of all cerebral palsy42 but not in studies restricted to term 
infants. More than three previous miscarriages were reported in 10 (2%) Term-CCCP 
subjects compared with 5 (1%) controls:  OR=1.9 (95% CI 0.7-5.8) suggesting that 
recurrent miscarriage may also be a risk factor for cerebral palsy in those born at 
term.  
 
ANTENATAL FACTORS 
The presence of birth defects was the antenatal factor with the highest odds ratio 
for cerebral palsy in the Term-CCCP consistent with the systematic review. Term-
CCCP data also confirmed that growth restriction and low birth weight were 
associated with a significantly increased risk of cerebral palsy. This convergence of 
findings confirmed that birth defects and growth restriction should be a central 
focus for the thesis. 
 
Perinatal infections and chorioamnionitis were all associated with an increased risk 
of cerebral palsy in the Term-CCCP, but did not reach statistical significance. 
Chorioamnionitis had a wide range of central estimates in the systematic review 
and reflects the different definitions employed across studies. As with other 
population based studies, the great majority of placentas were not sent to 
pathology, so the diagnosis of chorioamnionitis relied on observations by the 
midwife attending the delivery.  
 
Disturbance of amnionitic fluid volume (polyhydramnios or oligohydramnios) was 
more strongly associated with cerebral palsy in the Term-CCCP than in the 
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systematic review of term infants and were more consistent with the studies that 
looked at “all” cerebral palsy. Thirteen of 19 cerebral palsy cases but none of three 
controls with either condition also had a birth defect.  
 
Maternal anaemia (in contrast to the systematic review), hypertension and pre-
eclampsia were the maternal conditions with the highest risk of subsequent 
cerebral palsy in the infant.  
 
INTRAPARTUM FACTORS 
As identified in the systematic review ‘Birth asphyxia’ was the strongest risk factor 
identified in the Term-CCCP, and similarly the strongest risk factor in the systematic 
review. There was much variation in the definition of birth asphyxia, some defined it 
as hypoxic-ischemic encephalopathy, others as experiencing an intrapartum 
sentinel event and some by low Apgar scores. Individual sentinel events were also 
strongly associated with increased risks in the Term-CCCP, but occurred rarely. We 
made a decision based on this evidence to focus some of our efforts on those 
potentially asphyxial intrapartum (sentinel) events, and instead of classifying “birth 
asphyxia” as a risk factor, we used neonatal encephalopthy that was clinically 
reported as “asphyxial” in origin as an outcome by which to stratify future analyses.  
 
Inflammation has also been known to mimic signs of birth asphyxia. Fever during 
labour was not reported in the primary findings of the systematic review because 
only three studies reported it. The Term-CCCP confirmed this was a risk factor for 
cerebral palsy. It was decided that signs of inflammation, including fever in labour 
should be an additional focus because of the increased risk of placental 
abnormalities, fever and chorioamnionitis, its potential to directly affect the brain of 
the fetus, and it propensity to mimic birth asphyxia.   
 
The systematic review identified a number of modes of delivery as consistently 
statistically significant risk factors for cerebral palsy. The Term-CCCP did not find 
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any of these to be statistically significant risk factors. The use of forceps showed an 
increased risk in the Term-CCCP but there were inconsistent findings in the 
systematic review. Meconium aspiration was the only other intrapartum factor that 
was associated with increased risk across all studies.  
 
NEONATAL FACTORS 
The Term-CCCP confirmed findings of the systematic review that the presence of 
seizures was associated with a marked increase in the odds of cerebral palsy. It is 
agreed that seizures do not directly cause the brain damage that is responsible for 
cerebral palsy,43 but it is less certain whether seizures can exacerbate brain 
damage.44 The presence of seizures was one element contributing to our definition 
of neonatal encephalopathy and is not treated as an independent risk factor in the 
coming chapters. Hypoglycaemia, infections as a newborn and jaundice requiring 
treatment were confirmed by the Term-CCCP as risk factors for cerebral palsy. 
Apnoeas also increased the odds of cerebral palsy in the Term-CCCP, but were not 
reported in the primary findings of the systematic review because it was 
investigated in few studies. 
 
SYNOPSIS OF CHAPTER 5 
This chapter compared risk factors identified in a systematic review with those 
found in the Term-CCCP. Compared with the systematic review more 
preconceptional factors were identified by the Term-CCCP. Associations with mode 
of delivery variables were not as apparent however those with antenatal and 
neonatal factors and with birth asphyxia were similar. Risk factors that were 
identified in this chapter will be used throughout the remainder of this thesis. 
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CHAPTER 6 
MAJOR CAUSAL PATHWAYS TO CEREBRAL 
PALSY AND PERINATAL DEATH 
INTRODUCTION 
 
This chapter presents a paper which further investigates four of the 
antenatal/intrapartum risk factors identified in the preceding chapters. We sought 
to understand whether the magnitude of their associated risk with cerebral palsy 
and perinatal death altered, dependent on neurological status as a newborn. Figure 
7 shows the way we subdivided cerebral palsy and perinatal death for this paper. 
The systematic review in Chapter 4 highlighted that very few papers have explored 
the contribution of combined risk factors in a causal pathway approach. We sought 
to redress this and clarify the extent to which each of the four factors work together 
and whether combinations further increased risk.  
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Figure 7: Group selection for Chapter 6 
 
PAPER 3: ANTECEDENTS OF CEREBRAL PALSY AND PERINATAL DEATH IN TERM AND NEAR-
TERM SINGLETONS 
Antecedents of Cerebral Palsy and Perinatal
Death in Term and Late Preterm Singletons
Sarah McIntyre, BAppSc, MPS, Eve Blair, PhD, Nadia Badawi, FRACP, PhD, John Keogh, FRCOG,
and Karin B. Nelson, MD
OBJECTIVE: To examine the antecedents of cerebral palsy
and of perinatal death in singletons born at or after
35 weeks of gestation.
METHODS: From a total population of singletons born
at or after 35 weeks of gestation, we identified 494 with
cerebral palsy and 508 neonates in a matched control
group, 100 neonatal deaths, and 73 intrapartum stillbirths
(all deaths in selected birth years). Neonatal death and
cerebral palsy were categorized as without encephalop-
athy, after neonatal encephalopathy, or after neonatal
encephalopathy considered hypoxic–ischemic. We
examined the contribution of potentially asphyxial birth
events, inflammation, fetal growth restriction, and birth
defects recognized by age 6 years to each of these out-
comes and to intrapartum stillbirths.
RESULTS: The odds of total cerebral palsy after potentially
asphyxial birth events or inflammation were modestly
increased (odds ratio [OR] 1.9, 95% confidence interval
[CI] 1.1–3.2 and OR 2.2, 95% CI 1.0–4.2, respectively).
However, potentially asphyxial birth events occurred in
34% of intrapartum stillbirths and 21.6% of cerebral palsy
after hypoxic–ischemic encephalopathy. Inflammatory
markers occurred in 13.9% and 11.9% of these outcomes,
respectively. Growth restriction contributed significantly to
all poor outcome groups. Birth defects were recognized in
5.5% of neonates in the control group compared with 60%
of neonatal deaths and more than half of cases of cerebral
palsy without hypoxic–ischemic encephalopathy. In chil-
dren with cerebral palsy, a potentially asphyxial birth event,
inflammation, or both were experienced by 12.6%,
whereas growth restriction, a birth defect, or both were
experienced by 48.6% (P,.001).
CONCLUSION: Fetal growth restriction and birth defects
recognized by age 6 years were more substantial contrib-
utors to cerebral palsy and neonatal death than potentially
asphyxial birth events and inflammation.
(Obstet Gynecol 2013;122:869–77)
DOI: 10.1097/AOG.0b013e3182a265ab
LEVEL OF EVIDENCE: II
Two thirds of cerebral palsy arises in the 97% ofsingletons born at or after 35 weeks of gestation.1
The prevalence of cerebral palsy in these relatively
mature neonates, unlike that of survivors of very pre-
term birth, has not fallen in recent decades.1,2 Our
knowledge of brain lesions in cerebral palsy has
improved with advances in neuroimaging, but the eti-
ology and prognostic value of these lesions remain
imperfectly understood.3 Historically, research on
the etiologies of cerebral palsy in term and late pre-
term births has focused on asphyxial birth events.
More recently, the diversity of cerebral palsy etiology
has been explored with studies examining antenatal
factors including inflammation, suboptimal intrauterine
growth, malformations, multiple gestations, genetic fac-
tors,4 and how risk factors may interact to form causal
pathways to cerebral palsy5; we aimed to build on
this work.
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The objective of this study was to gain more
specific information concerning pathways to perinatal
death or cerebral palsy in term and late preterm
singletons. We sought to identify etiologically more
homogenous groups of cerebral palsy and neonatal
death by stratifying according to newborn neurologic
status, then quantified the contributions of four major
risk factors: potentially asphyxial birth events, indica-
tors of inflammation, fetal growth restriction, and
birth defects, alone or in combination, to each of these
outcomes.
MATERIALS AND METHODS
This article reports on the total population case–control
study of cerebral palsy and perinatal death in Western
Australian births from 1980 to 1995.6–8 Cerebral palsy
was defined as a disorder of movement, posture, or
both affecting activities of daily living resulting from
nonprogressive lesions or abnormalities of the develop-
ing brain.1 Eligible cases of cerebral palsy for this study
comprised all registrants of the Western Australian
Cerebral Palsy Register (now called the Western Aus-
tralian Register of Developmental Anomalies–Cerebral
Palsy)1 born in Western Australia between January 1,
1980, and December 31, 1995, excluding those whose
cerebral palsy was acquired postneonatally.
Perinatal and vital outcome data are available for
all Western Australian births in the Maternal Child
Health Research Database, which links statutory birth
and death registries with statutory pregnancy and
delivery information and includes more than 99.5% of
registered births. From this database, we selected
controls (matched for gestational age [within 1 week],
year of birth [within 12 months], and plurality) and
intrapartum stillbirths and neonatal deaths (deaths in
the first 28 days of life) in birth years specified in
Figure 1. We included all 791 children with cerebral
palsy born in or after 1980 (the year that the gesta-
tional age variable was added to the statutory birth
data set) who were available at the time of initiating
data collection. We limited etiologic heterogeneity by
selecting only singletons born at or after 35 weeks of
gestation, resulting in 508 participants in the control
group and 494 cerebral palsy cases. With these num-
bers, and considering that the direction of any associ-
ation would for most exposures be self-evident, we
estimated there was 80% or higher power at P,.05
to detect associations likely to be of clinical impor-
tance (odds ratios [ORs] less than 0.4 or greater than
1.8) if the exposure was observed in 5–50% of partic-
ipants in the control group.
This study was approved by the Princess Margaret
Hospital/King Edward Memorial Hospital Human
Research and Ethics Committee, individual hospital
and region human research and ethics committees,
ratified by the University of Sydney Human Research
and Ethics Committee and approved by the Confi-
dentiality of Health Information Committee of the
Western Australia Department of Health.
To achieve more homogenous etiologic groups,
we categorized cerebral palsy and neonatal death
according to presence or absence of moderate or
severe neonatal encephalopathy. Moderate or severe
neonatal encephalopathy was defined as any admis-
sion to special or intensive care (for neonatal death)
for 2 days or more (for cerebral palsy) with seizures,
abnormal consciousness (lethargic or comatose), or
abnormal tone.9–11 Neonatal encephalopathy was cat-
egorized as hypoxic–ischemic only if there was also a
clinical diagnosis of birth asphyxia or hypoxic–ischemic
encephalopathy in the medical record and is now
referred to as hypoxic–ischemic encephalopathy.
We considered seven adverse outcomes: intrapar-
tum stillbirth; neonatal death without encephalopathy,
after neonatal encephalopathy, and after hypoxic–
ischemic encephalopathy; and cerebral palsy without
encephalopathy, after neonatal encephalopathy, and
after hypoxic–ischemic encephalopathy; and two com-
bined outcomes “all cerebral palsy” and “all neonatal
deaths” (Fig. 1). We examined the association of each
of these outcomes with four repeatedly identified risk
factors: 1) potentially asphyxial birth events: uterine
rupture, amniotic embolism, tight nuchal cord
(described by the treating clinician as “tight”; eg,
requiring cutting for delivery), cord prolapse, placental
abruption, severe intrapartum hemorrhage (a minimum
of 100 mL fresh blood), maternal cardiac arrest, or
severe shoulder dystocia12,13; 2) signs of inflammation:
maternal pyrexia (greater than 37.5°C), uterine tender-
ness, malodorous amniotic fluid, high leukocyte count,
maternal or fetal tachycardia, and inflammatory placen-
tal histology14; 3) fetal growth restriction: birth weight at
least two standard deviations below optimal for gesta-
tional age and gender, maternal height and parity,15 or
to a decrease the risk of false-negatives with this restric-
tive criterion, a diagnosis of growth restriction noted in
the medical record; and 4) birth defects: a structural or
functional abnormality that is present at conception or
occurs before the end of pregnancy. We identified birth
defects by linking with the State Registry for birth
defects (Western Australian Register of Developmental
Anomalies), which collects information on defects diag-
nosed by age 6 years.16
For those with cerebral palsy, the predominant
motor impairment was categorized as spastic
hemiplegia, diplegia or quadriplegia, dyskinesia
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(dystonia or athetosis), or other (ataxia or isolated
hypotonia).
For each outcome group, we estimated frequen-
cies and proportions of each risk factor and pre-
dominant motor impairment. Odds ratios for each
outcome with each risk factor were estimated by
unconditional logistic regression using SAS 9.2 and
SPSS 19. Statistical significance was accepted at
a ,.05. The proportion of each outcome group that
would be prevented were the risk factor removed in
isolation was estimated from the OR obtained on uni-
variate analysis using the equation: attributable
fraction5p(OR-1)/(1+p[OR-1]), where p is the pro-
portion of participants in the control group exposed
to that factor.17 Median and interquartile ranges were
calculated for 5-minute Apgar scores.
RESULTS
Data were available for 508 participants in the control
group, 494 children with cerebral palsy, 100 neonatal
Western Australian
births 1980–1995
N=380,918 
Cerebral palsy
cases from the 
Western Australian
cerebral palsy register
(excluding postneonatal
and minimal cases)
n=782
Controls without
cerebral palsy
from the Maternal
Child Health Research
Database matched on
gestational age, year
of birth, and plurality
n=738
Intrapartum stillbirths
from 1985, 1987, 1989, 
1991, 1993, and 1995;
n=289*
Excluded: n=288
Registered 
after participant
selection: 12
Medical records not
located: 29
Multiple births and 
singletons under 
35 weeks of
gestational age: 247
Excluded: n=230
Multiple births
and singletons 
under 35 weeks of 
gestational age: 230
Excluded: n=216
Multiple pregnancies 
and intrapartum 
stillbirths under 35 weeks 
of gestational age: 216
Neurologic status
in the newborn period:
No encephalopathy; 
neonatal 
encephalopathy 
with clinical diagnosis
of hypoxic-ischemic
encephalopathy
Final groups for analysis
n=1,175
Total infants with
cerebral palsy
n=494†
Controls
n=508‡ 
Neonatal deaths
n=100
Intrapartum stillbirths
n=73
Neonatal deaths from
1985, 1987, 1991, 1995
n=336*
Excluded: n=236
Multiple births 
and neonatal deaths 
at under 35 weeks of 
gestational age: 236
Neonatal
encephalopathy
n=60
No neonatal
encephalopathy
n=323
Hypoxic-ischemic
encephalopathy
n=103
No neonatal
encephalopathy
n=54
Neonatal
encephalopathy
n=24
Hypoxic-ischemic
encephalopathy
n=22
Singletons with cerebral 
palsy at or above 35 
weeks of gestation
n=494
Singleton controls at 
or above 35 
weeks of gestation
n=508
Singleton neonatal
deaths at or above 35 
weeks of gestation
n=100
Singleton intrapartum
stillbirths
n=73
Fig. 1. Group selection fromWestern Australian total population. *Terminations and lethal birth defects excluded. †Includes
eight children with missing data for neurologic status in the newborn period. ‡No hypoxic–ischemic encephalopathy; mild
neonatal encephalopathy.
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deaths, and 73 intrapartum stillborn singletons born at
or after 35 weeks of gestation. There were no differ-
ences among these four groups with respect to
maternal age, number of previous births and number
of previous pregnancy losses, maternal epilepsy,
intellectual disability or other neurologic disorders,
coagulation disorders, or thyroid disease. Two pre-
conceptional factors were statistically different from
the control group. Of those with nonmissing data,
0.8% of participants in the control group, 1.6% of
cerebral palsy, 3.1% of neonatal deaths, and 1.4% of
intrapartum stillbirths had received treatment for
infertility. Private health insurance was held by
52.8% of mothers of participants in the control group,
46.8% of cerebral palsy, 36% of neonatal deaths, and
34.2% of intrapartum stillbirths and was the only
marker of social status widely available.
Eight children with cerebral palsy and missing
data for neonatal neurologic status were retained for
analyses of “all cerebral palsy” only. Of the 486
remaining children with cerebral palsy, 66.5% did
not exhibit encephalopathy, 12.4% exhibited neonatal
encephalopathy, and 21.2% were diagnosed with
hypoxic–ischemic encephalopathy (Table 1). Of the
100 neonates who died in the neonatal period, 22%
were diagnosed with hypoxic–ischemic encephalopa-
thy before death, a further 24% exhibited neonatal
encephalopathy, and 54% were not considered
encephalopathic (Table 2). Three participants in the
control group met our criteria for neonatal encepha-
lopathy but none for hypoxic–ischemic encephalopa-
thy. All 508 participants in the control group were
used as the comparison group. Apgar scores at 5
minutes were consistent with assigned neonatal neu-
rologic status: the median and interquartile range was
9 (interquartile range 9–9) for participants in the
control group and children with cerebral palsy with-
out encephalopathy, 9 (8–9) for children with cere-
bral palsy after neonatal encephalopathy, 4 (3–6) for
children with cerebral palsy after hypoxic–ischemic
encephalopathy, 9 (6–9) for neonatal deaths with-
out encephalopathy, 7 (5–8) for neonatal deaths with
encephalopathy, and 3 (1–5) for neonatal deaths
with hypoxic–ischemic encephalopathy.
The value for at least one of the four risk factors
was missing for no participants in the control group,
35 (7.1%) cerebral palsy cases, two (2%) neonatal
deaths, and one (1.4%) intrapartum stillbirth. Of those
with complete data, most (83%) of participants in the
control group, 40.5% of cerebral palsy, 23% of neonatal
Table 1. Distribution, Odds, and Central Estimate of Population-Attributable Fraction of Risk Factors in
Participants in the Control Group and Each Cerebral Palsy Outcome
Risk Factor
Cerebral Palsy
Control
(n5508)
No
Encephalopathy
(n5323)
Neonatal
Encephalopathy
(n560)
Hypoxic–Ischemic
Encephalopathy
(n5103) All* (n5494)
Potentially asphyxial birth event 24 (4.7) 15 (4.6) 5 (8.5) 22 (21.6) 42 (8.5)
Odds ratio (95% CI) Reference 1.0 (0.5–1.9) 1.9 (0.7–5.1) 5.5 (3.0–10)† 1.9 (1.1–3.2)†
Population-attributable
fraction central estimate (%)
0 4 17† 4†
Inflammation 12 (2.4) 7 (2.3) 3 (5.3) 12 (11.9) 22 (4.8)
Odds ratio (95% CI) Reference 1.0 (0.4–2.5) 2.3 (0.6–8.4) 5.6 (2.4–13)† 2.1 (1.0–4.2)†
Population-attributable
fraction central estimate (%)
0 3 10† 3†
Growth restriction 27 (5.3) 44 (13.7) 21 (35.0) 15 (14.6) 81 (16.5)
Odds ratio (95% CI) Reference 2.8 (1.7–4.7)† 9.6 (5.0–18.5)† 3.0 (1.6–5.9)† 3.5 (2.2–5.5)†
Population-attributable
fraction central estimate (%)
9† 31† 10† 12†
Birth defect at age 6 y 28 (5.5) 140 (43.3) 40 (66.7) 26 (25.2) 209 (42.3)
Odds ratio (95% CI) Reference 13.1 (8.4–20.4)† 34.3 (17.8–66)† 5.8 (3.2–10.4)† 12.6 (8.3–19)†
Population-attributable
fraction central estimate (%)
40† 65† 21† 39†
None of the above 424 (83.5) 138 (45.7) 9 (16.1) 39 (39.0) 186 (40.5)
CI, confidence interval.
Data are n (%) unless otherwise specified.
Denominators vary with the number of patients for whom the datum was missing; percentages given are those with a known value.
* Includes eight with missing data for neonatal neurologic status.
† Statistically significant at P,.05.
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deaths and 40.3% of intrapartum stillbirths experienced
none of the four risk factors (Tables 1 and 2).
Potentially asphyxial birth events occurred with a
similar low frequency in control children and those with
cerebral palsy or neonatal death who were not enceph-
alopathic in the newborn period. Potentially asphyxial
birth events occurred most frequently in intrapartum
stillbirths (34.3%) and in children with cerebral palsy or
neonatal death after hypoxic–ischemic encephalopathy
(21.6% and 22.7%, respectively) (Tables 1 and 2). Tight
nuchal cord, intrapartum hemorrhage (including pla-
cental abruption), and cord prolapse accounted for
87 of the 100 events reported and there were no instan-
ces of amniotic embolism (see Appendix, available on-
line at http://links.lww.com/AOG/A420).
Indicators of inflammation showed a similar pat-
tern to potentially asphyxial birth events, being rare in
participants in the control group and in cerebral palsy
with or without neonatal encephalopathy, but occurring
in significantly higher proportions of intrapartum
stillbirths, neonatal deaths, and cerebral palsy with
hypoxic–ischemic encephalopathy (Tables 1 and 2).
Inflammation occurred in combination with potentially
asphyxial birth events in 8.2% of intrapartum stillbirths
but infrequently in neonatal death or cerebral palsy
(Table 3).
Our criteria for growth restriction (see Appendix,
http://links.lww.com/AOG/A420) were met by 5.3%
of participants in the control group and at least 13% of
each poor outcome, being highest in poor outcome
groups after neonatal encephalopathy. For each sub-
group of neonatal neurologic status, growth restriction
was associated with higher odds of neonatal death
than of cerebral palsy (Tables 1 and 2).
Birth defects recognized by age 6 years were
associated with significantly elevated ORs and with
the highest attributable fraction of the four risk factors
examined for all outcome groups except for intrapartum
Table 2. Distribution, Odds, and Central Estimate of Population-Attributable Fraction of Risk Factors in
Participants in the Control Group and Each Perinatal Death Outcome
Neonatal Death
Risk Factor
Control
(n5508)
Intrapartum
Stillbirth
(n573)
No Neonatal
Encephalopathy
(n552)
Neonatal
Encephalopathy
(n524)
Hypoxic–Ischemic
Encephalopathy
(n522) All (n5100)
Potentially asphyxial
birth event, n (%)
24 (4.7) 25 (34.3) 4 (7.7) 1 (3.9) 5 (22.7) 10 (10.0)
Odds ratio (95% CI) Reference 10.5 (5.6–20)* 1.7 (0.7–5.0) 0.8 (0.1–6.2) 5.9 (2.0–17)* 2.2 (1.0–4.8)*
Population-
attributable fraction
central estimate (%)
31* 3 0 19* 5*
Inflammation, n (%) 12 (2.4) 10 (13.9) 6 (11.3) 1 (3.9) 3 (14.3) 10 (10.0)
Odds ratio (95% CI) Reference 6.7 (2.8–6.1)* 5.4 (1.9–15)* 1.7 (0.2–13.2) 6.9 (1.8–27)* 4.6 (1.9–11)*
Population-
attributable fraction
central estimate (%)
12* 10.5* 1.5 12* 8*
Growth restriction, n (%) 27 (5.3) 16 (21.9) 12 (23.5) 11 (42.3) 7 (31.8) 30 (30.3)
Odds ratio (95% CI) Reference 5.0 (2.5–9.8)* 5.3 (2.6–11.7)* 13.1 (5.5–31)* 8.3 (3.1–22)* 7.7 (4.3–13.8)*
Population-
attributable fraction
central estimate (%)
17* 19* 41* 28* 26*
Birth defect at age 6 y,
n (%)
28 (5.5) 9 (12.3) 30 (57.7) 22 (84.6) 8 (36.4) 60 (60.0)
Odds ratio (95% CI) Reference 3.1 (1.3–7)* 34 (12.0–46)* 94 (30–292)* 9.7 (3.8–25)* 25.7 (14.9–45)*
Population-
attributable fraction
central estimate (%)
10* 55* 84* 32* 54*
None of the above, n (%) 424
(83.5)
29 (40.3) 14 (27.4) 3 (11.5) 6 (28.6) 23 (23.5)
CI, confidence interval.
Data are n (%) unless otherwise specified.
Denominators vary with the number of patients for whom the datum was missing; percents given are those with a known value.
* Statistically significant at P,.05.
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stillbirths (Tables 1 and 2). They were identified in
almost half of the largest outcome group, cerebral palsy
without encephalopathy. Birth defects occurring in
combination with a potentially asphyxial birth event
or inflammation were seen in only a small proportion
of both cerebral palsy and neonatal death cases. Birth
defects and growth restriction were the most common
combination of risk factors, particularly in neonatal
death and cerebral palsy (Table 3). In children with
cerebral palsy, a potentially asphyxial birth event,
inflammation, or both was experienced by 12.6%,
whereas growth restriction, a birth defect, or both was
experienced by 48.6% (P,.001), making these the dom-
inant antecedents of term and late preterm singletons.
All cerebral palsy subtypes were represented
across all outcome groups (Table 4). Despite confirm-
ing the association between quadriplegia or dyskinesia
and hypoxic–ischemic encephalopathy, 65% of those
with quadriplegia or dyskinesia were not diagnosed
hypoxic–ischemic encephalopathy, and conversely
of 103 cases of cerebral palsy after hypoxic–ischemic
encephalopathy, 36 were not classified quadriplegic
or dyskinetic. Of the four risk factors, only birth
defects (OR 1.6, 95% confidence interval [CI] 1.1–2.3),
growth restriction (OR 1.7, 95% CI 1.1–2.8), and the
combination of growth restriction and a birth defect
(OR 1.9, 95% CI 1.1–3.6) significantly predicted quad-
riplegia or dyskinesia.
Table 3. Distributions and Odds of Combinations of Risk Factors in Participants in the Control Group,
Perinatal Deaths, and Cerebral Palsy
Factor Combination Control
Intrapartum
Stillbirth
Neonatal
Death
Cerebral
Palsy
Potentially asphyxial birth event and inflammation 1 (0.2) 4 (5.6) 0 2 (0.4)
OR (95% CI) Reference 29.4 (3.2–266)
Growth restriction and potentially asphyxial birth event 2 (0.4) 2 (2.8) 0 0
OR (95% CI) Reference 7.1 (1–51.4)
Growth restriction and inflammation 0 2 (2.8) 2 (2.0) 1 (0.2)
Potentially asphyxial birth event, inflammation and growth
restriction
0 2 (2.8) 1 (1.0) 0
Potentially asphyxial birth event and birth defect 1 (0.2) 0 2 (2.0) 11 (2.4)
OR (95% CI) Reference 11.5 (1.5–89)
Inflammation and birth defect 0 1 (1.4) 3 (3.1) 1 (0.2)
Growth restriction and birth defect 3 (0.6) 3 (4.2) 20 (20.4) 38 (8.3)
OR (95% CI) Reference 7.2 (1.4–36) 42.1 (12.2–145) 14 (4.3–45.8)
Growth restriction, birth defect, and potentially asphyxial
birth event
0 0 1 (1.0) 2 (0.4)
Growth restriction, birth defect, and inflammation 0 0 1 (1.0) 3 (0.7)
OR, odds ratio; CI, confidence interval.
Data are n (%) unless otherwise specified.
This table shows only statistically significant odds ratios for combinations experienced by participants in the control group.
Table 4. Distribution of Cerebral Palsy Type by Neonatal Neurologic Status
Cerebral Palsy Type
Without
Encephalopathy
Neonatal
Encephalopathy
Hypoxic–Ischemic
Encephalopathy
All Cerebral
Palsy*
Hemiplegia, n 125 15 11 154 (31.2)
% hemiplegia 81.2 9.7 7.1
Diplegia, n 69 5 19 94 (19)
% diplegia 73.4 5.3 20.2
Quadriplegia, n 51 25 39 116 (23.5)
% quadriplegia 44 21.6 33.6
Dyskinesia, n 38 8 28 75 (15.2)
% dyskinesia 50.7 10.7 37.3
Ataxia or hypotonia, n 40 7 6 55 (11.1)
% ataxia or hypotonia 72.7 12.7 10.9
Total 323 60 103 494 (100)
* Includes eight children with missing data for neonatal neurologic outcome.
Data are n or n (%).
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DISCUSSION
By defining more etiologically homogenous outcome
groups, limiting study participants to singletons at or
after 35 weeks of gestation, and stratifying by neonatal
neurologic status, our study identified stronger asso-
ciations for these risk factors and cerebral palsy or
perinatal death than previously published.18 We were
also able to identify poor outcome groups that had
little or no association with these specific risk factors.
This more informative approach to considering the
etiologic pathways to term and late preterm cerebral
palsy and perinatal death allowed us to see which out-
comes were most related to each of these risk factors.
The term hypoxic–ischemic encephalopathy is
often understood to imply a uniform etiology. How-
ever, in this population of children with cerebral palsy
who had been diagnosed with neonatal hypoxic–
ischemic encephalopathy, only one child in five had
a clinically recognized potentially asphyxial birth
event, whereas one in eight had markers of inflamma-
tion, one in seven was growth-restricted, one in four
had a birth defect recognized by age 6 years, and two
in five had none of these factors. Similar etiologic
heterogeneity was found in neonatal deaths preceded
by a diagnosis of hypoxic–ischemic encephalopathy.
The most etiologically homogenous groups were neo-
natal death or cerebral palsy after neonatal encepha-
lopathy in which four in five and three in five
children, respectively, had a recognized birth defect.
As anticipated,19 potentially asphyxial birth
events were most important for intrapartum stillbirth
with a population-attributable fraction of 31%. How-
ever, population-attributable fractions for cerebral
palsy or neonatal death after hypoxic–ischemic enceph-
alopathy were higher for birth defects than for poten-
tially asphyxial birth events, an unanticipated finding.
Potentially asphyxial birth events were not associated
with cerebral palsy in the absence of neurologic abnor-
mality in the newborn period, confirming the position
of the consensus statement.12
Intrauterine inflammation was the least identified
risk factor but markers of inflammation available in
population studies are neither sensitive nor specific
and may underestimate its role. Inflammation can
produce clinical findings that closely mimic birth
asphyxia, so it is possible that in some children with
a diagnosis of hypoxic–ischemic encephalopathy, the
initiating pathologic process was inflammatory. Opti-
mal clinical management and strategies for prevention
require distinguishing neonatal neurologic depression
resulting from asphyxial injury from that associated
with inflammation or other processes.20 That differential
diagnosis will require incorporation of information
from placental examination and may also require dis-
tinguishing inflammation resulting from infection
(chorioamnionitis or funisitis) from that resulting from
immunologic processes (chronic villitis).21,22
Fetal growth restriction was an important factor in
all examined poor outcome groups and has been
shown in other studies to be an important predictor of
cerebral palsy,4 neonatal encephalopathy,9,23 and still-
birth.19 Growth restriction is itself etiologically heter-
ogenous with maternal, fetal, and placental antecedents
that vary in their strength of association with cerebral
pathology.7,24 Of note, the majority of neonates with
growth restriction and adverse outcomes in this study
also had a birth defect recognized by early childhood.
Birth defects have been recognized as risk factors
for cerebral palsy at least since 195525 but in the current
study were identified in a far greater proportion than is
usually reported with a population-attributable fraction
of 39% for total cerebral palsy. Only 1.7% considered
deformational, that is, possibly a result of the brain
damage that also caused cerebral palsy. This difference
may be related to our focus on term and late preterm
singletons because defects are identified in greater pro-
portions of term than preterm born children with cere-
bral palsy,26 the inclusion of all defects occurring before
delivery (because many studies of cerebral palsy etiol-
ogy exclude birth defects, at least those of the brain and
spinal cord), and the inclusion of defects recognized
up to the age of 6 years.27 Acceptance of defects with
delayed recognition raises the possibility of outcome
bias; in an effort to counter this bias, minor defects were
included in these analyses only if they were identified
neonatally, before the outcome of cerebral palsy was
known. The combination of growth restriction and
a birth defect was the strongest predictor of neonatal
death and quadriplegic or dyskinetic cerebral palsy. At
present, both birth defects and marked growth restric-
tion are exclusion criteria for trials of therapeutic hypo-
thermia. Birth defects are also exclusion criteria for
trials to improve neurologic outcomes associated with
growth restriction. Given the considerably elevated risk
this group faces, it may be necessary to investigate ante-
cedents and approaches to management for these two
risk factors, especially when they co-occur.
The strengths of this study include its prospective
design in a total geographically defined population
and ascertainment of birth defects as recorded in the
State Register up to 6 years of age. It includes perinatal
deaths and attempts to identify etiologically more
specific pathways by stratifying by neonatal neurologic
status. Among its limitations, antepartum stillbirths
were not included because retrospective data for these
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occurrences were of relatively poor quality. Popula-
tion-attributable fractions estimate the clinically inter-
pretable fraction of the outcome preventable on the
isolated removal of an exposure by considering both
frequency of exposure and relative risk; however, they
must be interpreted cautiously. Our case–control study
design necessitates estimation of ORs, which overesti-
mate relative risk particularly when risks are high, re-
sulting in overestimation of population-attributable
fractions even if the exposure is indeed causal. The
medical records from which our data were extracted
were not created for research and certain potentially
important observations were not regularly available,
the most significant omission being placental histology.
Cerebral imaging was not routinely performed in this
era so perinatal stroke, a common cause of hemiplegic
cerebral palsy in term neonates,28 is not reported.
Although these data are based on birth years 1980–
1995, the rate of cerebral palsy in term and late pre-
term singletons remained constant throughout the
study period and has been unchanged since.1,2
Concurrent investigation of major risk factors in
a total population and categorization of outcomes by
neonatal neurologic status allows a better understand-
ing of the association of specific antecedents with
perinatal death and cerebral palsy than was previously
available. When 33 research priorities for the etiology
and prevention of cerebral palsy were recently agreed
on, more than one third focused on infection or
inflammation and hypoxia–ischemia, whereas none
addressed birth defects or growth restriction.29 Surely,
research priorities in cerebral palsy need reconsidera-
tion. This study adds weight to the evidence that in
singletons born at or after 35 weeks of gestation, very
significant proportions of cerebral palsy and of perinatal
death are associated with antenatal maldevelopment.
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ADDITIONAL DATA – BIRTH DEFECT CLASSIFICATION 
Table 4 outlines the birth defect types classified as brain, major defects other than 
brain and minor defects only. The majority of defects for those with cerebral palsy 
without HIE were cerebral, whereas the majority of defects for infants with HIE 
were major non cerebral. These are discussed in more detail in Chapter 7. 
 
Table 4:  Distribution of birth defects by type and cerebral palsy outcome group in 
term or near-term singletons  
                                             Controls                                Cerebral palsy 
  
N=508 
No NE 
N=323 
NE 
N=60 
HIE 
n=103 
All 
cerebral 
palsy 
N=494* 
Birth defect      
Cerebral (n) 2 89 23 4 117 
Column (%) 0.4 27.6 38.3 3.9 23.7 
      
Major non cerebral (n) 17 40 11 16 69 
Column (%) 3.3 12.4 18.3 15.5 14.0 
      
Minor (n) 9 7 5 6 18 
Column (%) 1.7 2.2 8.3 5.8 3.6 
 
*Includes 8 cases with missing data concerning neonatal neurological status 
 
SYNOPSIS OF CHAPTER 6 
This chapter consisted of a paper that focused on four antenatal and intrapartum 
risk factors for cerebral palsy and for perinatal death. The findings suggest that for 
cerebral palsy and neonatal death, antenatal factors such as birth defects and 
growth restriction were more important than the more commonly assumed 
intrapartum factors, sentinel events and inflammation. These were more important 
for intrapartum stillbirths. Combinations of major risk factors were rare with the 
exception of birth defects and growth restriction. 
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In addition, for the first time we attempted to identify more aetiologically 
homogeneous groups by stratifying analysis according to newborn neurological 
status. By doing so, we identified that the strength of association for each of the risk 
factors varied by newborn neurological status. By analysing total populations of 
cerebral palsy in this manner we gained a greater understanding of the effect of 
these risk factors. The remainder of this thesis considers these more homogeneous 
outcome groups rather than the combined “all term and near-term cerebral palsy” 
group. 
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CHAPTER 7 
AETIOLOGY OF CLINICALLY DESCRIBED HIE IN 
THOSE WITH CEREBRAL PALSY 
INTRODUCTION 
Chapter 6 presented the findings of our case control study for cerebral palsy and 
perinatal death as well as for seven aetiologically more homogeneous outcome 
groups. This chapter focuses on one of those seven groups; infants with cerebral 
palsy who were diagnosed with hypoxic-ischaemic encephalopathy (HIE+CP) in the 
newborn period (Figure 8).  
 
This chapter investigates the antecedents identified for the HIE+CP group in the 
preceding chapter in greater detail and discusses their clinical implication. The 
content of this chapter will comprise a paper that is currently under development 
with the same authorship team. 
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Figure 8: Group selection for Chapter 7 
 
BACKGROUND 
Neonatal encephalopathy (NE) affects about 3 per 1000 term live born infants and is 
an important predictor of mortality or persisting neurologic disability.45 The term 
describes a clinical picture and does not imply a specific aetiology.  Neonates in 
whom the aetiology of the neurological depression is thought to be hypoxic or 
ischaemic are diagnosed as having Hypoxic-Ischaemic Encephalopathy (HIE).  
However the judgment as to an hypoxic-ischaemic aetiology is difficult to confirm 
because there is no measure that is sensitive, specific and widely available to 
establish the presence of neurological symptoms in the newborn that are caused by 
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deranged oxygenation or blood flow. The severity of derangement required to 
produce ongoing neurological symptoms may also vary between individuals. 
Surrogate measures such as bradycardia, fetal heart rate pattern abnormalities, 
passage of meconium, low cord pH and early abnormal neuroimaging patterns all 
have potential causes other than intrapartum hypoxia,46, 47 and many of these signs 
are consistent with abnormalities of placental and other functions that originate 
long before labour. Thus, adverse outcome may not always be preventable by 
intrapartum intervention, as is sometimes assumed. Despite these diagnostic 
difficulties, for infants who survive the neonatal period after a diagnosis of 
moderate to severe HIE, cerebral palsy is an established and feared outcome.48  
 
WHAT IS THE ROLE OF TOTAL POPULATION STUDIES IN HIE AND CEREBRAL PALSY 
Different study designs have complementary advantages. Total population studies 
are basic to the understanding of the natural history of human disease. This is 
chiefly because they aim to identify every affected individual meeting specific 
criteria in a specific time period and commonly in one or a number of specified 
geographic area(s), minimizing the many biases of selected samples. Population 
studies are most valuable for providing unbiased estimates of disease and risk 
factor prevalences and impact. The literature of perinatal medicine seldom cites 
epidemiologic studies, but relies heavily on studies in experimental animals, which 
are very informative about mechanisms of operation of known risk factors but 
cannot provide information about nature and frequency of important risk factors in 
human infants.  
 
For a reasonably rare and very heterogeneous condition like cerebral palsy, a large 
study population is necessary. It has repeatedly been shown that population-based 
studies provide relatively robust and repeatable data, while clinic-based samples 
asking the same question get widely varying answers.38 Population studies often 
involve very large sample sizes, however the trade-off for large sample size is lack of 
the meticulous detail that is possible in well-studied but relatively small clinical 
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samples. The convergence of all study types will help enable us to understand the 
picture in its entirety.  
 
RECENT FINDINGS FROM A TOTAL POPULATION CASE CONTROL STUDY 
Although the term HIE is often understood to imply a single dominant aetiology, we 
recently observed in a total population of term and near-term singletons that 
antecedents of HIE later followed by cerebral palsy (HIE+CP) were heterogeneous 
(Table 5). One child in five had a clinically recognized sentinel event, one in six had 
markers of inflammation, one in seven was growth restricted, and one in four had a 
birth defect recognized by six years of age. The fraction of HIE+CP attributable to 
any of these proximal etiological risk factors was just over half, indicating further 
heterogeneity of HIE+CP aetiology.49  
 
Table 5: Number, percentage and odds ratios of risk factors for HIE+CP in term or 
near-term singletons 
 Controls HIE+CP HIE+CP 
Maximum N 508 103^ 
Univariate analysis 
103^ 
Multivariate analysis* 
Risk Factor N (%) 
Ref 
N (%) 
OR (95% CI) 
 
OR (95% CI) 
Sentinel Events     24 (4.7)  
Ref 
22 (21.6)  
5.6 (3.0, 10.4) 
 
7.1 (3.7,13.9) 
Intrauterine Inflammation      12 (2.4)  
Ref 
12 (11.7)  
5.5 (2.4, 12.5) 
 
8.1 (3.4,19.7) 
Growth restriction   27 (5.3) 
Ref 
15 (14.6) 
3.0 (1.6, 5.9) 
 
3.1 (1.4,6.5) 
Birth defects by 7 days  17 (3.4) 
Ref 
12 (11.7) 
3.8 (1.8, 8.2) 
- 
Birth defects by 6 years 28 (5.5) 
Ref 
25 (24.3) 
5.5 (3.0, 9.9) 
 
5.9 (3.1, 11.2) 
Combinations of risk factors  
Growth restriction & 6 year 
birth defects  
3 (0.6) 
Ref 
5 (4.9) 
 8.6 (2, 37) 
- 
Sentinel events & 6 year birth 
defects 
1 (0.2) 
Ref 
3 (2.9) 
15.4 (1.6, 149) 
- 
 
*multivariate analyses controlled for each risk factor                                                                    
^Denominators change slightly between risk factors on account of missing data in HIE+CP 
(n=1 sentinel event; n=2 Intrauterine inflammation; n=3 birth defects identified neonatally). 
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IMPLICATIONS OF A HETEROGENEOUS AETIOLOGY FOR HIE PRECEDING CEREBRAL PALSY  
Therapeutic hypothermia was introduced following investigations of animal models 
of acute asphyxia. In these models it was demonstrated that lowering body 
temperature could interrupt the secondary phase of neuronal death which 
contributes much of the cerebral damage following asphyxia. Both animal and 
human studies have shown that the earlier therapeutic hypothermia is commenced, 
the better the results.50-52 In neurologically depressed term and near-term neonates 
therapeutic hypothermia has proven to be a partially effective treatment, reducing 
mortality and morbidity but, benefiting only one in 6-9 treated infants.32 Might the 
limited efficacy of therapeutic hypothermia be related to the presence of an 
instigating pathobiology that differs from hypoxia-ischemia in some cases? In 
addition to our findings, the infants of mothers who reported late reduced fetal 
movements also responded differently to hypothermia.53 There is also growing 
excitement about a number of proposed alternative or adjuvant therapies for HIE to 
further decrease mortality and morbidity.54, 55 The prospect of new therapeutic 
advances brings urgency to the need to fully understand the antecedents of HIE 
because aetiology might influence trial outcomes and ultimately best treatment.  
 
DISCUSSION OF PRIMARY FINDINGS 
POTENTIALLY ASPHYXIAL BIRTH EVENTS 
Recognised intrapartum events capable of sufficiently disrupting blood flow to 
generate an hypoxic ischaemic injury form a class of antecedents for which we can 
be reasonably confident of the timing of the injury. Such events were found in 21% 
of HIE+CP compared to 5% in controls. Table 6 demonstrates that the majority 
(88%) of events seen in controls were a tight nuchal cord, and this was also the 
most numerous sentinel event in cerebral palsy cases (40%). We observed no 
amniotic embolisms, uterine ruptures or maternal arrests within these two groups. 
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Table 6: Potentially asphyxial birth events   
 Controls 
n=508  
N (%) 
CP+HIE 
n=103 
N (%) 
None 484 (95.3) 80 (77.7) 
Intrapartum haemorrhage/placental abruption 2 (0.39) 4 (3.88) 
Cord prolapse 0 (0) 6 (5.83) 
Tight nuchal cord or true knot 21 (4.13) 9 (8.74) 
Shoulder dystocia 0 (0) 3 (2.9) 
Shoulder dystocia & tight nuchal cord 1 (0.20) 0 (0) 
TOTAL  24 (4.7) 22 (21.4) 
  
To our knowledge, no previous population-based cerebral palsy study has reported 
the proportion of neonates with a clinical diagnosis of HIE that have experienced a 
potentially asphyxial birth event. Instead they have employed varying definitions of 
birth asphyxia (some of which include sentinel events as a criterion) and report 
proportions of total cerebral palsy attributable to birth asphyxia ranging from <3% 
to over 50%.47 One systematic review suggested that 15% of cerebral palsy was 
associated with intrapartum hypoxia ischemia.46 In our total CCCP study there were 
741 infants with cerebral palsy, a clinical diagnosis of HIE was associated with 14%, 
and a potentially asphyxial intrapartum event was associated with 3%. 
 
In randomized controlled trials of hypothermia that excluded neonates with 
identified birth defects and/or marked growth restriction, the proportions of 
subjects with potentially asphyxial birth events was higher, ranging from 4056 - 
60%.57, 58 Since these trials were published, reports of hypothermia used for HIE 
outside of a clinical trial setting indicate that 2259 - 51%60 of those treated 
experienced a potentially asphyxial birth event. These figures suggest that there are 
antecedents of HIE being treated by hypothermia for whom the timing and nature 
of injury is less certain.  
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The relationship between potentially asphyxial birth events and neurologic outcome 
differs in different settings and a great deal has been achieved in contemporary 
obstetric and neonatal care. In high resource areas, primary prevention of NE/HIE 
has advanced remarkably since the days in which William Little wrote about 
“asphyxia neonatorum” in what came to be known as cerebral palsy. In developing 
countries, Lee and colleagues found that as proportions of births in medical facilities 
increased from ten to 90%, the incidence of NE from all causes decreased by 75%.61 
Some hospitals in developed countries are finding a significant reduction over time 
in the incidence of both sentinel events and HIE following the adoption of 
multifaceted patient safety programs including training teams of practitioners to 
respond to these rare acute catastrophic events.34, 62 Continuing to decrease the 
incidence of rare sentinel events along with maximizing the efficacy of treatment 
following them should be prioritized, but it will not greatly reduce the frequency of 
cerebral palsy. 
 
RISK FACTORS OTHER THAN THOSE CLEARLY ASSOCIATED WITH HYPOXIA ISCHAEMIA ALSO 
OCCUR IN EXCESS IN HIE+CP  
INFLAMMATION 
Markers of intrauterine infection or inflammation during the intrapartum period 
occurred in 12% of infants with HIE+CP compared to 2% in controls. Inflammation is 
probably the least well recognized of major risk factors for HIE+CP at a population 
level, and perhaps clinically. Cooling studies have reported inflammation identified 
by maternal pyrexia in 3-10% of subjects56, 57, 63 various clinical signs of intrauterine 
infection in 9%58 and by systemic infection in the neonate in 3%.64 As with our 
study, these methods of identifying perinatal inflammation/infection are 
insensitive, suggesting that the true proportions may be higher. A meta-analysis of 
data from these cooling studies stratified by the presence of markers of 
inflammation may help to elucidate whether neonates exposed to inflammation 
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respond differently to hypothermia than those experiencing potentially asphyxial 
birth events.65  
 
Histological examination of the decidua (placenta, cord and membranes) is the gold 
standard for identifying intrauterine inflammation and for differentiating infections 
from immune responses (eg. chronic villitis). Our study and the cooling trials did not 
use placental examinations to identify the presence of inflammation, but 
Wintermark65 observed a high rate of placental lesions in infants with HIE and 
Chang et al identified placental inflammation in 73% of neonates admitted for 
hypothermia who did not have a sentinel event.60 In a recent placental study of NE 
“due to presumed hypoxia ischaemia”, at least one placental lesion was identified in 
12 of 13 neonates who were later identified as having cerebral palsy.59 Placental 
examinations are much more feasible for studies of HIE than studies of all cerebral 
palsy as most babies diagnosed with HIE are symptomatic in the delivery room, 
where the placenta can still be retrieved. In such cases, histological examination 
should become routine and include distinguishing infection from immune 
responses. Findings should not only be recorded, but be sent to the location of the 
baby – especially if they have been transferred for specialist care. In addition, 
recent experimental studies are exploring approaches to intrauterine detection of 
placental inflammation with MRI,66 which may open a neuroprotective window for 
emerging treatments.67, 68 
 
INTRAUTERINE GROWTH RESTRICTION 
Intrauterine growth restriction was defined as birth weight at least two standard 
deviations below optimal for gestational age and gender, maternal height and parity 
69 or, to decrease the risk of false negatives with this restrictive criterion, a diagnosis 
of fetal growth restriction noted in the medical record. With this definition, growth 
restriction was associated with a trebling of odds of HIE+CP in this study. Small size 
for gestational age has consistently been observed to increase risk of cerebral palsy 
and was associated with heightened risk of NE in a previous population-based 
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study.20 The previous paper highlighted that growth restriction was most strongly 
associated with cerebral palsy when co-occurring with birth defects in the absence 
of HIE.49 It therefore supports other findings that fetal growth restriction does not 
increase the risk of cerebral palsy primarily by increasing vulnerability to hypoxia 
experienced in labour.70-72 However, there were ten infants with HIE+CP and growth 
restriction that did not have accompanying birth defects. They tended to be long for 
weight, relative to growth restricted controls or cerebral palsy not diagnosed with 
HIE, indicative of growth restriction of recent onset. This finding suggests that fetal 
growth restriction may increase vulnerability to hypoxia in labour, but it is a 
relatively minor pathway. We are unable to say what caused the late onset growth 
restriction. Pregnancy induced hypertension was seen in one fifth of controls with 
isolated growth restriction, but in only one of the ten HIE+CP. Smoking later than 20 
weeks was seen in two of the ten but it is not usually associated with this degree of 
growth restriction, nor late onset growth restriction.  
 
Fetal growth restriction is itself aetiologically heterogeneous and it is reasonable 
that there may be a number of pathways to cerebral palsy that include growth 
restriction. It is a challenge for future research to identify which types of impaired 
fetal growth contribute to pathways to neonatal and subsequent neurologic 
dysfunction, and how these can be prevented.  
 
BIRTH DEFECTS 
Birth defects identified by age six years contributed at least as much to HIE+CP as 
potentially asphyxial birth events. In the National Collaborative Perinatal Project, 
more than a third of infants with neonatal seizures, considered by some to be a 
sufficient criterion for HIE, had major malformations identified by one year of age.73 
Conversely, in consecutively diagnosed patients with malformations of cortical 
development and cerebral palsy, 10% had been diagnosed as asphyxiated at birth.74 
Table 7 shows that the proportion of those with identified birth defects increased 
 Page | 104  
 
significantly (11.7% to 24.3%) when all defects identified by six years of age were 
added to neonatal data. 
 
Table 7: Birth defect subtypes identified by 7 days and by 6 years in controls and 
HIE+CP 
 First birth defect  
identified by 7 days 
First birth defect 
identified by 6 years 
N (%) N (%) 
Controls 
N=508 
Cerebral 1 (0.2) 1 (0.2) 
Major 5 (0.8) 12 (2.3) 
Minor* 11 (2.8) 15 (2.9) 
Any 17 (3.1) 28 (5.5) 
HIE+CP 
N=103 
Cerebral 3 (2.9) 4 (3.9) 
Major 6 (6.8) 11(10.7) 
Minor* 3 (1.9) 10 (9.7) 
Any 12 (11.7) 25 (24.3) 
 
*Minor defects also include male genital and deformational defects 
 
Cerebral palsy registers and studies that link with birth defect registers all report an 
increased proportion of cerebral palsy with a birth defect,75, 76 compared to those 
that are not linked in this manner. Furthermore, birth defect registers that collect 
information up to age six have higher ascertainment than those that collect to age 
one.77 Birth defect details of those with HIE+CP are presented in Table 8. There was 
no discernible pattern that could suggest a specific pathway for the role of birth 
defects in those with cerebral palsy following HIE. The majority of central nervous 
system defects were identified before the second week of life. For both cases and 
controls the birth defects with delayed recognition were predominantly major 
defects outside the central nervous system (Table 7), with 7 of 508 controls and 5 of 
103 HIE+CP having delayed recognition of a major defect.  Recognition of minor 
birth defects were also delayed, but in a higher proportion (p<0.001) of cases, 
suggesting the possibility of bias in this group due to ongoing medical attention. 
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One control and three HIE+CP infants’ sole minor defect was undescended testes 
requiring surgical correction (Table 8). This particular difference in the minor defect 
category is unlikely to be due to chance, as testing for undescended testes is routine 
practice, suggesting that for some types of defects in this category the difference is 
real. Two deformational defects in those with HIE+CP were developmental dysplasia 
of the hip which may have been the result of the brain damage that caused the 
cerebral palsy. Both of these children also had the same sentinel event – 
intrapartum haemorrhage. There was no obvious pattern between defects and the 
other risk factors considered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page | 106  
 
Table 8: Birth defect details of children with cerebral palsy who had HIE 
 
Birth defects indentified before 7 days  
of age 
 
Birth defects identified by age 6 years 
 
Central nervous system +/- other major/minor 
1 Hydrocephalus, bilateral talipes 1 Corpus callosum dysgenesis 
2 Porencephalic cyst, hydrocephalus 
with absent septum  pellidium 
2 √ 
3 Porencephalic cyst, alloimune 
thrombocytopenia, developmental 
dysplasia of hips 
3 
 
4 
√  
 
Microcephaly, cerebral hypoplasia,  
vertebrae anomaly + IUGR 
Major – Chromosome  
4 Trisomy 21 5 √ 
  6 Williams Syndrome + IUGR 
  7 46,XY,INV(Y)(P11.3Q12)PAT  
Major – Urogenital  
5 Kidney dysplasia, Potters Facies 8 √ 
  9 Hydronephrosis 
  10 Vesico ureteric reflux 
Major – Gastrointestinal 
  11 Pyloric stenosis 
Major – Other 
6 Fetal alcohol syndrome 12 √ 
7 Left hand infarction +IUGR 13  √ 
8 Hydrops fetalis + II + IUGR 14  √ bilateral cataracts, glaucoma  
Major – Metabolic 
9 Lactic acidosis, dysmorphic features 15 √ 
Minor only 
10 Single umbilical artery 16 √ 
11 Dysmorphic features + SE-CP 17 √  
12 Unilateral undescended testes 18  √ 
  19 Short metatarsal + IUGR 
  20 Micrognathia 
  21 Absent depressor anguli oris muscle 
  22 Bilateral undescended testes + SE-SD 
  23 Unilateral undescended testes 
  24 
 
25 
Developmental dysplasia of the hips  
+ SE-IPH 
Developmental dysplasia of the hips  
+ SE-IPH 
 
SE-CP Cord prolapse; SE-SD shoulder dystocia; SE-IPH Intrapartum haemorrhage; II Intrauterine 
inflammation; IUGR Intrauterine growth restriction 
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The large randomized controlled trials of hypothermia for HIE aimed to exclude 
major defects but could only exclude those detected in the first few hours of life, 
before treatment commenced. No reports of these trials state what proportion of 
otherwise eligible neonates were excluded by this criterion. Applying the same 
criterion to our sample, 15 infants had major defects, six of whom (40%) were not 
identified in the first seven days. If growth restriction (as we define it) were an 
additional exclusion criterion two of these six would have been excluded for growth 
restriction, leaving four of 15 being treated with hypothermia despite a major birth 
defect because the defect was not identified early enough. With only 20% of 
treated neonates currently benefitting from hypothermia,32 it should be asked 
whether undiagnosed birth defects or inflammation are associated with an 
unfavourable therapeutic response. Or conversely, whether those with major 
defects and diagnosed with hypoxic ischemic encephalopathy would also benefit 
from cooling? Questions that remain are: Which defects lower the individual’s 
capacity to compensate for the inevitable hypoxia accompanying birth and which 
defects produce symptoms that mimic HIE? 
 
With more frequent use of antenatal ultrasound, has time to diagnosis of birth 
defects been reduced since these data were collected? Bower et al reported in their 
most recent birth cohort that the proportion of birth defects diagnosed in the first 
month of life (66%)77 was comparable to the proportions reported during the birth 
cohorts from which our study subject arose (70%) suggesting that this potential bias 
is unlikely. Children with HIE+CP had early and continuing medical problems and 
undoubtedly received more medical attention than control children, and may 
therefore be more likely to have had defects detected. A study of non-cerebral 
defects in an overlapping sample suggested that biased ascertainment resulting 
from increased medical attention meant that non-cerebral defects in controls were 
under-ascertained by 5.7%.78 A bias of similar magnitude in our controls suggests 
that with comparable ascertainment their rate would be 5.55% rather than 5.3%. 
 
 Page | 108  
 
CONCLUSION 
This study and others cited indicate that in contemporary high-resource areas, 
obstetric catastrophes now account for only a minority of HIE in those with cerebral 
palsy and much encephalopathy in neonates with later cerebral palsy is related to 
maldevelopment during pregnancy. The possibility that underlying aetiology might 
alter response to hypothermic treatment in the newborn has not yet been 
examined. We are about to enter an era of cooling-plus trials, with many more 
treatments designed to address different pathways. HIE is fortunately uncommon 
so its study will require large sample sizes and international collaboration.79 I 
recently helped to organize, and attended a two day meeting “Neonatal 
encephalopathy and Hypoxic Ischemic Encephalopathy: Improving the science and 
outcomes” held at the National Institutes of Health and supported by the Cerebral 
Palsy Alliance. There was general agreement amongst the 40+ researchers in 
attendance that in this field there is a need for: (i) aligning the definitions of factors 
under study to facilitate collaboration and (ii) seeking a better understanding of 
underlying mechanisms, thus allowing these new therapeutic approaches to be 
directed to the infants most likely to respond. The group agreed that such an 
approach will require secondary analyses of clinical trial data incorporating 
information on placental histology, maternal indicators of inflammation and 
investigation of birth defects identified throughout early childhood.  
 
SYNOPSIS OF CHAPTER 7 
Chapter 7 has detailed the aetiological heterogeneity found in the group of children 
that were diagnosed with HIE as a newborn and later identified as having cerebral 
palsy. The next chapter will focus on a more aetiologically homogeneous group, 
those with a brain injury of presumed hypoxic cause with intrapartum timing and 
will then determine; Is this a complete pathway? 
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CHAPTER 8 
ACUTE INTRAPARTUM HYPOXIA – IS THIS A 
COMPLETE PATHWAY? 
INTRODUCTION 
Building on Chapter 7, this chapter discusses the theoretically most homogeneous 
aetiological group of term cerebral palsy; those with acute intrapartum timing of a 
presumed hypoxic cause. All infants were diagnosed with either a sentinel event 
during birth or with metabolic acidosis, followed by moderate to severe 
encephalopathy, and had confirmed spastic quadriplegia or dyskinesia by age five. 
However, within a paradigm of causal pathways, we ask if this intrapartum event is 
the whole pathway or could it be one component on the pathway to cerebral palsy?  
 
I presented these findings at the American Academy of Developmental Medicine in 
Toronto 2012. The presentation was chosen as a finalist for the Gayle G Arnold 
Award for Excellence (Appendix L). This paper has been submitted to 
Developmental Medicine & Child Neurology in September 2013. 
 
Figure 9 illustrates the groups that are used for this paper. 
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Figure 9: Group selection for Chapter 8  
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What this paper adds 
 
 Contrary to long standing belief, acute intrapartum hypoxia was on the causal 
pathway for a minority of term singletons  
 In a clinical and population wide setting definitions used to identify acute intrapartum 
hypoxia need further examination 
 For most experiencing acute intrapartum hypoxia other strong risk factors were 
present prior to labour 
 Pathways to CP that include acute intrapartum hypoxia may include risk factors in the 
antenatal and neonatal period 
 Less than 1.5% of term infants had a pathway to CP that only included acute 
intrapartum hypoxia 
 
Aim:  To investigate risk factors prior to acute intrapartum hypoxia (AIH), in children with 
cerebral palsy (CP). 
Methods: Instances of AIH were sought in a total population of 457 singletons with CP, born 
at term in Western Australia (1980-1995). AIH was defined as moderate/severe neonatal 
encephalopathy, spastic quadriplegia or dyskinesia and either: cord blood pH<7 and base 
deficit ≥12 or a sentinel event. Risk factors were compared between cases meeting criteria for 
AIH and 468 matched (for being singleton, born at term and in the same birth years) controls.  
Results:  Twenty-one of the 457 (4.6%) children with CP met criteria for AIH, 6 met the first 
and 16 the second set of criteria, with one meeting both sets. Four of six with pH<7 and base 
deficit ≥12 experienced antenatal risk factors as did ten of 16 with sentinel events. Sentinel 
events included: eight tight nuchal cords, one true knot in cord, three cord prolapses, three 
severe intrapartum haemorrhages, one severe shoulder dystocia and one sustained 
bradycardia (FHR<60) only. In six of 16, the sentinel event was probably the sufficient 
initiating event. Nineteen of 21 had conditions in the neonatal period that may have 
exacerbated the injury or limited the potential for recovery.  
Interpretation: AIH appeared to be the initiating event and an isolated pathway to CP for 
1.7% of all term singletons. Suboptimal antenatal events were recorded prior to the AIH for 
3.1%. Pathways to CP that include AIH are rare and may be more complex than current 
theories suggest. 
WORDS: 250 
 
Shortened title: Acute intrapartum hypoxia and cerebral palsy 
 
 
 
 
 
 
 
 
 
 
 
Acute intrapartum hypoxia (AIH) sometimes referred to as birth asphyxia, was in the past 
thought to be the principal cause of cerebral palsy (CP). Current estimates suggest that the 
proportion of CP attributable to AIH is 12% or less.
1
 Other factors that have been identified 
to cause or increase the risk of CP include genetics, maternal illness, premature birth, 
intrauterine growth restriction, birth defects, congenital infections, stroke, multiple birth, and 
post neonatal events.
2, 3
 It is generally agreed that all these risk factors lie on causal paths to 
CP and research is now focussed on how and when they interact with each other. AIH 
however, is often dramatic in nature and is assumed to represent a single sufficient cause, a 
complete causal path. Therefore once AIH is diagnosed antecedents are seldom sought.  
 
The hypothesis of this study was that singleton infants with CP born at term with AIH were 
also exposed to antecedents that made them vulnerable to the normal hypoxia of labour and 
increased their risk of sustaining permanent brain damage. In a total population case control 
study of cerebral palsy we asked: What proportion of CP can be attributed to AIH? And, do 
other aetiological risk factors exist on pathways that include AIH? 
 
Methods 
 
This report uses data collected for a total population case-control study of all CP in Western 
Australia (1980-1995). Cases were identified from the Western Australian CP Register where 
CP was defined as a disorder of movement and/or posture affecting activities of daily living 
due to nonprogressive lesions or abnormalities of the developing brain, not acquired 
postneonatally.
4
 Controls, neonatal survivors without CP, were selected from the Maternal 
and Child Health database of all births in Western Australia and were individually matched to 
cases for date of birth (within 12 months), gestational age at delivery (within 1 week), and 
plurality. 
 
Pregnancy and delivery information are available for more than 99.5% of all registered births 
in Western Australia. More detailed clinical data were collected for cases and controls by 
trained research nurses blind to case status from the medical records of hospitals of birth, any 
additional transferring or receiving hospitals, general practitioners and obstetricians identified 
in medical records as associated with pregnancy, delivery or neonatal care. A further data 
linkage was carried out with the Western Australian Register of Developmental Anomalies to 
ascertain birth defects identified up until the age of six years. 
http://kemh.health.wa.gov.au/services/register_developmental_anomalies/warda.htm 
 
This study was approved by the Princes Margaret Hospital/King Edward Memorial Hospital 
Human Research and Ethics Committee, individual hospital and regional human research and 
ethics committees, ratified by the University of Sydney Human Research and Ethics 
Committee and approved by the Confidentiality of Health Information Committee of the 
Western Australia Department of Health. 
 
The criteria for acute intrapartum hypoxia to be considered a possible cause of cerebral palsy 
have been previously developed by an international consensus group
5
. The essential criteria 
in that statement were: 
1. Metabolic acidosis as defined by pH <7 and base deficit ≥12mmol/L in fetal umbilical 
cord arterial blood obtained at delivery. 
2. Early onset of moderate or severe neonatal encephalopathy. We defined this as 
admission to a neonatal intensive care unit for two or more days with either abnormal 
consciousness – lethargy or coma, seizures or abnormalities of tone. 
3. Cerebral palsy of the spastic quadriplegic or dyskinetic type. 
All cases meeting these criteria were considered to have experienced AIH. 
Others
 
have rejected metabolic acidaemia as the essential first criterion
6
 since acid-base status 
is often not measured during labour and, may change rapidly. Furthermore intrapartum 
acidaemia may no longer be apparent by the time of delivery and may also have other causes. 
These authors have suggested instead that a sentinel event just prior to or during labour must 
occur to meet the concept of timing being “around birth”. For this report we therefore also  
accepted  those with a sentinel event in place of criterion 1 above where a sentinel event was 
defined as: uterine rupture, amniotic embolism, tight nuchal or true knot in cord, cord 
prolapse, tight knot in cord, placental abruption, severe intrapartum haemorrhage, maternal 
cardiac arrest or collapse during labour, severe shoulder dystocia or in the absence of one of 
the above, sustained (more than five minutes) bradycardia (Fetal Heart Rate <60bpm).  
 
Unconditional logistic regression was used to determine the odds ratios for risk factors 
occurring prior to or directly after the AIH. They were calculated by comparing frequencies 
in those meeting a definition of AIH and controls. Statistical significance was accepted at 
alpha=0.05 A descriptive analysis of each infant meeting AIH criteria was also performed.   
 
Results: 
Six of 457 (1.3%) term born singletons with CP met the three essential criteria of the 
consensus statement. A sentinel event (true knot in cord) was noted in only one of these 
infants. A further 15 infants without cord blood data had a sentinel event and met the 
remaining criteria.  Thus, 21 of 457 (4.4%) CP cases met our criteria for AIH (AIH+CP). 
Sentinel events included: eight tight nuchal cords, one true knot in cord, three cord prolapse, 
three severe intrapartum haemorrhages, one severe shoulder dystocia and one sustained 
bradycardia. The median Apgar score at five minutes was three and for 19 their quadriplegia 
and/or dyskinesia was severe (equivalent to GMFCS IV or V).  
In the preconceptional period the only risk factor that occurred statistically significantly 
more frequently in AIH+CP than controls was previous infertility for longer than one year 
(Table 1). Preconceptional factors that were investigated but were comparable between 
groups were: a family history of CP/birth defects/other neurological disorders; rural residence 
and mothers who smoked. 
During the antenatal period statistically significant risk factors included oligohydramnios, 
intrauterine growth restriction (defined as weight more than 2 standard deviations below 
optimal
7
 or, to minimise false negatives, a neonatal diagnosis of growth restriction), the 
presence of a birth defect, indicators of placental abnormality and late onset (37+weeks) of 
maternal hypertension (Table 1). Other risk factors investigated but not associated with 
increased risk of AIH+CP included primiparity, maternal illnesses (diabetes, anaemia, thyroid 
disorders, asthma) during pregnancy, number of antenatal admissions to hospital, number of 
bleeds after the first trimester and maternal smoking or alcohol consumption after 20 weeks.  
During the intrapartum period, ten of the 21 with AIH+CP had their lowest fetal heart rate 
recorded as 80 or below, one had sustained bradycardia, with a fetal heart rate of 50 for more 
than five minutes. All 21 required resuscitation in the delivery room with 13 requiring 
ventilation. None were diagnosed with clinical chorioamnionitis or had maternal fever in 
labour. Meconium aspiration was a statistically significant risk factor, in addition to the 
intrapartum factors from which AIH was inferred (Table 1).  
Hypoxic ischemic encephalopathy was clinically diagnosed in the neonatal period for 18/21 
infants. Transient metabolic conditions, bacterial infections, temperature regulation problems 
and apnoea were associated with CP in those with AIH. 19/21 were exposed to at least one of 
these neonatal conditions with most infants (14) exposed to more than one. Jaundice 
sufficiently severe to require transfusion was noted in two infants (Table 2), neither of whom 
was diagnosed with hypoxic ischemic encephalopathy but each experienced a sentinel event 
(intrapartum haemorrhage and tight nuchal cord).  
Table 2 details the risk factors identified in each time period for each of the 21 AIH+CP. Of 
the six meeting the consensus criteria two infant/mother pairs did not have strong risk factors 
prior to the intrapartum period, however one had multiple neonatal complications. The 
remaining four had placental problems, growth restriction and dysmorphic features, all 
suggesting antenatal problems prior to the intrapartum period. 
Of the 15 children with AIH+CP not meeting consensus criteria but with a sentinel event, six 
had no risk factors prior to the intrapartum period. Two infants both with tight nuchal cord 
had bacterial infections in the newborn period, two further infants with tight nuchal cords had 
placentas described as gritty, and one infant with severe shoulder dystocia also had a calcified 
placenta. Placentas described as calcified or gritty in this descriptive analysis were not 
considered to be strong antenatal risk factors. Six of the 15 infants did have risk factors prior 
to the intrapartum period: One infant with a tight nuchal cord also had multiple birth defects 
and was growth restricted, two also with tight nuchal cords had placental risk factors 
(vascular congestion and placental infarcts), one with a cord prolapse had a thin cord laterally 
inserted, another with cord prolapse had dysmorphic features, and the third cord prolapse was 
preceded by two bleeds, two urinary tract infections and late onset of hypertension. The 
remaining three had antenatal factors of uncertain significance: two with congenital 
dislocation of the hip and one with decreased fetal movements. 
 
Discussion: 
The major findings of this study were the small proportion of term born singletons whose CP 
could possibly be attributed to acute intrapartum hypoxia as per recommended statements and 
that only one third of these infants did not have other plausible risk factors for CP in addition 
to the AIH. 
Many studies have sought to identify the proportion of CP that is attributable to AIH, often 
referred to as birth asphyxia. A recent review identified that definitions for birth asphyxia 
were broad and often non-specific and the definitions for CP differed between studies. These 
factors, along with differences in aetiological profile in developing countries, may account 
for the wide range of estimates (3 to 50%) of CP attributable to birth asphyxia
1
. Our study 
identified only 21 (4.6%) term born singletons whose CP could be attributed to our criteria 
for AIH. The major limitation of our study is the large proportion of missing data for 
umbilical arterial cord pH and Base Excess. Of the 21 infants in the final AIH group only 
seven (33%) had these data, since these births occurred when these tests were not routine. 
Missing data on this criterion remains a problem in clinical practice. A recent study identified 
that only 50% of infants with low Apgars had cord gases measured
8
. This is further illustrated 
by an important recent randomised controlled trial where these measurements were key 
inclusion criteria. Amongst high risk infants, blood gas data taken any time within the first 
hour was missing for 20%
9
. The maximum number of term singleton CP in our study that 
may have had AIH on their causal path (ie had moderate to severe encephalopathy and 
quadriplegia or dyskinesia without a brain birth defect or syndrome responsible for their CP) 
was 57. There was no missing data concerning sentinel events but there were 37 infants who 
did not have cord blood gas measurements. Therefore the proportion of term born singletons 
with CP in our study that had AIH on their causal path lies between 4.4 and 12% but is most 
likely to be closer to the lower bound than the upper. 
The criteria used to identify AIH in this study were metabolic acidosis or a sentinel event 
followed by moderate to severe encephalopathy, with an outcome at five years of 
quadriplegic or dyskinetic CP. For the very small number of total CP with AIH in this study, 
we can hypothesise a number of pathways to CP that in addition to the classic AIH scenario 
incorporates antenatal factors suggesting problems in the period prior to an AIH. In the past, 
it has been suggested that if other well acknowledged antenatal risk factors exist then AIH is 
not the cause or even on the causal path to CP
10,11
. We agree that some of these infants may 
have had brain damage before their AIH, but others may not have been able to respond to 
their AIH as well as infants without antenatal compromise. These data suggest that causal 
paths may also consist of acute on top of chronic injury, that is the antenatal risk factors and 
the AIH both playing a part in the causal path. Antenatal factors preceding a catastrophic 
sentinel event is seldom discussed in the literature except possibly in the context of 
intrauterine growth restriction, so it is interesting to note only one case in this series with a 
sentinel event was considered growth restricted. The other three with growth restriction had 
metabolic acidosis without a sentinel event. Also, seven of the 37 possible additional cases 
were growth restricted.  
 This study also hypothesises that neonatal conditions additional to those directly associated 
with neonatal encephalopathy (e.g. seizures) may play a role on the causal path. Some of the 
neonatal factors represent responses by the infant to an acute injury. However in our 21 cases 
there were no signs of clinical chorioamnionitis or maternal fever in labour, but eight of the 
21 infants had bacterial infections during the neonatal period. Animal studies have shown that 
infection prior to AIH has an additive detrimental effect
12,13
, but to our knowledge there are 
no animal studies of AIH followed by infection. It is possible that these infections could 
impede the neonates’ recovery from AIH, or have an additive effect to injury. In addition, 
some neonatal conditions have their causes commencing in the antenatal period, for example 
severe jaundice can stem from the antenatal or intrapartum period
14
. Our case series from a 
total population (in Table 2) shows that there are seldom two identical pathways even though 
all had children had quadriplegic/dyskinetic CP, moderate to severe encephalopathy and a 
sentinel event or metabolic acidosis suggesting an intrapartum cause. 
Some have suggested that problems exist with the consensus definition of essential criteria 
for AIH
6
. Our (larger N=457) study supports their concerns, for example: two cases with cord 
blood pH higher than 7 (7.19 and 7.22), base deficit ≥12 and the remaining criteria, and a 
further two cases described as spastic diplegia met the remaining criteria. These are a concern 
because base deficit is more important than pH
15
, and diplegia and quadriplegia are the two 
subtypes in CP found to be most difficult to differentiate in trials of inter-observer agreement. 
The Surveillance of CP in Europe have chosen to abandon both terms (diplegia and 
quadriplegia) and no longer differentiate between them, instead adopting the term bilateral 
CP
16
. This highlights the problem of attributing AIH to CP in the future when the term 
quadriplegia will not be used by some. In our study using both published criteria, one of these 
four children was classified as having AIH on account of a sentinel event (cord prolapse), 
despite cord pH being 7.19. The remaining three were not classified as AIH although there is 
a strong possibility that AIH was on their causal paths to CP. 
 
The strength of this study is its geographically defined population basis the completeness of 
which is assisted by the geographical isolation of Western Australia and its centralisation of 
tertiary medical services. Western Australia has only two neonatal intensive care units 
serving the entire State, both located in Perth, the capital city, where the great majority of the 
population resides. These factors assist complete ascertainment by the Western Australian CP 
Register the source of the CP cases which is one of two longest running CP registers in the 
world. Total population studies such as this case control study are difficult to conduct and are 
rare in research. They are indispensable for providing unbiased estimates of prevalence and 
indicating the relative contributions to outcome of a range of risk factors. They are most 
useful for generating new hypotheses as has been done in this study due to their lack of bias, 
that is, there is an attempt to include every infant within a geographical region with a given 
condition. 
This unique population-based case-control study of cerebral palsy has several key messages. 
It has demonstrated that acute intrapartum hypoxia is a rare antecedent of cerebral palsy in 
term born singletons. Furthermore most acute intrapartum hypoxia is preceded by antecedents 
which may render the infant vulnerable to events in labour, and events in the neonatal period 
may impede recovery. The study also draws attention to the problems surrounding published 
criteria for determining whether acute intrapartum hypoxia is a possible cause in any 
individual case. Pathways to cerebral palsy that include acute intrapartum hypoxia are rare 
and may be more complex than current theories suggest. 
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Table 1: Risk factors associated with acute intrapartum hypoxia and CP 
  Controls AIH + CP 
Maximum N  468 21 
 
Risk Factor                                            
 
Preconceptional 
Infertility for longer than one 
year 
N    (%)                                                        
OR (95%CI) 
4 (0.9)
Ref 
2 (11.8) 
12.9 (2.2, 75.6) 
Antenatal 
Oligohydramnios N    (%)                                                        
OR (95%CI) 
2 (0.4)
Ref 
1 (5.0) 
12.3 (1.1, 141) 
Intrauterine growth restriction 
(IUGR) 
N    (%) 
OR (95%CI) 
21 (4.5) 
Ref 
4 (20.0) 
5.3 (1.6, 17.3) 
Placental indicators (anything 
other than healthy &/or 
complete) 
N    (%) 
OR (95%CI) 
103 (22.0) 
Ref 
11 (55.0) 
4.3 (1.7, 10.7) 
Maternal hypertension 
Diagnosed at 37+ weeks  
N    (%) 
OR (95%CI) 
36 (7.7) 
Ref 
3 (15.0) 
2.1 (0.6, 7.6) 
Any birth defects (identified by 
the birth defect register)  
N    (%) 
OR (95%CI) 
27 (5.8) 
ref 
4 (20.0) 
4.1 (1.3, 13.1) 
Intrapartum 
Meconium aspiration N    (%) 
OR (95%CI) 
4 (0.9) 
Ref 
6 (29) 
38.7 (9.4, 158) 
Neonatal 
Transient metabolic conditions N    (%) 
OR (95%CI) 
21 (4.5%) 
Ref 
15 (71) 
49.7 (17.3, 142) 
Bacterial infections N    (%) 
OR (95%CI) 
11 (2.4) 
Ref 
11 (52) 
41.6 (14.4, 120) 
Apnoea N    (%) 
OR (95%CI) 
1 (0.2) 
Ref 
8 (38.1) 
272 (31, 2391) 
Temperature regulation 
problems 
N    (%) 
OR (95%CI) 
4 (0.9) 
Ref 
10 (47.4) 
103 (27, 392) 
Ref: Reference group  
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SYNOPSIS OF CHAPTER 8 
Chapter 8 identified a small proportion of term born infants who met consensus 
criteria for an acute intrapartum event possibly being responsible for their cerebral 
palsy. Thus these criteria may need further examination. For most experiencing 
acute intrapartum hypoxia other strong risk factors were present prior to labour. 
Less than 1.5% of term infants had a pathway to cerebral palsy that consisted only 
of acute intrapartum hypoxia.  
 
Chapter 8 concludes the investigations of this thesis for infants that are at high risk 
of cerebral palsy. Chapter 9 will look at those at the opposite end of the spectrum, 
those least at risk: term infants not admitted to special or intensive care in the 
neonatal period.  
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CHAPTER 9 
EXPLORING AETIOLOGY AND EARLIER 
IDENTIFICATION FOR THOSE AT LOW RISK 
INTRODUCTION  
Chapters 7 and 8 focussed on those at highest risk of cerebral palsy, those with 
neonatal encephalopathy. This chapter reports data from the largest group at the 
opposite end of the risk spectrum; term infants without encephalopathy in the 
newborn period (Figure 10). Families with term born infants who leave the birth 
hospital without any suspicion that a lifelong neurological condition lies ahead 
describe two major problems: the lack of information concerning the cause, and the 
time it takes (up to five years) for their child to be described as having cerebral 
palsy. To address these issues this chapter is comprised of three sections. The first 
section is a published paper that aimed to identify predictors of cerebral palsy in the 
neonatal period for this low risk group. The second section examines risk factors in 
the preconceptional, antenatal and intrapartum period that may warrant further 
investigation (both these sections consider the Term-CCCP subjects identified in 
Figure 11), and the third section suggests one way forward to help health 
professionals describe cerebral palsy earlier for these families. 
 
Figure 10: Proportions of cerebral palsy by level of risk at birth  
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Figure 11: Group selection for chapter 9 
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Population Case-Control Study of Cerebral Palsy:
Neonatal Predictors for Low-Risk Term Singletons
WHAT’S KNOWN ON THIS SUBJECT: Term infants account for the
majority of cases of cerebral palsy (CP). The strongest risk factor
for term infants is admission to the NICU with newborn
encephalopathy. Little research has focused on infants not
admitted to the NICU.
WHAT THIS STUDY ADDS: Two-thirds of term infants with CP
were not admitted to a NICU but contributed one-half of severe
cases. Six neonatal factors were identiﬁed as predictors of CP for
this group, but 60% of the subjects had none of these factors.
abstract
OBJECTIVES: For singletons with cerebral palsy (CP) whowere born at
term, the goals were (1) to determine the proportion not admitted to a
Special Care Unit/NICU (NICU), (2) to compare clinical descriptions of
those admitted to NICUs and those not admitted, and (3) to identify
neonatal predictors of CP among those not admitted to a NICU.
METHODS: A total-population case- (N 442) control (N 468) study
of, singleton, term-born infants with CP, as ascertained from the West-
ern Australian Cerebral Palsy Register, was performed.
RESULTS: All types of CP were represented among the 67% of term
infants with CP (N 295) who were not admitted to a NICU, which also
included 54% of the subjects with the most severe impairments. Inde-
pendent neonatal predictors were abnormalities of tone (odds ratio
[OR]: 7.3 [95% conﬁdence interval [CI]: 2–26.8]), temperature regula-
tion (OR: 4.1 [95% CI: 1.2–14]), consciousness (OR: 3.7 [95% CI: 2–7]),
and fontanelles (OR: 4.4 [95% CI: 0.8–23]), requirement for resuscita-
tion (OR: 2.9 [95% CI: 2.2–12.9]), and birth defects (OR: 5.1 [95% CI:
2.4–10]). The risk of CP increased with the number of factors, but 58%
of subjects who were not admitted to a NICU exhibited none of these
factors.
CONCLUSIONS: Neonatal predictors of CP among term infants not ad-
mitted to a NICU were identiﬁed. However, 39% of all term singletons
with CP were not admitted to a NICU and exhibited none of these pre-
dictors. Pediatrics 2011;127:e667–e673
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Cerebral palsy (CP) is a motor disorder
that results from injury to thedeveloping
brain.1 Research to prevent CP (through
identiﬁcation of causal paths and inter-
vention) has focused on individuals at
highest risk, that is, infants born very
premature2,3 or infants born at term and
admitted to Special Care Units/NICUs
(NICU) with newborn encephalopathy
(NE).4–8 However, 40% of all infants
who develop CP have an apparently
normal neonatal course.9 Term infants
represent the majority of this intrigu-
ing group, which has received little at-
tention.
For identiﬁcation of causal pathways
and prediction of CP among infants
born at term, associated clusters of
neonatal factors have been identiﬁed.
These factors include abnormal cere-
bral MRI ﬁndings, neonatal seizures,
low Apgar scores, and birth defects;9–15
however, none of these factors are
usually present for infants receiving
routine care. This leaves a signiﬁcant
proportion of CP cases without known
predictors. It would be helpful to iden-
tify CP earlier in this group, to better
understand causes, to identify causal
pathways, and to provide opportuni-
ties for early intervention.
Using the data from a total population-
based, case-control study in Western
Australia, we aimed (1) to determine the
proportion of personswith CPwhowere
born at term and received routine care
in a postnatal ward, with no specialized
neonatal care (the no-NICU group), (2) to
compare their distributions of motor
types, topographical patterns, and se-
verity with those of term-born persons
with CPwho had been admitted to a spe-
cial care unit or NICU (the NICU group),
and (3) to identify whether neonatal risk
factors for CP exist for term infants not
admitted to a NICU.
METHODS
For the Western Australian case-
control study of children with CP not
attributable to postneonatal injury
who were born in 1980–1995, CP case
subjects were drawn from the
population-based Western Australian
Cerebral Palsy Register.16 For this re-
port, singleton children with CP who
were born at term (37 weeks of ges-
tation) were selected from the West-
ern Australian study database (N 
442). Motor impairment was catego-
rized as spasticity (hemiplegia, diple-
gia, or quadriplegia), dyskinesia (dys-
tonia or athetosis), ataxia, or isolated
hypotonia. Severity was categorized as
mild, moderate, or severe, approxi-
mating Gross Motor Function Classiﬁ-
cation System levels I/II, III, and IV/V,
respectively. Overall disability was
assessed with a 12-point scale ad-
dressing cognitive, sensory, andmotor
impairments and epilepsy.17 Distribu-
tions of clinical descriptors were com-
pared between the NICU and no-NICU
groups, with NICU indicating all higher-
level nursery care (both special care
and intensive care).
Neonatally surviving control subjects
without CP (N  468) were selected
from the birth ﬁle of the Maternal and
Child Health Research Data Base,18 a
total population database. They were
matched with respect to date of birth
(within 12 months), gestational age at
delivery (within 1 week), and plurality.
For all case and control subjects, pre-
conceptional, prenatal, intrapartum,
immediate postpartum, and neonatal
information was extracted from the
medical ﬁles of obstetricians, general
practitioners, hospitals of birth, and
hospitals of transfer and was re-
corded on standardized collection
forms. Data collectors were research-
registered nurses whowere blinded to
case/control status and who under-
went training for consistency of data
extraction.
For this analysis, the following neona-
tal factors were considered: Apgar
scores, time to spontaneous respira-
tions, resuscitation, birth trauma,
other delivery problems, vitamin K ad-
ministration, infant’s blood group, Rh
factor incompatibility, abnormal tem-
perature regulation, birth defects, dys-
morphic features, fontanelle abnor-
malities, renal function, jaundice, liver
failure, respiratory distress, meco-
nium aspiration, hypotension, anemia,
infections, patent ductus arteriosis,
necrotizing enterocolitis, bronchopul-
monary dysplasia, pneumothorax,
apnea, clinical diagnosis of birth
asphyxia/hypoxic-ischemic encepha-
lopathy or small for gestational age,
metabolic conditions, seizures, abnor-
mal tone, poor sucking, conscious
state, neonatal transport, and total
number of days in the hospital.
To compare the proportions of no-NICU
case and control subjects with each
variable, 2  2 tables were con-
structed for each category of all vari-
ables. Each factor was then expressed
as a dichotomous variable for logistic
regression analyses. For continuous
variables, the cutoff point was chosen
on the basis of literature ﬁndings (eg,
an Apgar score of7 at 5 minutes is a
standard cutoff point). Because litera-
ture reports did not provide a consis-
tent cutoff point for time to spontane-
ous respirations, a cutoff point was
chosen at which a distinct difference
in proportions between case and con-
trol subjects was observed; that is,
similar proportions of case and con-
trol subjects initiated spontaneous
respirations at 1 minute and at 2 min-
utes but not at3 minutes. For all cat-
egorical variables, the abnormal cate-
gories were combined if there was no
trend. We deemed that dichotomizing
continuous variables and combining
categories in this manner was appro-
priate because of the exploratory na-
ture of this study. Case/control distri-
butions of the matching variables
were comparable; therefore, for this
report, all control subjects were in-
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cluded in the analyses, which dictated
that unconditional, multivariate, logis-
tic regression analyses be used. Uni-
variate analyses estimated unadjusted
odds ratios (ORs) and their 95% conﬁ-
dence intervals (CIs). Only variables
whose CIs did not include 1 were in-
cluded in the multivariate analyses.
Given the sample size, there were ade-
quate numbers of events per variable
for these multiple logistic regression
models. Unconditional, multivariate,
logistic regression analyses were
used to calculate ORs and 95% CIs to
identify neonatal risk factors for CP.
Backward selection was used, with a
threshold of P .1.
RESULTS
NICU Admission
In this study, there were 442 singleton
case subjects with CP who were born
at term, of whom 295 (67%) received
routine care (no-NICU case subjects).
There were 468 singleton control sub-
jects who were born at term, of whom
450 (96%) received routine care (no-
NICU control subjects). There were no
major differences in the distributions
of the matched variables (plurality,
gestational age, and year of birth) for
those who received routine care;
therefore, all control subjects were in-
cluded in this study.
Comparison of Clinical
Descriptions
No-NICU case subjects were repre-
sented in all clinical descriptions of CP.
In comparisons of motor severity, the
no-NICU group had larger proportions
of mild and moderate motor impair-
ment, compared with the group of in-
fants who were admitted to NICUs. Be-
cause of the greater size of the no-NICU
group, however, 54% (n  90) of the
166 term case subjects with CP with
severe motor impairment had not
been admitted to NICUs. One-half of the
no-NICU group had overall disability
scores of 1 to 4, which represented
mild disability, compared with only
one-fourth of the NICU group. As with
severity scores, however, 58% of those
with overall disability scores of 9 to 12,
representing high levels of overall dis-
ability, were from the no-NICU group
(Table 1).
Neonatal Risk Factors for CP
Among Term Infants Not Admitted
to NICUs
Fourteen neonatal factors were found
to be statistically signiﬁcantly associ-
ated with CP (P  .05) in univariate
analyses and were included in themul-
tivariate model. When many associa-
tions are being examined, it is antici-
pated that, by chance, 1 in 20 may
appear spuriously statistically signiﬁ-
cant (at P  .05). Because we were
generating rather than testing hypoth-
eses, however, we thought that it was
better to err on the side of being too
inclusive. In multivariate analyses, 6
factors, namely, birth defects, fonta-
nelle abnormalities, resuscitation in-
tervention, abnormal tone, abnormal
consciousness, and abnormal temper-
ature regulation, were found to be pre-
dictors of CP for infants not admitted
to NICUs. Fontanelle abnormality was
the only independent predictor whose
CI included 1. Removal of this factor
would have made a signiﬁcant change
to the model, however, which suggests
that lack of statistical signiﬁcancemay
be attributable to its rare occurrence.
This factor had the highest univariate
OR and was reported for fewer control
subjects (n 2), compared with other
variables (Table 2).
Although these 6 factors were predic-
tors of CP in the no-NICU group, none
was seen for 20% of case subjects.
Table 3 shows that, for 58% of case
subjects (n 172) and 90% of control
subjects (n  405), none of the 6 fac-
tors was present. At least 1 factor was
found for 42% of infants with CP (n 
123), comparedwith 9% of control sub-
jects (n  41). At least 2 factors were
present for 14% of infants with CP (n
42), compared with 1% of control sub-
jects (n  4). An association existed
between increasing numbers of fac-
tors identiﬁed and CP (P  .01). No
combination of neonatal factors was
predictive of motor type or topo-
graphic features of CP; however, an as-
sociation existed between the number
of factors identiﬁed and the severity of
motor impairment (P .05). As a pre-
dictor of CP, 2 factors compared
with any factors decreased sensitivity
from 40% to 14% but increased speci-
ﬁcity from 90% to 99%.
DISCUSSION
The majority (65%) of infants with CP
are born at term. The severity of motor
impairment in term-born children with
CP is greater than that in infants born
prematurely, and the rate of severe CP
among term-born infants is increas-
ing.16,19 Research with term infants is
necessary. In this population-based,
TABLE 1 Comparison of Types, Topographic
Features, and Severity of Motor
Impairments Among Term-Born
Infants With CP According to NICU
Admission
n (%)
No-NICU NICU
Singleton cases 295 147
Primary motor type and
topographic features
Spasticity
Hemiplegia 110 (37) 25 (17)
Diplegia 61 (20) 23 (16)
Quadriplegia 51 (17) 55 (37)
Dyskinesia
Dystonia 23 (8) 19 (13)
Athetosis 15 (5) 14 (10)
Ataxia 32 (11) 8 (5)
Hypotonia 3 (1) 3 (2)
Severity of motor impairment
Mild 111 (38) 44 (30)
Moderate 94 (32) 26 (18)
Severe 90 (31) 76 (52)
Overall disability score
1–4 148 (50) 34 (23)
5–8 71 (24) 56 (38)
9–12 76 (26) 56 (38)
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case-control study, two-thirds (67%) of
term-born infants later described as
having CP, including more than one-
half of those with severemotor impair-
ment, were not admitted to a special
care unit or NICU. Similarly, a study of
metropolitan births in northern Cali-
fornia reported that 70% of infants
born at term (deﬁned as 36 weeks)
with later-described spastic or dyski-
netic CP were not admitted to NICUs.20
All motor types and topographic fea-
tures of CP were represented in this
no-NICU group. We think that this is the
ﬁrst reported description of a total
population of term-born infants with
CP who were not admitted to NICUs.
The size of this group and the severity
of their impairments have been under-
estimated in the past and nowwarrant
greater attention.
Neonatal predictors of CP in the no-
NICU group of term-born infants were
identiﬁed. In multivariate analyses, 6
neonatal predictors of CP were identi-
ﬁed for a subset of this group, but no
combination of these factors pre-
dicted motor type or topographic fea-
tures. One additional factor identiﬁed
in univariate analyses requires discus-
sion. Comparedwith 1% of control sub-
jects, 9% of term-born case subjects
with CP who were not admitted to a
NICU were identiﬁed as having dysmor-
phic facial features in the neonatal pe-
riod. In the past, it was hypothesized
that congenital facial dysmorphisms
were overascertained retrospectively
for children with CP, because of post-
natal growth restriction of the brain
and hence cranial volume.21 This can-
not be the case in this study, because
the data in perinatal medical records
was collected prospectively.
One predictor, an abnormal fontanelle,
was retained in themodel although the
CI included 1. It is known that there are
many causal pathways to CP and it is
possible that an abnormal fontanelle
may be an important factor in only 1 or
TABLE 2 Neonatal Factors Identiﬁed for Term Infants Not Admitted to NICU
Variable n (%) OR (95% CI) P
Control Subjects
Not Admitted to
NICU (N 450)
Case Subjects
Not Admitted
to NICU
(N 295)
Univariate
Analysis
Multivariate
Analysis
Birth defect 5.7 (3.1–11.0) 5.1 (2.4–10.0) .0001
CNS 2 10
Major 1 9
Minor 11 25
Major and minor 0 0
Total 14 (3) 44 (15)
None 436 (97) 239 (81)
Not known 0 (0) 12 (4)
Metabolic abnormality 1.9 (1.0–3.6) 0.9 (0.3–1.9) .601
Hypoglycemia 18 19
Hypocalcemia 0 1
Multiple 0 1
Total 18 (4) 21 (7)
None 432 (96) 266 (90)
Not known 0 (0) 8 (3)
Dysmorphic facial features 8.9 (3.4–4.0) 2.4 (0.7–7.7) .130
Yes 5 (1) 26 (9)
None 445 (99) 257 (87)
Not known 0 (0) 12 (4)
Small for gestational age 3 (1.4–6.6) 0.9 (0.3–2.7) .860
Yes 10 (2) 18 (6)
None 438 (98) 263 (89)
Not known 2 (0) 14 (5)
Abnormal fontanelle 11.8 (2.7–54) 4.4 (0.8–23.0) .081
Tense 0 8
Bulging 0 1
Sunken 0 1
Abnormal, unspeciﬁed 2 4
Total 2 (0.4) 14 (5)
None 448 (99) 265 (90)
Not known 0 (0) 16 (5)
Resuscitation 2.4 (1.4–3.9) 1.2 (0.5–3.2) .661
Yes 29 (6) 40 (14)
None 421 (94) 242 (82)
Not known 0 (0) 13 (4)
Resuscitation intervention 5.4 (2.2–12.9) 2.9 (2.2–12.0) .028
Intubation1 min 3 12
Bag and mask1 min 4 10
Total 7 (2) 22 (8)
None 440 (97) 245 (83)
Not known 3 (1) 28 (9)
Time to spontaneous
respirations
4 (2.0–7.9) 3.6 (0.7–6.8) .840
3 min 13 (3) 30 (10)
3 min 423 (94) 241 (82)
Not known 14 (3) 24 (8)
Apgar score at 5 min 4.5 (1.4–4.1) 1.1 (0.2–5.3) .907
7 4 (1) 11 (4)
7 446 (99) 275 (93)
Not known 0 (0) 9 (3)
Abnormal tone 8 (3.3–20.0) 7.3 (2.0–26.8) .002
Yes 6 (1) 27 (9)
None 441 (98) 247 (84)
Not known 3 (1) 21 (7)
Abnormal consciousness 6 (3.5–11.0) 3.7 (2.0–7.0) .0001
Irritable 11 27
Lethargic 6 22
Other 1 8
Comatose 0 0
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a few of these pathways, in which case
it would be seen for only a small pro-
portion of case subjects and an even
smaller proportion of control subjects.
This association should be investi-
gated with independent data sets for
neonates not receiving special care.
Cerebral and noncerebral birth de-
fects have been associated with
CP.22–25 The presence of birth defects
suggests prenatal developmental ab-
normalities, and they may be on a
causal pathway to CP.23,26 The remain-
ing predictors (abnormal temperature
regulation, tone, and consciousness
and the need for resuscitation) all may
be associated with a variety of medical
conditions but are reminiscent of
criteria used to deﬁne NE.27 Several
prospective studies of NE reported
that mild or Sarnat stage 1 NE does
not increase the risk of CP.7 This
study starts with CP rather than NE
and poses a concerning question
for health care professionals and
researchers. If mild NE is underas-
certained, then have the risks asso-
ciated with mild NE been underesti-
mated? Or is there a distinct
group of mild neurologic distur-
bances that currently escapes clini-
cal concern?
Although neonatal risk factors were
identiﬁed, their sensitivity and speci-
ﬁcity for CP do not allow satisfactory
prediction. Because of the plethora of
causal pathways to CP,28 it is not sur-
prising that speciﬁcity was low. It also
is possible that the 1% of control sub-
jects with2 factors had other neuro-
logic impairments, as found previous-
ly.29 Therefore, the clinical signiﬁcance
of these ﬁndings for health care pro-
fessionals and families is unclear. Pre-
diction at the individual level cannot be
achieved with these 6 factors. At most,
the presence of 2 of these risk fac-
tors might prompt further investiga-
tion in the form of cerebral MRI and
close follow-up monitoring. Families of
term infants with CP talk of the difﬁcult
protracted process of obtaining a di-
agnosis.30,31 For the presence of these
predictors to lead to an earlier diagno-
sis for families, many births would
need to be monitored for each earlier
diagnosis obtained.
The most signiﬁcant ﬁnding was that
39% of all term singletonswith CP (n
172) had not been admitted to a spe-
cial care unit or a NICU and had none of
these neonatal risk factors by the time
they left the hospital of birth, pre-
sumed to be in neurologically intact
condition. This supports the ﬁndings of
the National Collaborative Perinatal
Project, which found that, of those with
moderate to severe CP, 43% were con-
sidered in neurologically normal con-
dition at the time of discharge and 36%
were considered in neurologically nor-
mal condition at 4 months of age.9,32
CP among term births has been under-
researched for a number of reasons.
(1) Subjects are difﬁcult to monitor
prospectively, because many are not
identiﬁed as being at risk in the neona-
tal period and the infrequency of the
TABLE 2 Continued
Variable n (%) OR (95% CI) P
Control Subjects
Not Admitted to
NICU (N 450)
Case Subjects
Not Admitted
to NICU
(N 295)
Univariate
Analysis
Multivariate
Analysis
Total 18 (4) 57 (19)
None 427 (95) 225 (76)
Not known 5 (1) 13 (4)
Abnormal temperature
regulation
7.2 (2.4–22.0) 4.1 (1.2–14.0) .024
Hypothermic 0 4
Hyperthermic 0 0
Fluctuating 4 13
Total 4 (1) 17 (6)
None 446 (99) 263 (89)
Not known 0 (0) 15 (5)
Infection 3.7 (1.6–8.2) 2.2 (0.8–5.8) .131
TORCH 0 3
Group B streptococci 2 4
Urea/mycoplasma 0 1
Gram-negative bacteria 7 9
Systemic Candida 0 1
Not speciﬁed 0 2
Total 9 (2) 20 (7)
None 440 (98) 264 (89)
Not known 1 (0) 11 (4)
Poor sucking at24 h 4.3 (2.5–7.2) 1.2 (0.5–2.5) .656
Yes 23 (5) 53 (18)
No 427 (95) 228 (77)
Not known 0 (0) 14 (5)
CNS indicates central nervous system; TORCH, toxoplasmosis/other/rubella/cytomegalovirus/herpes simplex virus.
TABLE 3 Sensitivity and Speciﬁcity for CP According to Number of Risk Factors
No. of Factors
Present
Proportion, % Sensitivity,
% (95% CI)
Speciﬁcity,
% (95% CI)
Proportion of CP
Cases Moderate
or Severe, %
Case
Subjects
Control
Subjects
0 58 90 NA NA 60
1 42 10 40 (36–43) 90 (87–92) 73
2 14 1 14 (13–15) 99 (98–100) 76
NA indicates not applicable.
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condition makes universal follow-up
monitoring expensive. (2) Large co-
horts must be considered, because
term-born infants are generally at low
risk.33 (3) Some subjects experience in-
juries in the neonatal period after
they have been discharged from the
hospital, some present after experi-
encing seizures in the neonatal period,
and others are virtually without
symptoms. Retrospective studies us-
ing population-based registers are re-
quired to amass the numbers needed
to study CP among persons born at
term,34 as has been achieved in this
study.
We think that virtually all case subjects
have been identiﬁed and this study of
term infants does represent the com-
plete population of individuals with CP
born at term in Western Australia in
1980–1995. The rate of CP among
term-born infants was stable over the
16-year period, at 1.6 to 1.8 cases per
1000 neonatal survivors,16 and was
consistently higher than ﬁndings from
other registers/surveys, whose rates
ranged between 1.1 and 1.5 cases
per 1000 term-born neonatal survi-
vors.19,35–38 Those authors reported
that missing cases were likely to be
cases of mild CP, particularly involving
infants born outside tertiary centers.
There were a number of infants with
mild CP whowere born at term outside
tertiary centers in this study. Other
strengths in the design of this study
were that data collectors were blinded
to case/control status and the docu-
mented data were recorded prospec-
tively, before long-term outcomes
were known. Finally, because this
study considered data collected over
16 consecutive years, large numbers
had been amassed.
CONCLUSIONS
This is the largest population-based,
case-control study of CP in infants born
at term and the ﬁrst that has focused on
those least at risk since the National Col-
laborative Perinatal Project identiﬁed
the group. This study described the CP
characteristics of term infants not ad-
mitted to a special care unit or NICU and
established that this low-risk group in-
cluded more than one-half of the most
severely impaired persons with CP born
at term. We also identiﬁed 6 new but im-
precise predictors of termCP. Additional
study is needed to determine whether
preconceptional, prenatal, or intrapar-
tum factors can increase the sensitivity
of prediction. Discovering causal path-
ways to CP for thosebornat termbut not
admitted to a special care unit or NICU is
of major importance if we are to reduce
the ratesof CP throughout theworld. The
presence or absence of these factors
may be a starting point for these path-
ways. In addition, identifying children at
risk of CP early is important, because
novel techniques for early intervention
are being developed rapidly.
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ADDITIONAL DATA FOR PREDICTION OF SUBTYPES 
The previous paper included one sentence that stated “no combination of neonatal 
factors was predictive of motor type or topographical features”80, 81. This was in 
response to one of our original hypotheses that certain combinations of variables 
would predict subtypes of cerebral palsy. This hypothesis was rejected and the 
following tables demonstrate the lack of any discernible pattern by subtype. When 
only one variable was present it too did not predict subtype.  
 
Children with quadriplegia and two or more neonatal variables  
Case Severity Abnormal 
fontanelle 
Abnormal 
Temperat
ure 
regulation 
Birth 
defects 
Abnormal 
Tone 
Resuscitat
ion 
Abnormal 
Conscious
ness  
1 Mod       
2 Severe       
3 Severe       
4 Severe       
5 Severe       
6 Severe       
7 Severe       
8 Severe       
9 Severe       
10 Severe       
11 Severe       
12 Severe       
13 Severe       
14 Severe       
15 Severe        
 
Additionally, for ten children with quadriplegia and only one neonatal variable 
present, n=4 abnormal consciousness, n=4 birth defects, n=2 resuscitation.   
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Children with diplegia and two or more neonatal variables  
Case Severity Abnormal 
fontanelle 
Abnormal 
Temperat
ure 
regulation 
Birth 
defects 
Abnormal 
Tone 
Resuscitat
ion 
Abnormal 
Conscious
ness  
1 Mild       
2 Mild       
3 Mod       
4 Mod 
 
     
5 Mod       
6 Severe        
 
Additionally, for fifteen children with diplegia and only one neonatal variable 
present, n=1 abnormal fontanelle, n=5 abnormal consciousness, n=4 birth defects, 
n=2 abnormal tone, n=3 resuscitation.   
 
Children with hemiplegia and two or more neonatal variables  
Case Severity Abnormal 
fontanelle 
Abnormal 
Temperat
ure 
regulation 
Birth 
defects 
Abnormal 
Tone 
Resuscitat
ion 
Abnormal 
Conscious
ness  
1 L mild       
2 L mild       
3 L mild       
4 L mild       
5 L mild       
6 L mild       
7 L mild       
8 R mod       
9 L mod       
10 L mod       
11 L mod       
12 L mod       
13 L sev        
 
Additionally, for 36 children with hemiplegia and only one neonatal variable 
present, n=1 abnormal fontanelle, n=5 abnormal temperature regulation, n=2 
abnormal tone, n=10 abnormal consciousness, n=8 birth defects, n=10 
resuscitation.  
 
100 
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Children with non-spastic cerebral palsy and two+ neonatal variables  
Case Severity Abnormal 
fontanelle 
Abnormal 
Temperat
ure 
regulation 
Birth 
defects 
Abnormal 
Tone 
Resuscitat
ion 
Abnormal 
Conscious
ness  
1 Sev dys       
2 Sev dys       
3 Sev dys       
4 Sev dys       
5 Sev dys       
6 Sev dys       
7 Sev hyp       
8 Mild at       
9 Mild at       
10 Mild at       
11 Mod at        
 
Additionally, for sixteen children with non-spastic cerebral palsy and only one 
neonatal variable present, n=1 abnormal fontanelle, n=4 abnormal consciousness, 
n=4 birth defects, n=3 resuscitation, n=3 abnormal tone, n=1 abnormal temperature 
regulation.  
 
RISK FACTORS PRIOR TO THE NEONATAL PERIOD  
The previous section identified that there were six independent neonatal factors 
that predicted cerebral palsy. We hypothesised that for “symptomatic” cases (those 
with one or more of these factors present) causal pathways might differ from cases 
that were virtually “asymptomatic” in the newborn period (none of the 
independent predictors present). For this reason, identified risk factors in the 
preconceptional, antenatal and intrapartum periods for the low risk group as a 
whole, were then stratified by those “symptomatic” and those “asymptomatic” in 
the neonatal period to see if pathways and risk factors differed between the groups.  
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PRECONCEPTIONAL FACTORS  
Appendix M shows the numbers, proportions and results of univariate and 
multivariate analyses of risk factors in the preconceptional period. Following 
multivariate analysis (including all those with statistically significant univariate 
findings) four independent preconceptional factors increased the odds for cerebral 
palsy for term infants receiving routine care: a family history of either cerebral 
palsy, intellectual disability or birth defects adjusted odds ratio aOR1.58 (95% CI 
1.01-2.46) p=0.044; mother’s age at the time of birth ≤18 aOR3.23 (95%  CI 1.54-
6.76) p=0.002, having a rural address at the time of birth aOR1.38 (95% CI 1.05-
1.88) p=0.046, or having no private insurance at the time of delivery aOR1.4 (95% CI 
1.04-1.9) p=0.027. 54% of the cases and 41% of controls had at least one of these 
factors present. 
 
Table 9 shows the independent statistically significant risks associated with 
preconceptional factors stratified by neonatal symptoms. 
 
Table 9 Preconceptional factors for term singletons asymptomatic or symptomatic 
in the newborn period  
Risk factor Asymptomatic  
aOR (95%CI) 
Symptomatic 
 aOR (95%CI) 
Mother’s age ≤18 4.1 (1.8-9.3) - 
4 or more previous births 2.6 (1.0-6.7) - 
Family history birth defects/CP/ 
intellectual disability 
1.8 (1.1-2.9) - 
Rural residence - 1.5 (1.1-2.1) 
Maternal migraine - 2.5 (1.0-6.0) 
First birth - 1.4 (1.1-2.8) 
Single mother - 1.8 (1.0-3.2) 
 
Non significant - 
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The risk factor profile differs between the two groups. Being a very young mother 
increases the odds of the child having cerebral palsy. So too does having four or 
more previous births, more so than older age. These findings were only found 
within the term infants who were asymptomatic. A family history of cerebral palsy, 
birth defects or intellectual impairment was also associated with increased odds of 
cerebral palsy only in term singletons asymptomatic in the newborn period. Having 
a prior diagnosis of maternal migraine increased the odds of having a child with 
cerebral palsy who is a singleton, born at term and symptomatic. This was the only 
outcome group throughout the thesis where maternal migraine was a significant 
risk factor, suggesting that it may be on one pathway to cerebral palsy. Being born 
in a rural location and “symptomatic” also increased the odds of cerebral palsy. 
 
ANTENATAL FACTORS 
Appendix N shows the numbers, proportions and odds ratios generated by 
univariate and, where appropriate, multivariate logistic regression of risk factors in 
the antenatal period. Following multivariate analysis (including all those with 
statistically significant univariate findings) two independent antenatal factors 
increased the odds for cerebral palsy for term infants receiving routine care: a bleed 
during pregnancy occurring between the 24th and 31st week aOR5.1 (95% CI 1.04-
24) p=0.044, and the presence of a birth defect aOR57 (95% CI 4.7-750) p=0.002. 
Forty two percent of the cases and 5% of controls had at least one of these factors, 
the great majority being a birth defect. 
 
The paper in the earlier section of this chapter81 identified predictors among factors  
identifiable in the neonatal period. One of those was birth defects that were 
identified by hospital staff prior to leaving hospital as a newborn. Forty four infants 
(15%) later described as having cerebral palsy met this criterion. However, the 
current analyses of antenatal factors are concerned with aetiology, and since birth 
defects arise antenatally, birth defects as identified by linkage with WARDA were 
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considered here. As discussed in earlier chapters, WARDA collects information on 
birth defects up to the age of six years. Using this data, the  number of this group 
later described as cerebral palsy identified with a birth defect increased to n=119, 
(40%.)  
 
Further multiple regression analyses were not undertaken for antenatal factors 
stratified by “asymptomatic” or “symptomatic” because some of the birth defects 
(those identified before the end of the neonatal period) were part of that criterion 
and some weren’t. However, in both groups birth defects remained the dominant 
risk factor, present in 33% of the “asymptomatic” cerebral palsy group and in 50% 
of the “symptomatic” cerebral palsy group compared to 4.4% of the controls. 
 
The true risk of cerebral palsy following birth defects depends on the type of birth 
defect that is present. The table below outlines the types of birth defects seen in 
these low risk infants receiving routine care as a newborn.  As expected the majority 
of birth defects in cerebral palsy were brain defects and many will be the 
pathological substrate of these children’s cerebral palsy. Some of the causes of 
these defects were environmental, for example infections and alcohol, but many of 
the causes of each defect remain unknown and will form the basis of postdoctoral 
studies. 
 
Birth defect types in those receiving routine care 
 Controls n (%) Cerebral Palsy n (%) 
Brain  1 (0.2) 83 (28.1) 
Other major  14 (3.1) 34 (11.5) 
Minor only 8 (1.7) 6 (2.0) 
None 427 (94.8) 172 (58.3) 
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INTRAPARTUM FACTORS 
Appendix O  shows the numbers, proportions with intrapartum factors, and odds 
ratios for cerebral palsy estimated by univariate and, where appropriate, 
multivariate analyses. Following multivariate analysis (including all those with 
statistically significant associations on univariate analysis) four independent 
intrapartum factors increased the odds for cerebral palsy for term infants receiving 
routine care: meconium both at rupture of membranes [thin/moderate aOR2.07 
(95% CI 1.02-4.21) p=0.045 or thick/old aOR2.81 (95% CI 1.34-5.88) p=0.002] and 
fresh at delivery [moderate/thick aOR2.56 (95% CI 1.23-5.28) p=0.011 and  breech 
presentation at delivery aOR2.66 (95% CI 1.23-5.76) p=0.013; 15% of the cases and 
6% of controls had at least one of these factors. There was no difference in odds 
when stratifying the multivariate analysis by neonatally identified factors.   
 
DESCRIBING CEREBRAL PALSY EARLIER FOR THESE FAMILIES 
The average age of receiving a description of cerebral palsy is nineteen months, but 
varies from one week to five years of age. There are a number of reasons for this 
but the principle one is that cerebral palsy cannot be “diagnosed” as there is no 
biological marker or definitive test, and the term does not infer anything about 
aetiology or prognosis. Instead it is defined by the clinical description of motor 
function. For infants, motor assessments were traditionally instigated after motor 
milestone acquisition was noted to be delayed. However motor milestone have 
large ranges of what is considered “normal”, and delayed motor milestones are not 
specific to cerebral palsy. This in turn has forced health professionals into a “wait 
and see” approach before applying the term cerebral palsy,80 especially for those 
without major risks such as being born premature, as one of a multiple birth, or 
having encephalopathy in the newborn period.  
 
This delay in recognition is unhelpful for a number of reasons. From a research 
point of view: a) Cerebral Palsy registers are not able to report birth prevalence for 
a given year until five years later, delaying real world dissemination of outcomes 
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following the uptake of interventions aimed at reducing birth prevalence; b) early 
intervention studies on at risk infants need to have long term (expensive) follow up 
to ensure the validity of their findings; c) a large proportion of infants miss the 
opportunity of early intervention (and trials) as their disability is not recognised 
during the time that the brain is at its most plastic (before two years of age); 
similarly d) the pool of infants eligible for early intervention studies is much smaller 
than it could be, limiting the number of potential subjects available. Therefore few 
early intervention trials for infants at risk of cerebral palsy have been conducted, 
thus its potential has not been fully explored. The paucity  of evidence concerning 
motor outcomes following early intervention means we are unable to say whether a 
delay in recognition of cerebral palsy has a detrimental effect on the child’s 
outcome. From a parent’s point of view, a delay in professional recognition of their 
child’s impairments has been associated with higher rates of parental depression.82  
 
It was hoped that neonatal signs predicting cerebral palsy in this group could lead to 
an earlier description of cerebral palsy. However, two or more of the factors 
identified yielded a high specificity 99% but an extremely low sensitivity of 14%, and 
a subsequently low positive predictive value.81 With 58% of infants not having any 
of the identified neonatal risk factors this low sensitivity was not surprising. Two 
other groups had previously researched a similar concept with selected abnormal 
neonatal signs, but both considered the group of ‘all cerebral palsy’ rather than a 
low risk group, similar to the one considered here. The National Collaborative 
Project in the United States prospectively examined all babies for neurological 
impairment and identified that 43% of children with cerebral palsy were assessed as 
“neurologically normal” at the end of the neonatal period.8, In the United Kingdom, 
Eva Alberman and colleagues identified that 74% of all those with cerebral palsy 
and other severe disability could not be identified using neonatal signs. 83     
 
However, in recent years there has been good evidence that earlier detection of 
cerebral palsy is possible by using a combination of neurological examinations, 
standardised motor assessments, imaging and taking careful note of risk factors. We 
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have suggested in a recent invited review article (Appendix P) that instead of 
waiting to give a formal description of cerebral palsy, health professionals could  
describe the child as “at high risk of cerebral palsy” after following the flow chart 
below, thereby making them eligible to receive early intervention, or to enter trials 
(Figure 12).  
 
This concept of “at risk” is not a new one. “At risk” registers existed in the United 
Kingdom in the 1960s, however the criteria used identified 60% of the population, 
making this process unsustainable.83 The assessments that are used today have 
much higher specificity and sensitivity, making this proposed flow chart a realistic 
one.     
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Figure 12: Recommended assessment process for earlier recognition of infants and 
children at high risk of cerebral palsy. Adapted with permission from “Cerebral Palsy – Don’t 
delay” 
80
 
GMs Qualitative assessment of General movements; AIMS Assessment of Infant 
Motor Scale; NSMDA Neuro-Sensory Motor Development Assessment; HINE 
Hammersmith Infant Neurological Assessment. 
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SYNOPSIS OF CHAPTER 9 
This chapter focussed on the largest group, singletons born at term receiving 
routine care in the newborn period. We demonstrated that all subtypes and 
severities are represented in this group with 54% of the term born singletons with 
severe motor impairment not considered to require special care as a newborn. Six 
independent predictors of cerebral palsy in the newborn period were identified, 
however they were not sensitive, with a very poor positive predictive value. Most of 
these predictors were reminiscent of a mild encephalopathy. Independent risk 
factors existed in the preconceptional, antenatal and intrapartum period were also 
recognised with the presence of birth defects being the strongest risk factor for 
cerebral palsy. Finally, a flow diagram recommending an assessment protocol has 
been developed and published which aimed to decrease the time it takes for these 
children to be described as having cerebral palsy. It is hoped that these publications 
will also bring attention to the fact that almost every second child with cerebral 
palsy is considered low risk at birth. 
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CHAPTER 10 
SUMMARY AND CONCLUSIONS 
INTRODUCTION 
The concluding chapter will summarise the main findings of this doctoral program 
of research. It will also outline the limitations of the Term-CCCP and suggest further 
research required to maximise the findings of this study.  
 
Interest in the aetiology of a condition tends to become a dominant paradigm of 
study during serious epidemics, when prognosis is poor and the limitations of 
treatments are obvious to all. This is when epidemiology is at its most efficient. Is 
this why there has been a lack of research focussed on term and near term cerebral 
palsy? In the 1980s when there was a rapid increase in very and extremely preterm 
infants with cerebral palsy there was an explosion of research aimed at aetiology 
and intervention; resulting in a sustained decrease over the ensuing decades. 
Conversely, term infants have been remarkable in their stability and relatively low 
birth prevalence. What has been overlooked though, are the sheer numbers 
associated with this stable low birth prevalence. We know that prognosis for these 
infants is poor and term infants have more severe outcomes than preterm infants. 
Those who work in the area know the limitations of current treatments, but these 
may not be evident to all.  
 
Subdividing term and near-term infants into those at highest risk (following 
neonatal encephalopathy) and those at lowest risk (receiving routine care only as a 
newborn) gives a more accurate picture of research in this infant population. There 
has been a rapid increase in research for those at highest risk following the 
discovery of cooling as a neuro-protective treatment. However exciting as this line 
of enquiry is, it has limited potential, as only 1 in 6-9 infants33 respond favourably, 
and the vast majority of term and near term infants are not eligible for this 
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treatment. The research world is set to test multiple adjuvant therapies to cooling 
to increase this success rate, yet little is known about the pathway of these infants 
prior to labour and being neurologically depressed in the newborn period. There is 
also minimal to no research occurring throughout the world for the majority of term 
born infants, those without encephalopathy as a newborn. As a result, this doctoral 
program aimed to address this deficit and increase understanding of aetiology for 
term and near-term singletons with cerebral palsy. 
 
AIM AND METHODS OF THIS STUDY 
The primary aim was to identify new discrete groups of causal pathways to cerebral 
palsy for singletons born at or near-term by:  
 identifying aetiologically more homogeneous groups of cerebral palsy  
 identifying new associations within aetiologically more homogeneous groups  
 testing existing hypotheses in a total population of cerebral palsy  
 developing new hypotheses for further research in this area 
  
The methods chosen to address this aim and hypotheses were a systematic review 
of risk factors for cerebral palsy in term infants, and the analysis of a total 
population case-control study with additional data from a State-wide birth defect 
register.  
 
STRENGTHS AND LIMITATIONS OF THIS DESIGN 
Strengths and limitations of this study and the thesis have been reported in each 
paper. However the overarching strengths and limitations will be outlined here.  
 
The strengths of this thesis are the population base of the data used, the rigorous 
design of the CCCP and the attempt to highlight groups of term cerebral palsy that 
have had limited previous investigations.  
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The WARDA-CP is one of the longest running registers in the world, and it has 
maintained its multidimensional, high quality methods of case ascertainment since 
the 1980s. Consent has never been required for this register ensuring complete 
ascertainment and this has recently been changed to a statutory requirement in 
Western Australia, ensuring this will continue in the same manner. Western 
Australia has a number of high quality population based data bases that are all able 
to be linked together. This is not the case in much of the world, nor in other states 
of Australia. Thus, data from this study in addition to the cerebral palsy data came 
from other population based data bases: the WARDA for birth defects, and MCHRD 
for data, and selection of controls and perinatal deaths.  
 
The CCCP itself was developed by a number of highly respected researchers, who 
had just completed the previous case control study of spastic cerebral palsy4, 36 
therefore potential for bias in the CCCP was minimised in advance wherever 
possible. The data collection was methodical and of an extremely high quality as a 
result of the processes put in place, and the ability to access all medical records 
across the state without requiring consent.  
 
The concept for this thesis was generated by discussions with consumers while 
completing CP Register notifications. Focusing some efforts on the least at risk led 
to a novel finding – the magnitude of this problem. A subsequent novel finding was 
the larger than anticipated contribution that birth defects made to this group’s 
aetiology.  
 
Limitations of the CCCP and the thesis centre on the age of the data. The era 
dictates that there is no MRI data available, very little placental histology and no 
genetic enquiries; all of which would be essential for future studies. A limitation of 
the thesis is the restricted use of the perinatal death data, the day by day NICU data 
and neonatal imaging (ultrasound) data when performed. This data set was so big, 
that I had to concentrate on answering the developed research questions rather 
than using all the potential data. Following the completion of this thesis there is still 
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an opportunity to keep using this data set. Despite the age of this data set, 
importantly the proportions of live births with cerebral palsy for term and near term 
singletons did not change during the fifteen year period of the study, nor since 
then.  As dictated by the observational nature of this methodology, the final overall 
limitation is that the key findings for each hypothesis represent an opinion and 
judgement about the results, not a claim of proof. 
 
KEY FINDINGS AND RECOMMENDATIONS FOR PRACTICE, POLICY AND RESEARCH 
HYPOTHESIS 1 KEY FINDINGS 
It was hypothesised that risk factors of various strengths would exist across the 
preconceptional, antenatal, intrapartum and immediate postpartum/neonatal 
periods. I tested this hypothesis by conducting a systematic review of the literature, 
and then a comparison with Term-CCCP findings. The analysis was hampered by an 
inability to conduct a meta-analysis of any of the variables that were studied. Since I 
conducted this review, another review was also published with differing 
inclusion/exclusion criteria and they too were unable to conduct any meta-
analyses.85 This demonstrates that there is no standard agreement for definitions, 
outcome measures and cut points for risk factors that are of importance to cerebral 
palsy. Term-CCCP findings and the systematic review findings were mainly 
comparable, but this analysis was also hampered by the lack of standardisation. 
Despite this limitation, we were able to identify that risk factors generally differed 
between term and preterm infants, they existed across the four epochs, and some 
deserved a special focus. Since our systematic review was published there have 
been two further papers from one study that would have been included. Ahlin and 
colleagues’ results confirmed that infection and inflammation86, malformations, 
intrauterine growth restriction, hypoxia and neonatal encephalopathy87 were 
appropriate risk factors for this doctoral program to focus on.  
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RECOMMENDATION FOR PRACTICE, POLICY AND FUTURE RESEARCH 
After I completed the systematic review of risk factors for this doctoral program, I 
instigated another study that is currently under review (Appendix Q). With 
colleagues, I examined 22 Cochrane reviews of interventions for infants at risk of 
cerebral palsy and 165 randomised controlled trials within them. High consistency 
existed in types of outcome domains listed as important in meta-analyses. 
However, for 10/16 most frequently cited outcome domains, <50% of randomised 
controlled trials contributed data for meta-analyses. The problem does not seem to 
be limited to aetiology research. Once again, low consistency in outcome 
definitions, measures, and cut points prohibited data aggregation.  
 
It is recommended that a core set of risk factors, their definitions and means of 
measurement are agreed upon and adopted for clinical practice and future 
research. This is not an easy recommendation to implement in practice. Cerebral 
palsy is a long term outcome (i.e. not described until on average, 19 months of age) 
and only one of many outcomes related to risk factors that were studied in this 
thesis. Other long term outcomes associated with the same or similar risk factors 
include intellectual disability, autism, Attention Deficit Hyperactive Disorder and 
Developmental Coordination Disorder. As such, when obstetricians, midwives, 
neonatologists and others involved in the care of pregnant women and their 
newborn babies are writing in notes and partaking in research for short term 
outcomes, they are not thinking about outcome measures and definitions that 
cerebral palsy and other disability researchers are requesting. As such there is an 
imperative for disability researchers to work together with maternal and neonatal 
researchers, and their associations/colleges to develop a coordinated approach to 
implement this recommendation. A new research network is in the processes of 
being developed IMPACT for CP (International Multidisciplinary Prevention And 
Cure Team for Cerebral Palsy) and it is hoped that this network might be able to 
drive this recommendation into practice. 
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HYPOTHESES 2 KEY FINDINGS 
The hypothesis that newborn neurological status will define aetiologically more 
homogeneous groups of cerebral palsy and neonatal death was partially supported 
by the increased importance of risk factors in some outcome groups and the 
decreased to no importance in others. However there was still significant overlap 
between outcome groups suggesting that these risk factors may work on various 
pathways to cerebral palsy and neonatal death. There was also a significant 
proportion not exposed to any of these risk factors suggesting even greater 
heterogeneity.  
 
The primary finding of this doctoral program centred around the much larger than 
anticipated contribution that birth defects made to cerebral palsy in term and near 
term singletons. This was found to be particularly important when combined with 
intrauterine growth restriction. Just under half of the group at lowest risk (term 
singletons without encephalopathy) were identified by age six to have a birth 
defect. As this group cannot be identified at birth, they cannot participate in neuro-
protective and early intervention trials. However, we now know that if some 
substantive efforts are directed toward the prevention of birth defects, and growth 
restriction then this group will benefit from that research.  
 
RECOMMENDATIONS FOR FUTURE RESEARCH 
Findings from this doctoral program have identified new avenues for investigation. 
primarily in the area of birth defects and their combination with growth restriction. 
The first paper presented in the background of this thesis was a Delphi study to 
identify research priorities for cerebral palsy88. Aetiology researchers surveyed, 
identified 33 research questions of high importance. None of these research 
questions were focussed on growth restriction or birth defects. In the discussion of 
that paper I stated that research priorities change over time, as new findings are 
published, and some questions answered. We recommend that research priorities 
now incorporate a focus on birth defects and growth restriction. There are long 
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term possibilities of prevention and treatment for some of these pathways and 
further research is required. Specifically, I am planning a post doctoral program that 
will contain at a minimum: 
Conducting a new linkage study in Western Australia between WARDA-CP and 
WARDA for the most recent birth years 1996-2008. 
This will answer the question, are these results repeatable? And will confirm, refute 
or show a change over time from the findings published throughout this thesis. 
I have invited other states within the Australian Cerebral Palsy Register Group to 
participate in the same linkage study. It is important for the primary analyses to 
only include states where the rigour of both registers is proven. Both South 
Australia and Victoria are considered population cerebral palsy registers, and their 
birth defects registers also collect data into early childhood. By including South 
Australia and Victoria the numbers of cases with cerebral palsy will be tripled, and 
will identify if this finding is similar in areas outside Western Australia. 
Developing an aetiological, causal path categorisation system for birth defects in 
cerebral palsy. 
There is a large diversity of birth defects found within the Term-CCCP, and many 
occurred together (up to ten per person are coded in WARDA). Therefore a 
classification system needs to be developed in collaboration with expert birth 
defect researchers. Professor Carol Bower has agreed to collaborate with us and will 
be a co-investigator in this next phase of research.  
Following the development of an aetiological classification system, use the 
current CCCP to hypothesise causal pathways. 
There is a need to identify mechanisms regarding which sub-groups of growth 
restriction and birth defects have neurological outcomes and which have outcomes 
that are within the normal range. A question also remains about which gestational 
age stratum to use for these future analyses. Some preliminary investigations by 
our group have identified that the cut off point for birth defects playing a major role 
in aetiology of cerebral palsy may be 32 weeks gestation, not the 35 weeks that we 
have used throughout this thesis. We will test this hypothesis in the above 
investigations as well.  
 Page | 155  
 
 
It is hoped that the papers that are published from this thesis will enthuse others 
around the world to also investigate the causal paths to cerebral palsy and neonatal 
death that include birth defects and growth restriction. A groundswell of research in 
this area might ultimately propose prevention and intervention strategies for these 
groups. Currently, those with birth defects identified early enough and growth 
restriction are excluded from cooling studies. We propose that intervention trials 
should be developed for those in this exclusion category, as they too might benefit 
from cooling.  
 
HYPOTHESIS 3 KEY FINDING 
I hypothesised that those with a diagnosis of HIE in the newborn period, followed 
by a description of cerebral palsy later in childhood would have a range of 
antecedents. This hypothesis was supported with one child in five experiencing a 
potentially asphyxial birth event, one in eight had markers of inflammation, one in 
seven was growth restricted, one in four had a birth defect recognised by age six 
and two in five had none of these factors suggesting even further heterogeneity of 
antecedents. This finding was supported by a similar pattern in those with HIE 
followed by neonatal death.  
 
RECOMMENDATION FOR FUTURE PRACTICE, POLICY AND RESEARCH 
This finding highlights an ongoing debate within the literature around the definition 
and use of the terms neonatal encephalopathy (NE) and hypoxic ischaemic 
encephalopathy (HIE).89, 90 The term NE does not imply a specific aetiology, however 
it is assumed that the term HIE does. Yet there is no measure that is sensitive and 
specific to encephalopathy caused by deranged oxygenation or blood flow, and the 
severity of derangement required for permanent neurological damage may differ 
between individuals. This group of term infants have received the most attention 
from researchers in recent years as the partially effective treatment of hypothermia 
moves into clinical practice. One in nine infants benefit from this treatment and 
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there is now a sense of urgency within the HIE research community to find adjuvant 
therapies (six different therapies in current clinical trials) to help the remaining 
eight in nine. However, in conjunction with these future trials, secondary aetiology 
trials should be incorporated that  
Investigate the possibility that underlying pathobiology might alter response to 
hypothermia.  
Additional data would need to be collected in the hypothermia plus adjuvant 
therapy trials including: consent to access maternal records at a later data, bloods 
taken from the mother and baby for later analysis, placental histology, maternal 
indicators of inflammation, an agreed measure of growth restriction and follow up 
for later identified birth defects. This concept has already been suggested and 
discussed recently at the NIH and Cerebral Palsy Alliance co-sponsored Summit “NE 
and HIE: Improving the science and outcomes”. A coordinated approach to future 
trials is required as there are a large number of competing therapies for 
(fortunately) a relatively uncommon outcome; HIE. This coordinated approach is 
also hoped to be undertaken by IMPACT for CP and would increase the 
opportunities for subsequent studies to help unravel the complexities of how 
underlying pathobiology influences treatment outcomes. 
 
HYPOTHESIS 4 KEY FINDINGS 
I hypothesised that even in the most aetiologically homogeneous group, term 
singletons who met consensus criteria for acute intrapartum hypoxia to be 
considered a probable cause of their cerebral palsy, they were also exposed to 
antecedents that could increase their vulnerability to brain injury. We identified 
only a small proportion of infants that met the consensus criteria, so extended the 
criteria which increased the proportion to 4.4% of term infants. Two of the six 
meeting consensus criteria and five of the 15 meeting extended criteria only had 
factors in the intrapartum period. This suggested that multiple pathways to cerebral 
palsy exist in this small group too. The pathway for one in three probably 
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commences in the intrapartum period, however the pathway for two in three may 
include additional risk factors.  
 
It must be remembered that there was a large amount of missing blood gas data for 
infants in this study, therefore the true proportion of term infants that could 
potentially have met this criteria if there was no missing data lies between 4.4 and 
12%. Pathways to cerebral palsy that include acute intrapartum hypoxia are rare 
and may be more complex than current theories suggest. 
 
HYPOTHESIS 5 KEY FINDINGS 
Finally I hypothesised that in those whose risk of cerebral palsy was lowest, term 
singletons receiving only routine care, there would be subtle neurobehavioral 
predictors. This was proven to be the case by our subsequent investigations. Six risk 
factors in the neonatal period were identified as early predictors, and the more 
predictors that existed, the higher the risk of cerebral palsy. However the 
combination of two or more of these factors was not sensitive or specific enough to 
use them as a predictor of cerebral palsy, with too many false positives in the term 
population. Antenatal risk factors for this group as previously described was 
dominated by the presence of birth defects, with over half being cerebral defects 
and on a direct causal path to cerebral palsy. Another key finding of this 
investigation was that more than one half of the most severely impaired term 
infants came from this group. This meant that not only numerically is this group 
very important, but they comprise the majority of severely impaired term infants. 
 
RECOMMENDATION FOR PRACTICE 
Apart from the uncertainty of the cause of their child’s cerebral palsy, parents also 
spoke of a burdensome and extended process to obtain a description of cerebral 
palsy. In the absence of being able to identify a set of predictors in the neonatal 
period to facilitate this process, a paper was written (Appendix P) that focussed on 
this group, and a flowchart was developed to help paediatricians and allied health 
 Page | 158  
 
professionals to recognise cerebral palsy at an earlier age. Parents talk of bringing 
their child to their general practitioner or paediatrician with their concerns around 
delayed motor milestones and generally told to “wait and see”. We recommend 
that instead of “waiting to see” if they grow out of their “delay” that they are 
assessed by evidence based assessments on the flow chart. I suggested in the paper 
that for health professionals that find it difficult to describe a young child as having 
cerebral palsy, or are themselves unconvinced, they instead should state they “are 
at risk of cerebral palsy”. This would allow young children to receive intervention 
earlier and permit entry into trials of early intervention, which would also lead to an 
earlier description of cerebral palsy. 
 
SYNOPSIS OF CHAPTER 10 
This final chapter outlined the strengths and limitations of this doctoral program of 
research. It also identified the key findings and recommendations for practice, 
policy and future research from each hypothesis. The most important finding was 
the more than anticipated contribution that birth defects play in direct and indirect 
pathways to term and near-term singletons with cerebral palsy, particularly for 
those without a diagnosis of neonatal encephalopathy in the newborn period.  
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May 9, 1995) *Please note the original protocol that was submitted in my 
previous correspondence forms a part of this application. 
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hesitate to contact me again, 
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APPENDIX K: PERINATAL DEATH DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables with increasing risk between controls, cerebral palsy cases and perinatal 
deaths 
 
Preconceptional factors 
Mother Aboriginal: perinatal death 9.8%, CP cases 7.6%, controls 6.1% 
No assisted conception: perinatal death 96.4%, CP cases 98.6%, controls 99.1% 
Mothers age at birth of index pregnancy ≤18: perinatal death 8.8%, CP cases 6.8%, 
controls 2.5% 
Insurance status private: perinatal death 36.5%, CP cases 49%, controls 54.2% 
 
Antenatal factors 
Evid antepart fetal distress ↓ fetal movement: perinatal death 17.9%, CP cases 8.8%, 
controls 6.6% 
Pregnancy related anaemia: perinatal death 11.2%, CP cases 5.7%, controls 3.3% 
Pregnancy related polyhydramnios: perinatal death 10.3%, CP cases 1.4%, controls 
0.2% 
37+ weeks at recognition of hypertension: perinatal death 15.2%, CP cases 10.4%, 
controls 5.4% 
 
Intrapartum factors 
Meconium at ROM – thick: perinatal death 16.1%, CP cases 5.5%, controls 1.1% 
Factors associated with chorioamnionitis: perinatal death 7.4%, CP cases 4.2%, 
controls 2.1% 
Presentation in labour/del frank breech: perinatal death 7.5%, CP cases 1.8%, 
controls 0.9% 
Complications of lab/delivery – prolapsed cord: perinatal death 6.4%, CP cases 1.2%, 
controls 0.2% 
Complications of lab/delivery – transverse lie: perinatal death 2.2%, CP cases 1.2%, 
controls 0% 
Complications of lab/delivery – uterine rupture: perinatal death 1.5%, CP cases 0.2%, 
controls 0% 
Complications of lab/delivery – shoulder dystocia: perinatal death 3.7%, CP cases 
1.6%, controls 0.9% 
Complic of lab/delivery – cephelopelvic disproportion: perinatal death 4.4%, CP cases 
3.5%, controls 1.7% 
Thick fresh meconium: perinatal death 17.6%, CP cases 8.1%, controls 1.9% 
 
Immediate postpartum and neonatal factors 
Birthweigth ≤ 1999: perinatal death 10.2%, CP cases 7.2%, controls 1.9% 
Temperature regulation – hypothermia: perinatal death 8.8%, CP cases 3%, controls 
0% 
Abnormal renal function: perinatal death 23.3%, CP cases 18.5%, controls 1.3% 
Respiratory distress IMV: perinatal death 39.4%, CP cases 6.8%, controls 0.2% 
Anaemia: perinatal death 10.5%, CP cases 2.8%, controls 0.2% 
No infections: perinatal death 85.7%, CP cases 82.2%, controls 97.6% 
Patent ductus arteriosis: perinatal death 13.4%, CP cases 3.2%, controls 0.4% 
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APPENDIX L: FINALIST FOR GAYLE ARNOLD AWARD – BEST PAPER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 November 12, 2012 
 
Sarah J. McIntyre, MPS 
Cerebral Palsy Institute 
28 Ballantyne Rd 
Mortdale, NSW 2223 
AUSTRALIA 
 
Dear Ms. McIntyre: 
 
Your paper entitled “Acute Intrapartum Hypoxic Events And Cerebral Palsy: 
Is This A Complete Pathway?” has been nominated for the 2013 Gayle G. 
Arnold Award for Excellence.   
 
During the 2012 Annual Meeting in Toronto, the AACPDM Awards 
Committee selected a total of 14 free paper presentations to invite to submit 
a full manuscript. The Awards Committee will review the full papers 
submitted and select the winner for this highly prestigious Academy award. 
Papers will be judged on relevance to AACPDM membership, originality, 
scientific merit and clarity. 
 
If awarded, you will receive $2,000 for the best Free Paper, which will be 
presented to you during the AACPDM 67th Annual Meeting. Although not 
required, it is preferred that the work has not been offered to, promised to, or 
published by a journal other than Developmental Medicine and Child 
Neurology (DMCN). The paper would be peer reviewed like all other 
submissions to DMCN. 
 
If you wish to be considered for the Gayle G. Arnold Award, please submit a 
completed manuscript, including references, by way of an electronic file (in 
PDF file format) to the AACPDM office by February 18, 2013. 
 
Unless the manuscript is in press elsewhere, the manuscript needs tp be 
prepared in the format specified by Developmental Medicine and Child 
Neurology and the word limit must not exceed 4000 words. See the attached 
“Instructions for Contributors”. Papers will be reviewed only if they are 
submitted in this format.  
   
If your manuscript is chosen for this award, you will be asked to make a 10-
15 minute presentation of your work at the 2013 Annual Meeting to be held in 
Milwaukee, Wisconsin, on October 16-19, 2013. 
 
If you have any questions or concerns about any of the information above, 
please feel free to e-mail me or the AACPDM office.  We look forward to 
reviewing your paper and appreciate your interest in the AACPDM.   
 
Sincerely, 
 
Christine Houlihan, MD 
Chair, AACPDM Awards Committee 
ch9g@virginia.edu   
 
 Page | 229  
 
APPENDIX M: PRECONCEPTIONAL FACTORS FOR THOSE NOT RECEIVING SPECIAL CARE 
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b
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CEREBRAL PALSY—DON’T DELAY
Sarah McIntyre,1,2,3* Cathy Morgan,1,3 Karen Walker,2,4 and Iona Novak1,3
1Cerebral Palsy Alliance, Research Institute, New South Wales, Australia
2The University of Sydney, School of Paediatrics and Child Health, New South Wales, Sydney, Australia
3The University of Notre Dame, School of Medicine, New South Wales, Sydney, Australia
4Grace Center for Newborn Care, The Children’s Hospital at Westmead, New South Wales, Australia
Cerebral palsy (CP) is the most severe physical disability within the
spectrum of developmental delay. CP is an umbrella term describing a
group of motor disorders, accompanied by many associated impairments.
The disability is a result of injuries to the developing brain occurring any
time from the first trimester of pregnancy through to early childhood.
However, for the great majority, their full etiological causal pathway
remains unclear. It is important to discriminate as early as possible
between: (a) mild or nonspecific motor delay, (b) developmental coordi-
nation disorder, (c) syndromes, (d) metabolic and progressive conditions,
and (e) CP with its various motor types and distributions. The most prom-
ising predictive tool for CP is the general movements assessment, which
assesses the quality of spontaneous movements of infants in the first 4
months of life. We propose a change in diagnostic practice. We recom-
mend a shift away from referral for intervention following a formal (most
often late) description of CP, to one of referral for intervention
which occurs immediately once an infant is considered “at risk” of CP.
VC 2013 Wiley Periodicals, Inc. Dev Disabil Res Rev 2011;17:114–129.
Key words: cerebral palsy; early diagnosis; general movements;
perinatal risk factors; neonatal risk factors; brain injury
INTRODUCTION
G
lobal developmental delay is an umbrella term that
describes two or more delays in the area of speech
and language, social and emotional, cognitive and
motor development. Children with cerebral palsy (CP) often
fall under the umbrella of global developmental delay, but CP
cannot be considered “delay,” as children do not “grow out
of it.” Health professionals need to understand what clinical
features distinguish CP from other motor disorders, so the
most effective interventions can be commenced earlier. The
American Academy of Pediatrics have developed a policy for
the surveillance and screening of developmental disorders
(Council on Children with disabilities et al., 2006), however
this paper focusses specifically on CP. The objectives of this
review are fivefold:
1. Describe the nature of CP and what makes it different to
other motor or learning disorders.
2. Outline the prevalence of CP.
3. Determine who is at high risk of CP, what are the predictors
and early signs?
4. Identify tools that help clinicians to accurately predict CP.
5. Present an evidence based algorithmic approach to recogniz-
ing CP and developing intervention plans.
In the early months of life, global developmental delay
and CP present similarly, if delayed, acquisition of develop-
mental milestones is the only comparator. It is the movement
disorders (e.g., spasticity and dystonia), the level of functional
impairment, and the associated impairments that set CP apart
from other milder motor disorders or learning disorders such
as developmental coordination disorder (DCD). DCD is less
severe and 25 times more common than CP affecting 5–6%
the population and current practice is not to diagnose before
the age of 5. As a result, the diagnosis of CP is often delayed
while the possibility of DCD is explored.
DCD is primarily a learning problem where children
can achieve normal movement patterns and skills but have
problems with learning and planning the movements. CP
conversely is a physical disorder, where children are not able
to achieve the normal movement patterns and the primary
problem is motoric not learning, although deficits in learning
may compound the motor problem.
DCD is used to refer to children who fulfill a certain
criteria; poor motor performance which significantly interferes
with activities of daily living which are not explained by any
medical, neurological, or psychosocial condition. Thus a child
with CP whose motor disability is neurological cannot have a
diagnosis of DCD [Blank et al., 2011]. The physical disability
of CP is life-long whilst DCD is more apparent in the win-
dow where the child is learning key motor skills for example,
catching a ball, dressing independently, and handwriting.
WHAT IS CEREBRAL PALSY?
CP is an umbrella term which “describes a group of dis-
orders of the development of movement and posture, causing
activity limitations, which are attributed to nonprogressive dis-
turbances that occurred in the developing fetal or infant brain.
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